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1.1  The eye
1.1.1  Anatomy of human eye
e human eye is composed of three layers (Figure 1) [1]. e outer layer consists 
of the cornea and the sclera. e cornea is the most anterior part of the eye and 
it transmits light through the lens to the retina. It also acts as a shield against 
infection and damage of the inner part of the eye [1, 2]. e sclera is built of 
connective tissue and maintains the spherical shape of the eye, protecting it from 
internal and external pressure [1]. e middle layer of the eye consists of the iris, 
the ciliary body, and the choroid. e iris is a thin circular structure within the 
eye which is responsible for controlling the size of the pupil and thereby, controls 
the amount of light transmitted to the retina. e iris is heavily pigmented which 
determines the eye color of an individual [1, 2]. e ciliary body is composed of 
the ciliary muscle and the ciliary epithelium. e ciliary muscle controls the shape 
of the lens, enabling one to focus on close or far objects. e ciliary epithelium is 
responsible for producing the aqueous humor [1, 2]. e last part of the middle 
layer, the choroid, contains the vascular beds which supports the outer retina [1, 2]. 
e innermost layer of the eye is called the retina. It is a complex layered structure 
of dierent types of cells that converts the light signal from the environment into 
a neural impulse which is subsequently transmitted to the brain creating visual 
perception [1, 2]. 
Figure 1. Anatomy of the human eye. e dierent parts of the human eye are indicated.©Adobe Stock. 
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e three layers of the eye surround three transparent structures, namely the 
aqueous humor, the vitreous, and the lens. e aqueous humor is secreted by the 
aforementioned ciliary epithelium. It is a transparent liquid which lls both the 
anterior and posterior chamber of the eye and is responsible for maintaining the 
intraocular pressure to keep the eye globe inated as well as transporting nutrients 
to avascular eye parts [1]. e vitreous is a gelatinous transparent substance that 
lls the cavity between the lens and the retina. It consists of mainly water and 
obtains its gel-like consistency from collagen bers and hyaluronic acid [1]. e 
lens, together with the cornea, refracts light onto the retina. Its ability to change 
shape under the control of the ciliary muscle allows one to focus on objects at 
various distances [1].
1.1.2  Retina structure
e retina is the photosensitive layer of the eye which is a part of the central 
nervous system [2]. It is a ~0.2 mm thick tissue which is composed of several 
layers of dierent cell types, among which are ve types of neuronal cells, namely 
photoreceptor cells, horizontal cells, bipolar cells, amacrine cells, and ganglion 
cells [3]. ese cells are organized into three nuclear layers that are separated by 
two synaptic layers (Figure 2). e outer nuclear layer (ONL), which is the rst 
nuclear layer, consists of photoreceptor cells. e second layer is termed the inner 
nuclear layer (INL) and includes horizontal cells, bipolar cells and amacrine cells. 
e innermost layer is the ganglion cell layer (GCL), which as indicated by the 
name is composed of ganglion cells [2, 3]. e rst synaptic layer is called the outer 
plexiform layer (OPL) which separates the ONL from the INL. It is the site where 
photoreceptor cells are in contact with horizontal cells and bipolar cells. e INL 
and the GCL are separated by the inner plexiform layer (IPL) where the bipolar 
and amacrine cells make synaptic contacts with ganglion cells [2, 3]. Besides the 
ve types of neuronal cells, the retina also consists of Müller glial cells and retinal 
pigment epithelium cells (RPE). e Müller glial cells span across the retina and 
support the neuronal cells. e RPE is a layer of epithelial cells adjacent to the 
photoreceptor cell layer, which is essential for photoreceptor cells maintenance 
[2, 3]. 
Photoreceptor cells are specialized neurons which are responsible for the 
conversion of light into an electrical signal [2, 3]. Most vertebrates have two types 
of photoreceptor cells, the rods and the cones. e rods mediate vision in dim 
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light and are not involved in color vision, whereas the cones mediate vision in 
bright light and are involved in color vision [2]. e rods contain pigment with 
an absorption peak in the blue-green spectrum, while the cones contain pigments 
with absorption peaks in the blue, green or yellow parts of the color spectra. In 
human retina, the rods are approximately 20 times more abundant than cones [2]. 
However, the density of rods and cones diers between dierent regions of the 
retina. e peripheral retina is dominated by rods, whereas the very central region 
of the human retina, also known as the fovea, is dominated by cones. e center of 
the fovea, the foveola, is exclusively populated by cones [2, 4].
Figure 2. Schematic diagram of healthy retinal circuits. e mammalian retina consists of ve major types 
of neuronal cells –photoreceptor cells (i.e. rod cells (RC) and cone cells (CC)), horizontal cells (HC), bipolar 
cells (BC), amacrine cells (AC), and retinal ganglion cells (RGC). e Müller cells (MC) are glial cells that 
span the retina and their somata. e RPE provides metabolic and transport functions essential for 
homeostasis of the neural retina. Bruch’s membrane (BrM) is a highly specialized and multi-laminar 
structure separating the RPE from the choroid and mediates exchange of oxygen and nutrients between 
vasculature of choroid and neural retina. e RPE and BrM form the outer blood-retinal barrier. Choroidal 
capillaries (CC) are the blood capillaries present in the choroid that supply oxygen and nourishment to the 
outer layer of the retina. Reprinted with permission from Singh et al. (2018) [3].
e RPE is a monolayer of cuboidal pigmented epithelial cells that makes up 
the outermost part of the retina [2, 5, 6]. e apical side of the RPE faces the 
photoreceptor cells, whereas its basolateral side faces Bruch’s membrane which 
separates the RPE from the choriocapillaris [5]. e RPE is involved in multiple 
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mechanisms which are fundamental to the maintenance of structural integrity 
and function of the retina. e functions of the RPE include the maintenance of 
photoreceptor function by phagocytosis of outer segments shed by photoreceptors 
as well as synthesis and regeneration of visual pigments [5, 6]. e pigmented 
cells allow the RPE to absorb scattered light which protects the retina from 
phototoxicity. e RPE’s role as blood-retinal barrier (BRB) involves the transport 
of nutrients, growth factors, and waste from blood to the subretinal space and vice 
versa [5, 6]. Furthermore, the RPE is involved in the transport and metabolism 
of vitamin A as well as secreting growth factors and immunosuppressive factors 
required by neighbouring cells [5]. Additionally, the RPE is also involved in retinal 
adhesion [6].
1.1.3  Vasculature of the eye
e metabolic needs of the dierent ocular structures are supplied by separate 
circulation systems [7]. e avascular structures, such as the cornea, the lens, and 
the vitreous humor are served by an internal circulation of the aqueous humor 
[7]. e fovea, the central region of the retina which provides sharp vision, also 
lacks blood vessels and gets its nutrients by diusion from the choroid. e retina 
is known to be the most metabolically active tissue in the body [7, 8]. Its high 
metabolic activity is served by two vasculature beds, the choroidal vasculature 
and the retinal vasculature. e choroidal vasculature is responsible for the RPE 
and the outer layer of the retina (mainly photoreceptors), whereas the retinal 
vasculature serves the inner layer of the retina (Figure 3) [7, 9]. Circulation in 
the choroidal vasculature is characterized by a high blood ow and a low oxygen 
extraction, while the retinal circulation typically has a low blood ow with a 
high oxygen extraction. e choroidal capillaries are much wider compared to 
the retinal capillaries, resulting in low resistance in the choroidal capillaries and 
thereby facilitate the high blood ow. Furthermore, unlike the retinal capillaries, 
the choroidal capillaries are fenestrated and tend to leak plasma protein [7]. 
Both vasculature beds are also regulated by dierent mechanisms. e choroidal 
circulation is mainly controlled by autonomic innervations, whereas the retinal 
circulation is mostly controlled by autoregulatory mechanisms and local factors, 
such as variations in perfusion pressure, variations in oxygen and carbon dioxide 
level, pH, etc [7].
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Figure 3. Anatomy of eye vasculature. Le, the human eye in cross-section; right, the anatomy of the retinal 
and choroidal vasculatures (red). e retinal vasculature spans the GCL and INL; the choroidal vasculature 
is immediately beyond (to the right of) the RPE. Abbreviations: GCL, ganglion cell layer; INL, inner nuclear 
layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium. Reprinted with permission from Ye et al. 
(2010) [8].
Blood vessels can be formed by two dierent mechanisms, namely vasculogenesis 
and angiogenesis. Vasculogenesis is dened as de novo formation of vessels 
from endothelial precursor cells, whereas angiogenesis is a term describing the 
development of new vessels from pre-existing vascular network [10]. In humans, 
the development of retinal vasculature occurs in utero by both vasculogenesis 
and angiogenesis [8, 10, 11]. Initially, the retina develops avascularly and is 
supplied by the choroidal vasculature as well as the hyaloid vasculature [12]. e 
hyaloid vasculature is an arterial network in the vitreous which develops from 
the central hyaloid artery at around 6 weeks of gestation (WG). It runs through 
the vitreous to the posterior lens and exits through choroidal veins at the front of 
the eye (Figure 4a) [12, 13]. e hyaloid vasculature starts to regress around 13 
WG and simultaneously, a vascular plexus emerges from the optic nerve head by 
vasculogenesis [10]. is gives rise to the retinal vasculature, which contains both 
arteries and veins that both enter and exit through the optic nerve (Figure 4b) [12, 
13]. Subsequently, the primary plexus undergoes remodeling into three parallel 
but inter-connected networks, located in the nerve ber layer and the plexiform 
layers (Figure 4c) [12]. e development of the retinal vasculature is complete by 
38-40 WG, by which time the hyaloid vasculature has fully regressed [13]. 
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Figure 4. e vascular network inside the eye is remodeled during development. (A) e hyaloid 
vasculature (hv) is supplied by the hyaloid artery (ha) and drained into the venous, choroidal net (ch) on the 
outside of the eye (the choroidal net is not shown in B and C). (B) e hyaloid vasculature regresses as the 
primary plexus (pp) of the retinal vasculature grows into the retina. e primary plexus consists of arteries 
and veins. (C) e deeper plexus (dp) of the retinal vasculature develops from veins in the primary plexus. 
Reprinted with permission from Fruttiger (2007) [12].
e angiogenic sprouting of the primary plexus requires dierential behavior 
of endothelial cells, based on their location [13]. Endothelial cells at the leading 
edge of the vascular network, usually termed “tip cells”, are more motile and less 
proliferative compared to those in the stalk (also called “stalk cells”) [14]. Tip 
cells sense the vascular endothelial growth factor (VEGF) gradient as well as 
other angiogenic factors and thereby guide the direction of growth. Conversely, 
the stalk cells proliferate and form the vessel lumen, sustaining sprout extension 
and perfusion [15, 16]. e two types of endothelial cells also have dierent 
transcriptional proles [17, 18]. e tip-stalk state of endothelial cells are 
dynamically regulated by Delta like 4 (DLL4)-NOTCH signaling. Tip cells express 
DLL4, which activates NOTCH1 in adjacent cells where DLL4 transcription is 
suppressed, thereby inhibiting the tip cell state [19]. A VEGF gradient inuences 
this switch mechanism, by inducing the transcription of DLL4 upon VEGFR2 
activation by VEGF, thereby promoting the tip state. Furthermore, Notch1 
activation de-sensitizes the stalk cells to VEGF by downregulation of VEGFR2/3 
while activating the VEGF antagonist, VEGFR1 [20-22]. Since the VEGF 
concentration is highest at the leading edge of the growing plexus, the tip-stalk 
phenotype of endothelial cells is dependent on their location [13]. Such a VEGF 
gradient is likely to be also present in the retina. Higher VEGF mRNA expression 
has been observed in the peripheral retina which is not yet vascularized and hypoxic, 
compared to the central retina where oxygen is supplied by the developing vessels 
and represses VEGF expression [23]. Additionally, multiple other molecules have 
been demonstrated to modulate the endothelial tip-stalk state (reviewed in [13]), 
which creates a balance in the expansion of the primitive plexus.
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e primitive plexus is subsequently remodeled into structured, hierarchical 
vascular trees. is remodeling takes place by vessel regression as well as vessel 
stabilization. De-stabilizing factors such as lack of perfusion, endothelial cell 
migration, and apoptosis may eventually lead to vessel regression. Conversely, 
perfusion, endothelial-mural cell interactions, as well as vessel maturity positively 
contribute to vessel stabilization [24]. Vessels are highly proliferative at the 
growing edge of the developing primary plexus, while towards the centre of the 
retina less proliferation and more remodeling of the generated primitive plexus 
was observed. Despite the quiescent state of vessels at the remodeling region, 
they are unstable and either dierentiate into more mature vessels or are pruned 
[13]. Vessel maturation includes dierentiation of newly formed vessels into 
mature types, such as capillaries, arteries, and veins [13]. is process involves 
the interaction of endothelial cells with mural cells (pericytes and smooth muscle 
cells) [25]. 
e deeper plexus of the retinal vasculature sprouts from the primary plexus veins, 
starting from the center of the retina and expanding towards the periphery (Figure 
4c) [26]. It grows along the Müller cells into the retina. Once reaching the INL, it 
forms two networks in parallel to the primary plexus. Unlike the primary plexus, 
retinal astrocytes are not involved in the development of the deeper plexus [12]. 
Furthermore, the cellular and molecular mechanisms of deeper plexus development 
are also less well studied. Nonetheless, some signaling pathways that are involved 
in the primary plexus development, also seem to be relevant in the development 
of the deeper plexus. For example, deletion of genes in the transforming growth 
factor beta (TGFB) and Norrin signaling pathways, not only hindered the primary 
plexus development, but also that of the deeper plexus. Additionally, VEGF has 
been speculated as the molecule guiding angiogenic sprouting towards the outer 
retina (reviewed in [13]). 
e development of retinal vasculature requires cell-cell interactions between 
the endothelial cells in the developing vessels, retinal astrocytes, as well as retinal 
ganglion cells [13]. Retinal astrocytes emerge from the optic nerve head towards 
the retina, where they serve as a template for retinal angiogenesis [27, 28]. Retinal 
astrocytes are only found in species which have retinal vasculature and are the 
only astrocyte type in the central nervous system that express platelet derived 
growth factor receptor alpha (PDGFRA) [29, 30]. RGCs secrete platelet derived 
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growth factor alpha (PDGFA), which is a ligand of PDGFRA and a mitogen for 
retinal astrocytes [27]. Retinal astrocytes proliferate and migrate across the retina, 
establishing a mesh-like network. Since this occurs prior to the development of 
retinal vasculature, they experience hypoxia and express VEGF, a key inducer 
of angiogenesis [12]. As the retinal vasculature develops, the astrocytes stop 
proliferating and dierentiate into a more mature phenotype. Molecularly, this is 
marked by the upregulation of glial brillary protein (GFAP) and downregulation 
of VEGF [23]. Furthermore, retinal astrocytes secrete apelin (APLN) which 
stimulates leukemia inhibitory factor (LIF) production in endothelial cells, which 
is an inducer of astrocytes maturation as well as inhibitor of retinal astrocytes 
proliferation [31, 32]. e close proximity to astrocytes that is required by 
endothelial cells also suggest that they might have a role in providing physical 
growth substrate for the vessels [13]. RGCs constitute another cell type that is 
involved in the retinal angiogenesis, which are crucial in detecting hypoxia in the 
developing retina. Moreover, they produce semaphorin 3E (SEMA3E) which is 
anti-angiogenic and thereby prevents misdirection of developing vessels as well as 
limits the growth of the primary plexus to the nerve ber layer [33, 34]. 
1.1.4  Blood-retinal barrier
e blood-ocular barriers are crucial in the maintenance of a suitable environment 
of optimal visual function by regulating the contents of the inner uids in the eye, 
as well as protecting the internal ocular tissues from variations that occur in the 
circulation [35, 36]. e barriers keep the eye as a privileged site in the human 
body. ere are two main barrier systems, namely the blood-aqueous barrier and 
the blood-retinal barrier [35, 36]. e blood-aqueous barrier is located in the 
anterior segment of the eye and is formed by tight junctions in the non-pigmented 
epithelial cells of the ciliary epithelium, the endothelial cells in the iris vasculature, 
and the inner wall endothelium of Schlemm’s canal [35]. e blood-retinal barrier 
is located in the posterior segment of the eye and acts similar to the blood-brain 
barrier. It is a physiological barrier that regulates movement of molecules into and 
out of the retina, maintaining its appropriate microenvironment. e blood-retinal 
barrier (BRB) consists of the inner BRB (iBRB) and the outer BRB (oBRB) [36]. 
e iBRB is composed of tight junctions between adjacent endothelial cells, which 
are resting on a basal lamina covered by astrocytes and Müller cells. Although 
pericytes are also present in the basal lamina, they do not form a continuous layer 
and thereby, are not involved in the diusional barrier. On the other hand, the 
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oBRB is formed by tight junctions of the neighboring RPE cells. It is important 
in gate-keeping exchange of nutrients and waste products between blood and the 
photoreceptors [36]. 
Figure 5. Cell-cell signaling between RGCs,  retinal  astrocytes  and developing vessels controls the 
development of retinal vasculature. PDGFA released by RGCs acts on astrocytes to promote proliferation 
and migration.  VEGF  and APLN produced by retinal astrocytes and VEGF produced by RGCs and 
other neural cells act on endothelial cells. In reverse, endothelial cells stabilize retinal astrocytes via LIF. 
Similarly, oxygen provided by the growing vasculature feeds back on VEGF expression from retinal 
astrocytes and other neural cells. SEMA3E restricts growth of the developing plexus to the nerve ber layer. 
Endothelial derived PDGFB has chemo-attractant and mitotic eects on pericytes, but might also inuence 
retinal astrocytes (stippled arrow). Reprinted with permission from Selvam et al. (2018) [13].
1.2  Familial exudative vitreoretinopathy
Familial exudative vitreoretinopathy (FEVR) was rst described by Criswick and 
Schepens in 1969 [37]. It is an inherited retinal disorder, which is characterized 
by an abnormal vascularization in the peripheral retina. An avascular peripheral 
retina is observed in most FEVR patients. However, the clinical features and visual 
function of FEVR patients may be asymmetric and highly variable. In mild cases, 
the aberrant vasculature in the peripheral retina does not cause any symptoms. 
Neovascularization and brosis at the junction between the vascular and avascular 
retina may occur in the moderate to severe cases, which causes traction of the 
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macula and retinal vessels, thereby leading to varying degrees of macular ectopia 
and visual dysfunction. is traction, however, may also lead to retinal folds and 
detachment in severe cases that result in very poor vision in the most severe 
cases. FEVR can be diagnosed in an individual at any age, if there is evidence of 
avascularity in the peripheral retina in one or both eyes. ese ocular features 
are overlapping with those observed in retinopathy of prematurity (ROP) cases, 
in which the clinical signs are due to incomplete retinal vascularization aer 
premature birth and hyperoxia (in comparison to in utero) experienced during 
neonatal care. erefore, it is important that a person diagnosed with FEVR is 
born at full term [38]. 
Figure 6. Fundus photograph showing part of the avascular periphery of an FEVR patient. is picture 
shows temporal periphery of the le fundus of the patient. e retinal vasculature (at the le side) ends in 
small aberrant ramications in the equatorial area of the fundus. e peripheral retina (at the right side) is 
avascular, only choroidal vessels are present in this area. Reprinted with permission from Nikopoulos et al. 
(2010) [39].
Next to its heterogeneous clinical manifestations, FEVR is also genetically 
heterogeneous. It can be inherited in an autosomal dominant, autosomal recessive 
or X-linked manner. Mutations in several genes have been associated with FEVR, 
such as NDP [40], FZD4 [41, 42], LRP5 [42, 43], TSPAN12 [39, 44], ZNF408 [45], 
CTNNB1 [46, 47], RCBTB1 [48], and ATOH7. Four of these genes (NDP, FZD4, 
LRP5, and TSPAN12) are most commonly mutated in FEVR patients and are also 
the most well-studied FEVR-associated genes. e proteins encoded by these genes 
are involved in the Norrin signaling pathway. In this pathway, FZD4 and LRP5 act 
as receptor and co-receptor for Norrin, the protein encoded by NDP. TSPAN12 
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is required for the multimerization of FZD4-LRP5 complex and is exclusively 
involved in Norrin signaling. Binding of Norrin to its receptor complex, activates 
this signaling pathway. is leads to the translocation of β-catenin, the protein 
encoded by CTNNB1, to the nucleus where it subsequently activates the expression 
of its downstream genes [49]. Knock-out of Ndp, Fzd4, Lrp5, and Tspan12 in mice 
resulted in retinal vasculature defects, including the absence of two intraretinal 
capillaries that ank the INL, abnormal primary arteries and veins, as well as a 
delayed regression of hyaloid vessels (reviewed in [8]). Moreover, conditional 
knockout mice showed that the depletion of β-catenin in endothelial cells resulted 
in defective angiogenesis in the complete central nervous system including the 
retina [50, 51]. 
Defects in the aforementioned genes may also results in other clinical features, 
which may or may not overlap with the features of FEVR. Mutations in LRP5 
can result in FEVR-like features accompanied by bone abnormalities, a syndrome 
termed osteoporosis pseudoglioma [52]. Norrie disease, which is due to mutations 
in NDP, is a severe X-linked syndrome with ocular features overlapping with those 
of FEVR as well as developmental delay and hearing impairment [40, 53]. Besides 
FEVR, RCBTB1 mutations have been associated with Coats disease, a sporadic, 
unilateral retinal vasculopathy, and retinitis pigmentosa, an inherited retinal 
disease hallmarked by photoreceptor degeneration [48, 54]. Biallelic mutations in 
ZNF408 have also been implicated in autosomal recessive retinitis pigmentosa [55]. 
Finally, FEVR features have been described to be accompanied by microcephaly, a 
condition associated with mutations in KIF11 [56].
FEVR belongs to a spectrum of disease with overlapping clinical features. ese 
diseases, termed vitreoretinopathies, are mainly characterized by defects of the 
vitreous and the retina accompanied by typical features that specify the dierent 
diseases. Other clinical features may also be observed next to the ocular features in 
the syndromic form of these diseases, some of which have been discussed earlier 
in this section. e diseases that belong to the vitreoretinopathy spectrum are 
listed in Table 1.
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Table 1 Clinical characteristics and known causative genes for vitreoretinopathies. Summarized from [57, 
58]
Disease name Main clinical characteristics Genes
FEVR Avascular peripheral retina, retinal 
neovascularization, brosis, retinal traction and 
detachment
NDP, FZD4, LRP5, 
TSPAN12, ZNF408, 
RCBTB1, CTNNB1, 
ATOH7
Snowake vitreoretinal 
degeneration
Early onset cataract, vitreoretinal dystrophy, 
brillal degeneration of the vitreous, shiny 
crystalline-like deposits resembling snowakes, 
retinal detachment
KCNJ13
Enhanced S cone syndrome, 
Goldmann-Favre syndrome
(severe form)
Retinal degeneration, enhanced response 
of S cones. Severe manifestations constitute 
vitreoretinal degeneration and cataract
NR2E3
Autosomal dominant 
vitreoretinochoroidopathy 
Hyperpigmented cells at the peripheral retina with 
white opacities, breakdown of blood-retinal barrier 
with retinal neovascularization, presenile cataract, 
and choroidal atrophy
VMD2
Wagner syndrome/
Erosive vitreoretinopathy
Syneresis of the vitreous, cataract, high myopia, 
night blindness, and retinal detachment
VCAN
Osteoporosis pseudoglioma Osteoporosis, FEVR-like ocular features LRP5
Norrie disease Mental retardation, hearing impairment, 
intraocular mass in the retina, FEVR-like ocular 
features
NDP
Stickler syndrome Mid-face hypoplasia, small chin, cle palate, 
hearing impairment, vitreous abnormalities, 
cataract, retinal detachment
COL2A1, COL11A1, 
COL11A2, COL9A1
A range of disease severity within an individual or within families has been 
observed in FEVR. Relatives of patients presenting severe FEVR may have mild 
to asymptomatic symptoms, although they have the same mutation. is suggests 
incomplete penetrance of the associated mutation [38, 49, 59]. Such a reduced 
penetrance is observed in ~25% of mutation carriers in FEVR [45, 59]. Non-
penetrance itself is dened as a state in which a particular genetic trait fails to 
manifest itself in the phenotype. e penetrance of a mutation can be inuenced by 
many factors, among others epigenetic modication, allele dosage, modier genes, 
copy number variants, gene expression level, and environmental factors [60]. 
1.3  Animal models for retinal vasculature diseases
As described above, abnormal ocular vasculature development can underlie a 
broad spectrum of eye disorders. Over the last decades, numerous animal models 
have been generated to mimic these diseases with defective retinal, choroidal, or 
corneal angiogenesis. Studies employing these animal models not only broaden 
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our insight on the basic mechanisms of angiogenesis, but also shed light in the 
understanding of disease pathology. Various methods have been employed 
to generate these models, such as oxygen level manipulation, laser treatment, 
surgical treatment, as well as genetic modication. Besides, multiple species have 
been used to model ocular angiogenesis, such as feline, canine, rat, mouse, and 
zebrash (reviewed in [61]). In this chapter, mouse and zebrash models of retinal 
angiogenesis will be discussed in more detail.
1.3.1  Mouse models 
Mice are the most commonly used animals to model both development and 
disease. e procedures of creating transgenic strains as well as the characterization 
of the generated animals are well established, thanks to the extensive availability 
of recombinant proteins and antibodies that are compatible with mice [62]. 
Although mice as well as other rodents are nocturnal and therefore their eye and 
retinal architecture diers from that of human [63], the postnatal development of 
retinal vasculature in mice facilitated the investigation of retinal angiogenesis in 
development and disease. For instance, the pruning of hyaloid vessels as well as 
the parallel development of the intraretinal vasculature that occurs postnatally in 
mice has allowed the study of mechanisms underlying these processes [61, 62]. 
e time course of normal retinal vasculature development in wild-type mice varies 
between dierent strains, usually with a few days dierence. As an approximation, 
in C57BL/6 mice, the supercial vascular plexus grows from the optic nerve into 
the periphery during the rst week aer birth. It starts sprouting to form the deep 
and intermediate vascular plexus from postnatal day 7 (P7) onwards. e deep 
plexus in the OPL reaches the retinal periphery at approximately P12, while the 
intermediate plexus in the IPL does so between P12 and P15. All three vascular 
layers are fully mature by the end of the third postnatal week (Figure 7) [62].
One of the most popular mouse models to study retinal angiogenesis is the 
oxygen-induced retinopathy (OIR) model. is model is mainly used to 
mimic the pathological mechanisms present in patients with ROP or diabetic 
retinopathy. Abnormal retinal angiogenesis is the hallmark of both diseases, in 
which abnormal retinal avascularity is followed by aberrant neovascularization. 
Diabetes is associated with these clinical features in DR, whereas in ROP cases, 
these are associated with incomplete retinal vascularization aer premature birth 
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followed by hyperoxia during neonatal care (compared to in utero condition). To 
generate OIR models, neonatal mice are exposed to 75% oxygen from P7 to P12, 
which leads to vaso-obliteration that mimics the initial phase of ROP. Normoxic 
conditions are applied from P12 onwards for 5 days, leading to uncontrolled 
compensatory pathologic neovascularization resembling human proliferative 
retinopathies. It reaches its maximum at P17, which is a usual end point of this 
mouse model. Aerwards, the abnormal vascularization gradually regresses and 
disappears by P25 [64].
Mouse models mimicking pathologic neovascularization have also been 
generated by genetic modication. For example, vldlr-/- mice, which were 
generated by targeted disruption, showed subretinal neovascularization as well 
as choroidal anastomosis [65, 66]. Another example is the rho/VEGF mice, in 
which full-length cDNA of human VEGF is put under a bovine rho promoter 
to overexpress VEGF in the photoreceptor cells. is model showed intraretinal 
and subretinal neovascularization with vascular leakage as well as substantial 
photoreceptor degeneration [67, 68]. Both models are mainly used to investigate 
retinal angiomatous proliferation, a variant of neovascular age-related macular 
degeneration [61].
Mice with decient retinal angiogenesis such as that observed in FEVR and Norrie 
disease have also been generated, such as the knock-out mice models of the four 
genes that are most frequently mutated in FEVR, namely Fzd4-/-, Lrp5-/-, Tspan12-/-, 
and Ndp-/-. Loss of function of each of these genes showed comparable phenotypes 
[69-73]. ese mice usually lack two intraretinal capillary beds anking the INL 
and the sprouting that gives rise to these vessels are also stunted. Persistent hyaloid 
vasculature was also observed in these mice [69-73]. Moreover, the defective inner 
retina vascularization leads to hypoxia, which in turn upregulates VEGF and 
subsequently, compensatory vascularization [74].
1.3.2  Zebrafish models 
In recent years, zebrash have become more and more popular as a model 
organism to study vertebrate development as well as disease modeling. Zebrash 
are easy to maintain and also breed in large quantities in a short time with relatively 
low costs. e transparent embryo facilitates visualization during development. 
Furthermore, 70% of human genes as well as 84% of known human disease-
associated genes have a zebrash orthologue. ese, together with the possibilities 
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for genetic manipulation, render zebrash a suitable model organism for human 
inherited diseases [75]. 
Figure 7. Development of the deep and intermediate vascular plexus in C57BL/6 mouse retinas. Retinal 
whole mounts and cross sections from postnatal day (P)9 to P25 were stained for endothelial cells with 
isolectin B4-Alexa 594 (red) and for cell nuclei with DAPI (blue). N (normoxia) signies normal 
development. (A) At P9N, the supercial plexus has fully extended to the peripheral retina. e deep 
vascular plexus begins forming centrally from vertical vessels diving down from the supercial plexus. e 
intermediate vascular plexus has not begun to form yet. On cross section, the three neuronal layers of the 
retina and the supercial vascular plexus can be identied. Representative drawings on the right illustrate 
both supercial and deep vascular plexus in the immediate vicinity of the optic nerve, whereas in the 
periphery the supercial plexus remains the only vascular network. (B) At P12N, the intermediate vascular 
plexus becomes visible on retinal whole mounts. e deep vascular plexus is nearly fully developed. On 
cross section, vertical sprouting of vessels toward the intermediate plexus can be observed. Representative 
drawings illustrate the beginning of a three-layered vascular plexus around the optic nerve and supercial 
and deep vascular plexus with interconnecting vessels in the periphery. (C) At P15N, the intermediate 
vascular plexus continues to develop throughout the retina as illustrated both on retinal whole mounts and 
cross sections. Representative drawings illustrate complete formation of supercial and deep plexus with 
continued development of the intermediate vascular plexus in the periphery. (D) At P17N, the supercial, 
intermediate, and deep plexus can be seen both centrally and in the peripheral retina. Cross sections and 
representative drawings illustrate the three-layered vascular system in all parts of the retina along with 
multiple interconnecting vessels. (E, F) Between P21N and P25N, further maturation of especially the 
intermediate plexus can be observed. Cross sections and representative drawings illustrate the mature 
retinal vasculature. Note that isolectin B4 binds to choroidal vessels as well as nonspecically to RPE and the 
scleral wall in some of the cross sections (A-F). Reprinted with permission from Stahl et al. (2010) [62].
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Vision disorders are among the wide variety of human diseases that have been 
modeled in zebrash [75]. One might wonder how similar a human eye is to the 
zebrash eye. e visual system of zebrash is principally comparable to that of 
humans. Structurally, zebrash and human eyes dier in the shape of the lens as 
well as the space between the lens and the retina [76]. e retina of zebrash also 
contains ve layers (ONL, OPL, INL, IPL, and GCL), similar to the human retina 
(Figure 8). Since zebrash are diurnal species, they possess cone-rich retinas with 
a cone density close to humans. However, a macula is absent in the zebrash retina 
[75, 76].  
Figure 8. Cross-sectional histology of the human and zebrash retina demonstrating similarities in the 
arrangement of cells and structural features that dene the distinct retinal layers. RPE, pigmented 
epithelium; IS, inner segment; OS, outer segment; PR, photoreceptor; ONL, outer nuclear layer; OPL, outer 
plexiform layer; INL, inner nuclear layer; GCL, ganglion cell layer; and NFL, nerve bre layer. Reprinted 
with permission from Richardson et al. (2016) [75].
Similar to humans, hyaloid vasculature is also present in zebrash. e hyaloid 
artery originates from the optic ssure at 18-20 hours post fertilization (hpf), aer 
which it grows and branches to surround the medial part of the lens at around 48 
hpf. In parallel, another vasculature system develops at the surface of the eye, which 
is termed the supercial system. It is connected to the hyaloid vein and leads the 
formation of choroidal vessels [77]. e supercial system consists of three major 
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vessels which are interconnected by a ring-shaped vessel. e three major vessels 
are the nasal radial vessel (NRV), the dorsal radial vessel (DRV), and the ventral 
radial vessel (VRV) (Figure 9). Blood enters through the NRV and exits through 
the DRV and VRV [78]. At 5 days post fertilization (dpf), the hyaloid vasculature 
completely embraces the lens and continues branching forming a complex 
network. Unlike hyaloid vasculature regression that is observed in humans, the 
hyaloid vasculature starts loosening its contact with the lens and simultaneously, 
becomes more attached to the retina from approximately 15 dpf onwards. e 
zebrash retina shows an elaborate vasculature network similar to adults at 60 dpf 
and maintains the morphology to 18 months. Around 18-20 months, the retinal 
vessels progressively degenerate, consistent with an age-related loss of retinal 
vasculature function (Figure 10). Of note, zebrash lack intraretinal plexus which 
is present in human and other mammals, possibly because the surface retinal and 
choroidal vasculature are sucient to supply the thinner zebrash retina [79].
Figure 9. e hyaloid and supercial system vasculature of zebrash. On the le side, a projection of 
confocal z-stacks showing ocular vessels in Tg(kdrl:EGFP) live embryos at 59 hpf are shown and on the right 
side, the same confocal image is combined with a bright eld image showing the position of vessel relative 
to the eye. Arrows point at the hyaloid vein and arrowheads at the ring-shaped vessel where the three major 
supercial system vessels are interconnected. H: hyaloid, NRV: nasal radial vessel, DRV: dorsal radial vessel, 
and VRV: ventral radial vessel, L: lens. Both images are lateral views, anterior to the le, dorsal up. Scale bar 
is 50 μm. Adapted with permission from Kaufman et al. (2015) [77].
Zebrash have been used extensively to model multiple ocular disorders, including 
ocular coloboma, microphthalmia/anophthalmia, cyclopia, corneal dystrophies, 
cataract, retinal and RPE abnormalities, as well as vasculature defects (reviewed 
in [75]). e availability of transgenic zebrash with uorescent reporters on 
the blood vessels, such as Tg(i1:EGFP) line [80] and Tg(k1:GFP) line [81], 
facilitates in vivo investigation of vasculature-related ocular disease. For instance, 
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vhl-/- zebrash showed an aberrant vasculature development in the brain, eye, and 
trunk, as observed in von Hippel-Lindau (VHL) syndrome. Moreover, hyaloid 
and choroid neovascularization together with the vascular leakage and retinal 
detachment that is also observed in vhl-/- zebrash, is similar to those observed 
in proliferative diabetic retinopathy and age-related macular degeneration [82]. 
Gene expression alteration by antisense oligonucleotides such as morpholinos 
has also been used to study vasculature-related ocular disease. For example, 
morpholino-induced knockdown of znf408, a gene mutated in FEVR, resulted 
in aberrant development eye and trunk vasculature [45]. In addition, hypoxia 
treatment on adult zebrash has been used to mimic adult retinopathy. Aer 3-10 
days of hypoxia treatment, retinal neovascularization was observed in the adult 
zebrash [83]. Lastly, zebrash have also been used in small molecule screening 
for compounds that aect vascular development in the zebrash retina [78].
Figure 10. Dynamic development of the hyaloid and retinal vasculature in zebrash. Shown are 
uorescent images of blood vessels on lenses and wholemount retinas dissected 
from Tg(i1:EGFP) zebrash.  A) At 5 dpf the vasculature covers the lens from the optic disk to the inner 
optic circle. B) At 19 dpf an intricate network of hyaloid vessels branches around the lens. Some vessels at 
the posterior lens have lost contact and are attached to the retina (inset). C) Retina and D) lens from a 60 dpf 
zebrash. In this specimen some vessels are attached to the lens although most of them are found on the 
retina.  Inset in D:  Overlay of the retina from  pseudo-colored in red, and the lens from  D  depicts the 
complementing network of vessels. E) Typical vascular pattern of intraocular vasculature in a 6 month old 
sh. F) Inner retina of a 22 month old senescent zebrash showing slightly thinner and more fragile vessels. 
White circumferences demarcate the lens in A-D. Yellow arrows point from the posterior to the  anterior 
lens in A, B, and D and from the dorsal to the ventral retina in C, E, and F. Scale bars: 50 μm in A and B; 100 
μm in C and D; and 500 μm in E and F. Adapted with permission from Alvarez et al. (2007) [79].
1.4  Cellular models for vasculature-related diseases
Besides animal models, endothelial cells are mainly used as an in vitro model in 
vasculature-related research. ese cells form a monolayer that line the vascular 
lumen and are involved in various physiological processes of the vasculature, 
such as control of permeability, angiogenesis, coagulation, and inammation 
[84]. Primary endothelial cells have been isolated from various species, including 
bovine, canine, porcine, murine, and human. Endothelial cells have also been 
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isolated from various locations, such as the dermis for microvessels as well as the 
umbilical vein, jugular vein, and aorta for large vessels [85]. Endothelial cells are 
a heterogeneous population, that has dierences in expression patterns across 
developmental stage, vascular classes (i.e. capillary, artery, venous), and tissue 
types [86]. 
Human umbilical vein endothelial cells (HUVEC) are the most commonly 
used primary endothelial cells in vascular biology research. e second most 
popular are human dermal microvascular endothelial cells (HDMEC). Both cell 
types are widely used, since they are relatively easy to isolate and culture [85]. 
Although the use of primary cells gives the advantage of having the most similar 
characteristics as compared to an in vivo situation, the primary cells have a limited 
life-span which may complicate their application in long-term experiments. Many 
studies have attempted to generate endothelial cells with prolonged life-span or 
even immortalized endothelial cell lines (reviewed in [84]). However, these cells 
are oen developed using malignant factors, for instance SV40 large antigen or 
telomerase. Such procedures may alter the genetic and epigenetic properties of the 
cells and thereby, the immortalized cell lines may be less representative of the in 
vivo situation. e results obtained with such cell lines should thus be conrmed 
using primary cells [84]. 
In recent years, multiple methods have been employed to generate endothelial cells 
from pluripotent stem cells [87, 88]. e term ‘pluripotent stem cells’ describes any 
undierentiated cells that have the ability to dierentiate to any cell type of the 
body, excluding extra embryonic tissue. Pluripotent stem cells can be of embryonic 
origin, such as human embryonic stem cells (hESCs), or reprogrammed from 
somatic cells, which are termed induced pluripotent stem cells (iPSCs). Somatic 
cells are reprogrammed into iPSCs using a cocktail of reprograming factors 
(Oct3/4, Klf4, Sox2, c-Myc), originally described by Yamanaka et al. [89]. Various 
compositions of this cocktail as well as the delivery methods have been developed 
since the original nding. Many cell types have been successfully reprogrammed 
into iPSCs, but dermal broblasts remain the most commonly used cell type [90]. 
e possibility to obtain iPSCs from patients and dierentiate them into relevant 
cell type has beneted many disease investigations. It is applicable to studies in 
which it is challenging to obtain the disease-relevant cell type. Patient-derived 
iPSCs also present the advantage that they represent the genetic background of 
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the patient without the need of any manipulation. It is especially advantageous 
in research requiring cell types for which genetic modication is challenging, for 
instance, endothelial cells. 
iPSC cultures on OP9 feeder cell layer as well as embryoid body formation have 
been employed in the initial attempts to dierentiate iPSCs into endothelial cells. 
Nowadays, monolayer dierentiation employing dened factors directing iPSCs 
dierentiation to mesoderm and subsequently endothelial lineage is the most 
popular technique. e dierentiation eciency is improved using this method, 
compared to previous attempts. BMP4, Activin A/Nodal, FGF2, and GSK3β 
inhibitors or WNT ligands are usually used to induce dierentiation towards 
mesoderm layer, while VEGF and endothelial promoting culture conditions are 
employed to further direct the dierentiation into endothelial cells. e generated 
cells can be further selected for those expressing endothelial cell surface marker(s) 
by ow cytometry or immunomagnetic separation, to increase the purity of the 
generated endothelial cell population. As mentioned previously, endothelial cells 
represent a heterogeneous population and therefore, methods to further specify 
iPSC-derived endothelial cells are currently being investigated. Nonetheless, the 
existence of robust protocols to dierentiate human iPSCs into endothelial cells 
not only provides tools to study disease mechanisms, but also pave the way for 
cell-therapy of vascular-related diseases [88].
Next to its typical cobble-stone morphology (Figure 11), endothelial cells possess 
other distinctive in vitro characteristics. Endothelial cells isolated from donor 
(primary endothelial cells) as well as stem cell-derived endothelial cells need to 
be tested for these characteristics. Immunostaining is oen used to check for the 
expression of endothelial cell surface markers, such as CD31 (Figure 11), CD144 
(VE-cadherin), VEGFR2 (KDR) and von Willebrand factor (vWF). Furthermore, 
endothelial cells are also oen tested for their in vitro behaviors, which include 
tube formation on a 3D matrix (Figure 10), uptake of acetylated-LDL (Figure 11), 
migration in response to VEGF, as well as secretion of certain pro-angiogenic 
growth factors and cytokines [88].  
Lastly, the increasing availability of in vitro models of endothelial cells as well 
as other cells supporting the vasculature, such as pericytes and vascular smooth 
muscle cells, allowed the development of an in vitro physiological model of 
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vasculature using organ-on-a-chip technology. It allows the investigation of vessel 
development in the presence of uid ow as well as supporting cells (e.g. pericytes) 
in co-culture. Such a system mimics the in vivo situation more closely than the 
2D culture system and has been applied in multiple vascular investigations. 
For instance, it has been used in research on endothelial cell barrier functions; 
regulation of blood ow, hemostasis and thrombosis, as well as vasculogenesis and 
angiogenesis [87]. 
Figure 11. Endothelial cell characteristics. Endothelial cells have a characteristic endothelial cell 
cobblestone morphology, express the endothelial marker CD31, form tube-like structures in Matrigel and 
incorporate acetylated low-density lipoprotein (ac-LDL). Reprinted with permission from Wong et al. 
(2012) [91].
1.5  Technologies to unravel molecular mechanisms of 
disease
1.5.1 Genetic defect identification
e rst step in studying the mechanisms underlying an inherited disease is to 
determine the genetic defect causing this disease. Linkage analysis is a popular way 
to map Mendelian traits with familial segregation. is approach employs genetic 
markers to identify regions in the genome that are associated with a disease. Even 
now, in the advanced sequencing era, linkage analysis is still utilized to narrow 
down the disease locus, thereby reducing the number of variants to follow-up [92]. 
Sanger sequencing was the gold-standard in nding the genetic defect underlying 
Mendelian disorders. It allows very low rates of false-positive results and is also 
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very specic. However, it only allows sequencing of a (fraction of) gene in each 
reaction, rendering the process extremely expensive and time consuming. Recent 
advances in sequencing technologies, particularly massive parallel sequencing, 
oen termed next-generation sequencing (NGS), provide possibilities to screen a 
handful of genes in a single reaction or even to examine the whole genome of an 
individual. 
A targeted approach can be used to investigate the genetic cause of diseases for 
which there is a strong causative association with a gene or multiple genes. e 
use of NGS technology provides information of how many molecules have been 
sequenced (also termed number of reads), which allows one to determine the 
precise percentage of the detected variant. It provides high sensitivity, especially 
in a single gene approach, allowing the detection of low-grade mosaicisms (i.e. a 
genetic defect that is only present in some cells of an individual) which oen is 
not detected by Sanger sequencing. e possibility to sequence a panel of genes 
in a single step provides ecient and rapid identication of genetic defects in a 
genetically heterogenous disorder [93]. 
Hypothesis-free approaches, such as whole exome sequencing (WES) and whole 
genome sequencing (WGS), are applied in investigating the genetic cause of 
diseases for which there is no clear causative gene(s) as well as in nding novel 
causative genes. In WES, all protein coding regions (~1% of human genome) 
are analysed, whereas WGS targets the whole human genome. WES has been 
successfully applied to identify genetic cause in multiple diseases. It is particularly 
useful in highly heterogeneous diseases for which there are a large number of 
candidate genes. e technological development and a continuous decrease in 
sequencing costs have allowed more and more application of WGS, especially in 
nding genetic variant(s) that are not located in the coding regions. Nonetheless, 
both WES and WGS generate vast amounts of data which are oen challenging in 
terms of storage as well as analysis and interpretation. Furthermore, one should 
note that these techniques may generate incidental ndings, such as pathogenic 
or possibly pathogenic variant(s), that are not relevant to the clinical features for 
which the analysis was initially performed [93, 94]. 
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1.5.2  Characterization of gene expression regulation
the advances in sequencing technologies not only revolutionized the identication 
of genetic variants, but also enabled the study of dierent aspects of gene regulation 
at a genome-wide level. Various high-throughput techniques have been applied on 
dierent cell types and tissues to gain insight in the gene regulation networks. Two 
techniques that are relevant for the scope of this thesis will be discussed here.
Chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-
Seq) is a technique utilized to identify DNA binding sequences of transcription 
factors as well as histone modications. In a ChIP experiment, proteins are 
crosslinked to DNA by formaldehyde treatment, followed by chromatin shearing 
by means of sonication. Subsequently, an antibody specic to the protein of interest 
is used to precipitate the DNA-protein complex aer which the crosslinks are 
reversed to allow analysis of the DNA sequences bound to the protein of interest by 
high-throughput sequencing. Subsequent analysis of the obtained sequence then 
allows one to determine the genome-wide distribution of histone modications or 
transcription factors investigated in the study [95, 96]. 
e identication of DNA binding sequences of a transcription factor or histone 
modication does not provide information of its impact to gene expression. 
erefore, such experiments should be complemented with gene expression 
measurements at the RNA level to gain further knowledge in gene expression 
regulation, especially in determining the function of a transcription factor or 
histone modication [97]. High-throughput RNA sequencing (RNA-Seq) enables 
the identication and quantication of genome-wide gene expression in a given 
cell type/tissue under certain conditions. RNA isolated from the sample of interest 
is fragmented and reverse-transcribed into complementary DNA (cDNA). 
Subsequently, cDNA is amplied and subjected to high-throughput sequencing. 
e obtained sequences can be mapped to reference transcriptome or used 
in de novo transcript assembly prior to subsequent analysis such as dierential 
expression analysis, splicing analysis, etc [94]. 
1.5.3  Generation of animal models by genetic modification
e animal models used to study genetic diseases, such as inherited retinal diseases, 
may develop their phenotype as the result of a naturally occurring mutation or 
due to genetic modication. Both forward and reverse genetic screens have been 
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used to generate animal models. In forward genetic screens, lots of dierent loci 
are mutated simultaneously, allowing the generation of many dierent mutant 
animals. e mutation can be introduced by using mutagenic chemicals (e.g. 
N-Ethyl-N-nitrosourea (ENU)) or by viral-mediated DNA insertion. However, 
due to the high number of animals to be screened, this method may be costly and 
labor intensive. Conversely, in reverse genetic screens, specic modications can 
be introduced to a region of interest. Homologous recombination is one of the 
methods used to introduce specic modication. DNA double-strand breaks have 
been induced using nucleases, such as zinc nger nuclease (ZFN) or transcription 
activator-like eector nucleases (TALENs). Following cleavage, cellular non-
homologous end-joining (NHEJ) repair mechanisms will join the DNA ends, 
a process in which insertion and/or deletions may be introduced. If a donor 
template DNA is provided, the repair mechanisms can also be directed towards 
homologous recombination (reviewed in [98]). 
In the last few years, a new tool that uses similar principles as ZFN and TALENs, 
but with higher eciency, has become available. Clustered regulatory interspaced 
short palindromic repeat (CRISPR)-associated protein 9 (Cas9) originates from 
bacteria, specically Streptococcus pyogenes. A short RNA sequence (guide RNA/ 
gRNA) guides Cas9 to the target sequence, where it induces DNA double-strand 
breaks. Similar to ZFN and TALENs systems, both NHEJ and homology-directed 
repair (HDR) can be used to repair the cleavage [99]. Following its original 
application to cut DNA at various sites in vitro in 2012 [100], this system has been 
applied in genetic modication of a variety of cell types and organisms [99].
1.6 ZNF408 - What do we know about it?
In the following chapters in this thesis, the topic will mainly be around a single 
gene, ZNF408. Initially, a mutation (p.His455Tyr) in ZNF408 was reported in 
an autosomal dominant FEVR family by Collin et al. (2013) [45]. ZNF408 is 
ubiquitously expressed with highest expression in the retina. Subcellular localization 
showed that wild-type ZNF408 resides in the nucleus, whereas the p.His455Tyr 
mutant ZNF408 is mislocalized in the cytoplasm. Co-transfection of wild-type 
and mutant ZNF408 resulted in mislocalization to the cytoplasm, suggesting a 
dominant negative mode of action. Morpholino-induced knockdown of znf408 
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in zebrash led to abnormal development of eye and trunk vasculature [45]. 
Following these ndings, several other groups also reported ZNF408 mutations in 
FEVR [101-104]. Intriguingly, mutations in ZNF408 have also been identied in 
patients with retinitis pigmentosa, an inherited retinal disorder which is caused by 
photoreceptor degeneration [55, 105, 106]. Immunostaining showed that ZNF408 
is expressed in the retinal vasculature as well as the photoreceptor layer of human 
retina [55]. ZNF408 mutations reported in both FEVR and retinitis pigmentosa 
are spread throughout the gene without a clear correlation between the positions 
of the mutation with the resulting phenotype. How dierent mutations in ZNF408 
result in dierent clinical features is currently unclear. 
ZNF408 has ve exons and the encoded protein belongs to the PRDM (positive 
regulatory domain I-binding factor 1/PRDI-BF1 and retinoblastoma-interacting 
zinc nger protein 1/RIZ1 homology domain containing) family. Members 
of this family have been described to be highly cell-type and tissue-specic 
transcriptional regulators using either enzymatic activity towards histones or by 
recruitment of interaction partners to modify the expression of target genes. is 
protein family is characterized by an N-terminal PR domain and multiple zinc 
nger domains. e PR domain is a subfamily of SET methyltransferase, although 
enzymatic activity was only found in a few PRDM proteins [107, 108]. Zinc nger 
domains refer to a small peptide domain whose secondary structure is stabilized 
by a zinc ion bound to the cysteine and histidine residues of the nger. Such a 
domain is generally known to be involved in DNA binding, although RNA and 
protein binding have also been described [109, 110]. ZNF408 is predicted to have 
10 zinc nger domains, each of which consists of two histidine and two cysteine 
residues [45]. 
Although the ndings so far suggest an involvement of ZNF408 in the development 
of retinal vasculature as well as in photoreceptor degeneration, its molecular role 
is currently unknown. As a member of the PRDM family, it potentially acts as a 
transcriptional regulator in those processes. Investigation of the molecular role 
of ZNF408, particularly in the development of retinal vasculature as well as the 
pathogenesis of FEVR, will be described in the following chapters of this thesis. 
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1.7 Aim of the thesis
e main aim of this thesis is to elucidate the role of ZNF408 in the regulation of 
(retinal) vasculature development. Both in vitro and in vivo models were used to 
study the function of ZNF408 and how its defect leads to FEVR.
Chapter 1 provides the background information on the retina structure, 
development of retinal vasculature, the clinical and genetic features of FEVR as 
well as relevant models and technologies.
Chapter 2 presents an in vitro study on the role of ZNF408 in regulating gene 
expression and how the p.His455Tyr mutation aects its function. Transcriptome 
proling showed that ZNF408 regulates the expression of genes relevant to the 
development of vasculature, which are altered by the mutation. 
Chapter 3 describes the generation of zebrash models of ZNF408. A knock-in 
model mimicking the mutation in FEVR patients as well as knock-out models 
were generated using CRISPR-Cas9 technology. e zebrash models showed 
abnormal development of retinal vasculature, mimicking the clinical features of 
FEVR.
Chapter 4 presents a preliminary study of the reduced penetrance of ZNF408 -
-associated FEVR. Fibroblasts, derived from an FEVR patient and an unaected 
mutation carrier, were reprogrammed into iPSCs and subsequently dierentiated 
into endothelial cells. e pilot study showed the possibility to generate patient-
specic endothelial cells to study reduced penetrance in FEVR.
Chapter 5 reports the nding of a novel KIF11 mutation in a patient presenting 
FEVR and microcephaly. Deep sequencing revealed that the mutation is inherited 
from the mother who is mosaic for the mutation.
Chapter 6 and 7 provide the general discussion and summary.
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Abstract
Familial exudative vitreoretinopathy (FEVR) is an inherited retinal disorder 
hallmarked by an abnormal development of retinal vasculature. A missense 
mutation in ZNF408 (p.His455Tyr) was reported to underlie autosomal dominant 
FEVR in a large Dutch family, and ZNF408 was shown to play a role in the 
development of vasculature. Nonetheless, little is known about the molecular 
mechanism of ZNF408-associated FEVR. To investigate this, an in vitro model 
of ZNF408-associated FEVR was generated by overexpressing wild-type and 
p.His455Tyr ZNF408 in Human Umbilical Vein Endothelial Cells (HUVEC). 
Cells overexpressing mutant ZNF408 were unable to form a capillary-like network 
in in vitro tube formation assay, thereby mimicking the clinical feature observed in 
FEVR patients. Intriguingly, transcriptome analysis revealed that genes involved 
in the development of vasculature were deregulated by the p.His455Tyr mutation. 
Chromatin immunoprecipitation (ChIP) showed that p.His455Tyr ZNF408 has 
reduced DNA-binding ability, as compared to the wild-type protein. e fact 
that the p.His455Tyr mutation disrupts the expression of genes important for the 
development of vasculature, sheds further light on the molecular mechanisms 
underlying ZNF408-associated FEVR.
7-5 Dyah Karjosukarso.indd   48 17-05-19   12:18
A mutation in ZNF408 deregulates genes expression
49
2
2.1 Introduction
Familial exudative vitreoretinopathy (FEVR, MIM 133780) is an inherited retinal 
disorder that was rst described by Criswick and Schepens [1]. It is primarily 
characterized by abnormal and incomplete vascularisation of the peripheral 
retina [2-4]. us far, mutations in NDP [5], FZD4 [6, 7], TSPAN12 [8], LRP5 [6, 
9], ZNF408 [10], ATOH7 [11], RCBTB1 [12], and CTNNB1 [13, 14] have been 
reported in FEVR cases. Besides those of ZNF408, ATOH7, and RCBTB1, the 
proteins encoded by FEVR genes are involved in the Norrin/β-catenin signaling 
pathway [15]. Next to the genetic heterogeneity, various clinical manifestations 
can be observed in FEVR, ranging from asymptomatic to complete blindness [16]. 
We previously discovered a mutation in ZNF408 (c.1363C>T, p.His455Tyr, 
NM_024741.2) that segregates in a large autosomal dominant FEVR family 
[10]. e protein encoded by ZNF408 belongs to the PRDM (positive regulatory 
domain I-binding factor 1/PRD1-BF1 and retinoblastoma-interacting zinc nger 
protein 1/RIZ1 homology domain containing) family [17]. Members of this family 
typically have an N-terminal PR domain and multiple zinc nger domains. e 
PR domain belongs to a subfamily of SET methyltransferase domains, whereas 
zinc nger domains are generally involved in DNA binding and protein-protein 
interactions [17, 18]. ZNF408 is predicted to harbor ten zinc nger domains, each 
of which consists of two histidine and two cysteine residues. e p.His455Tyr 
mutation changes a histidine in the fourth zinc nger domain into a tyrosine 
[10]. We demonstrated that the mutant protein is mislocalised in the cell and 
knockdown of znf408 in zebrash resulted in abnormal development of eye 
and trunk vasculature [10]. ese data support the causality of the mutation 
and implicate an important role of ZNF408 in the development of vasculature. 
Nonetheless, very little is known about the exact molecular function of ZNF408. 
To unravel the role of ZNF408 in the development of vasculature and to assess their 
angiogenic ability, in vitro tube formation assays were performed on endothelial 
cells overexpressing wild-type or mutant p.His455Tyr ZNF408. ese cells were 
also subjected to transcriptome analysis to identify genes regulated by ZNF408, 
as well as the eect of the mutation on gene expression. Furthermore, chromatin 
immunoprecipitation followed by high-throughput sequencing (ChIP-Seq was 
employed to reveal the binding sites of ZNF408 in the human genome. Our 
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data suggest that ZNF408 indirectly regulates the expression of genes important 
for the development of vasculature, and that this regulation is disrupted by the 
p.His455Tyr mutation.
2.2 Materials and Methods
2.2.1 Cell culture
Human umbilical vein endothelial cells (HUVEC, a kind gi from Dr. William 
Leenders) were cultured in Endothelial Growth Medium 2 (EGM2, Promocell) 
supplemented with 1% penicillin/streptomycin or other required antibiotics. 
Culture dishes were coated with 0.01 mg/ml bovine bronectin (Promocell) for 
at least 1 h at 37°C before use for HUVEC culture. HEK293T cells (ATCC) were 
cultured in DMEM (Sigma) supplemented with 10% FCS, 1% sodium pyruvate 
and 1% penicillin/streptomycin. HUVEC and HEK293T cells were maintained at 
37°C and 5% CO2.
2.2.2  Lentivirus production
To generate lentiviral constructs that enable inducible expression of N-terminally 
HA-tagged ZNF408, the 2K7bsd  lentivirus vector [19] was used. A tetracycline 
inducible promoter was cloned into the pDONR-P4P1R entry clone, whereas full-
length human ZNF408 cDNA (wild-type and p.His455Tyr mutant) fused with 
sequence encoding HA-tag were cloned into the pDONR201 entry clone. LR Clonase 
II Plus enzyme mix (ermo Fisher Scientic) was used to insert the promoter and 
fusion gene into the 2K7bsd lentiviral vector. To produce lentivirus particles, 5 µg of 
2K7bsd_Tet_HA-ZNF408 construct was co-transfected with 3.2 µg psPAX2 and 1.8 
µg pMD2.G into HEK293T cells using CaPO4 (nal concentration of 250 mM CaCl2, 
0.5 mM Tris pH 7.5, EDTA, 25 mM HEPES-NaOH pH 7.3, 280 mM NaCl, 1.5 mM 
NaPO4) transfection method. Medium was refreshed 8 hours post-transfection 
and the supernatant containing lentivirus particles were collected 48 hours post-
transfection. Lentiviral particles of tetracycline-controlled transcriptional activator 
(rtTA, pLVX-EtO) were produced following similar procedures. 
2.2.3  Stable cells generation
HUVEC were seeded on 12-well plate with 2.5 x 105 cells/well density. Aer 6-8 
hours, they were transduced with supernatant containing lentiviral particles of 
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2K7bsd_Tet_HA-ZNF408 and rtTA with 1:1 ratio overnight. e following day, the 
medium was changed to EGM2 without selection antibiotics. Ninety-six hours 
post-transduction, 4 µg/ml blasticidin (Sigma) and 1000 µg/ml G418 (Sigma) were 
added to EGM2 to select for positively transduced cells. e selection medium was 
applied every 48 hours for 6 days. e obtained stable cells were further cultured 
in medium containing 25% of the antibiotics dose used for selection. 
2.2.4  Stable cells validation
e stable cells were validated for the integration of 2K7bsd_Tet_HA-ZNF408 (wild-
type and p.His455Tyr mutant) and rtTA constructs at the genomic DNA level. 
DNA was isolated from cell pellet using DNeasy Blood and Tissue kit (Qiagen) 
following manufacturer’s instructions. Twenty nanograms DNA was used as 
template for amplication. e expression of HA-ZNF408 was examined at RNA 
and protein level. Total RNA was isolated using Macherey-Nagel RNA isolation 
kit according to the kit manual. iScript kit (Bio-Rad) was used to synthesise cDNA 
from 250 ng RNA. Subsequently, GoTaq Green Master Mix (Promega) was used 
in the quantitative (qPCR) PCR reaction. Primers used in the genomic DNA 
amplication and qPCR are listed in Table S1. Western blot analysis was performed 
to check the expression at protein level. Mouse anti-HA (Sigma, 1:1,000) and rabbit 
anti-ZNF408 (Biorbyt, 1:500) was used to detect the expression of HA-ZNF408 at 
the protein level. Tubulin was stained as loading control using mouse anti-tubulin 
(Abcam, 1:2,000). Donkey anti-mouse IRDye 680 RD and donkey anti-rabbit 800 
CW (LI-COR, 1:20,000) were used as secondary antibodies. e blot was scanned 
on LI-COR Odyssey CLx system. 
2.2.5 In vitro tube formation assay
Non-transduced HUVEC as well as stable HUVEC were seeded at the density 
of 1.5 x 105 cells in 12-well plate format. Forty-eight hours post-seeding, the 
overexpression of wild-type and p.His455Tyr ZNF408 was induced by doxycycline 
treatment (100 ng/ml and 500 ng/ml, respectively) for 48 hours. e cells were then 
trypsinised and seeded on 96-well plate coated with Matrigel (BD Biosciences) at 
the density of 1.5 x 104 cell per well. Aer 20 hours, the cells were stained with 
Calcein Red (ermo Scientic) at a 6 µM nal concentration, followed by imaging 
on EVOS cell imaging station. 
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2.2.6  RNA-Seq
Non-transduced HUVEC as well as the stable HUVECs were seeded in duplicate 
at a density of 2.5 x 105 cells in 6-well plate format. Overexpression of wild-type 
and p.His455Tyr ZNF408 was induced in similar manner as mentioned previously. 
e cells were harvested for total RNA isolation using Macherey-Nagel RNA 
isolation kit, following manufacturer’s instructions. Ribo-Zero rRNA removal 
kit (Illumina) was used to eliminate rRNA from the sample. RNA fragmentation 
was performed as well as rst and second strand cDNA synthesis as described in 
[20], with the deviation that RNA fragmentation was performed for 3 minutes at 
95°C instead of 1.5 minutes. e obtained cDNA was used for next generation 
sequencing on Illumina NextSeq 500 platform. 
2.2.7  RNA-Seq data analysis
Sequence reads were mapped to the human genome (build hg19) using the 
STAR algorithm [21]. Number of reads per gene were counted using HTseq [22] 
followed by dierential gene expression analysis using DESeq2 package [23]. e 
cuto used to determine a signicant dierence in gene expression was set at a 
Benjamini-Hochberg adjusted p-value of <0.05 and a fold-change of ≥1.5. e 
FPKM of dierentially expressed genes was calculated using Cudi [24]. GO-
terms enrichment analysis was performed on the lists of dierentially expressed 
genes by DAVID with default settings [25, 26]. e list of enriched GO-terms was 
summarized using REVIGO, with the settings: small list (allowed similarity = 0.5), 
Homo sapiens database, and SimRel for semantic similarity measure [27].  
2.2.8  Real-time quantitative PCR
Some of the dierentially regulated genes detected in the RNA-Seq data were 
validated by means of real-time quantitative PCR (qPCR) using GoTaq Green 
Master Mix (Promega). qPCR was performed on three biological replicates and 
Student’s t-test was used to determine signicance dierence. e primers used 
for this are listed in Table S1. 
2.2.9 ChIP-Seq
Full-length human wild-type and p.His455Tyr mutant ZNF408 cDNA were cloned 
into pcDNA3-HA vector, to generate a construct encoding ZNF408 with the HA-
tag at the N-terminus. ese constructs were transiently transfected into HEK293T 
cells cultured in 15-cm dishes using Fugene HD reagent (Promega). Forty-eight 
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hours post-transfection, the cells were crosslinked using 1% formaldehyde at room 
temperature for 10 minutes. e crosslinking was stopped with 0.125 M glycine 
and the nuclear fraction was harvested as described in Denissov, et al., 2007 [28]. 
DNA was fragmented by sonication using Bioruptor (Diagenode). e settings 
of the sonication were high power, 16 cycles of 30 seconds ON and 30 seconds 
OFF. In each immunoprecipitation reaction, 100 µl sonicated nuclear lysate, 30 
µl ProtA/G beads (Santa Cruz), and 1-2 µg antibody was used. e antibodies 
used for chromatin immunoprecipitation were mouse monoclonal anti-HA 
(1 µg per reaction, Sigma) and rabbit polyclonal anti-ZNF408 (2 µg per reaction, 
Biorbyt). Immunoprecipitation reactions were incubated at 4°C overnight. 
Immunoprecipitated DNA was puried by phenol/chloroform extraction. Next 
generation sequencing was performed on Illumina HiSeq 2000 using 5 ng of the 
immunoprecipitated DNA.
2.2.10 ChIP-Seq Data Analysis
e sequence reads were uniquely mapped to the human genome build hg19 using 
bwa algorithm [29]. Peak calling was performed using MACS2 [30] with default 
settings and a p-value threshold of 1E-05. Data from non-transfected HEK293T 
cells were used as control le. e functional signicance of the detected peaks 
were assessed using GREAT with basal plus extension settings [31]. e list of 
enriched GO-terms was summarized using REVIGO, with the settings: small 
list (allowed similarity = 0.5), Homo sapiens database, and SimRel for semantic 
similarity measure [27].
2.2.11  Transactivation assay
Putative ZNF408 binding sites on the human genome were amplied and 
subsequently cloned into Gateway adapted pGL3-Enhancer vector. e constructs 
were co-transfected with pcDNA3-HA, pcDNA3-HA-ZNF408 wild-type, or 
pcDNA3-HA-ZNF408 p.His455Tyr vector into HEK293T cells using Fugene HD 
transfection reagent (Promega). e transfection was performed in triplicates 
on 24-well format. Forty-eight hours aer transfection, the cells were lysed and 
luciferase expression was measured using Dual Luciferase Assay kit (Promega) 
following the manufacturer’s instructions. Luciferase measurement was performed 
in duplicate using 5 µl of cell lysate. Student’s t-test was performed to test for 
signicant dierences between wild-type and mutant.
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2.2.12 Statistical analysis
Statistical tests used in the data analysis of the dierent experiments are described 
in detail in the sections that belongs to the corresponding experiments.
2.3  Results
2.3.1 Overexpression of ZNF408 p.His455Tyr prevents HUVEC from forming 
capillary-like structures 
To study the role of ZNF408, particularly in the development of vasculature, a 
cellular model for ZNF408-associated FEVR was established. A widely used 
endothelial cell system, Human Umbilical Vein Endothelial Cells (HUVEC), was 
transduced with lentiviral particles that contain constructs encoding HA-tagged 
wild-type or p.His455Tyr ZNF408. ese transgenes were stably integrated into 
the HUVEC genome, and allowed inducible overexpression of wild-type and 
p.His455Tyr ZNF408 (Figure 1a and b). e integration of ZNF408 wild-type 
and p.His455Tyr was conrmed at the genomic DNA level (Figure S1a), and their 
overexpression was validated both at the transcript and protein levels (Figure S1b 
and S1c). e phenotype of these cellular models was assessed by in vitro tube 
formation assay, which is commonly used to examine the angiogenic ability of 
endothelial cells [32]. Unlike overexpression of wild-type ZNF408, which did not 
interfere with the formation of capillary-like structures in this assay, overexpression 
of ZNF408 p.His455Tyr clearly inhibited the formation of these structures (Figure 
1c). is result showed that the in vitro models mimic the abnormal vasculature 
development observed in FEVR patients, demonstrating their suitability to study 
the role of ZNF408 in this process.
2.3.2 Overexpression of ZNF408 p.His455Tyr alters the expression of genes 
involved in development of vasculature
Next, we performed transcriptome analysis of the generated cells to study the 
underlying molecular mechanisms of the observed phenotype. Two biological 
replicates of each experimental condition, non-transduced HUVEC (NT), HUVEC 
overexpressing wild-type ZNF408 (WT), and HUVEC overexpressing p.His455Tyr 
ZNF408 (MUT), were included. e biological replicates clustered together in the 
principal component analysis (PCA), demonstrating their similarities. Notably, 
the three dierent conditions were separated from each other in PCA (Figure 
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1d), indicating their distinct gene expression proles. Furthermore, NT and MUT 
were located on the same end of PC2 axis, in contrast to WT that was located on 
the other end of PC2. e distinct gene expression proles observed are consistent 
with the heatmap of gene expression in the three experimental conditions (Figure 
S1d). Subsequently, dierential expressed genes between the conditions were 
determined. In this analysis, three pairwise comparisons were made, namely 
a comparison of WT vs MUT (Dataset S1, Figure 1e), NT vs WT (Dataset S2, 
Figure 1f), as well as NT vs MUT (Dataset S3, Figure S1e). Gene ontology (GO) 
analysis was performed to investigate the biological processes associated with 
the dierentially regulated genes. e terms nucleosome assembly and protein 
heterotetramerization were enriched for genes upregulated by WT (Figure 1f), 
as compared to NT. e genes associated with these two terms mainly encode for 
histone H1 and H2. For the genes downregulated by WT, the terms cell adhesion 
and response to hypoxia were enriched (Figure 1f), and included ITGA4, CTGF, 
COL8A1, and VCAM1, or MMP2, ANGPT2, TGFB2, and VCAM1, respectively. 
Interestingly, the GO terms enriched for the genes dierentially upregulated by 
WT as compared to NT, were rather similar to those downregulated by MUT 
as compared to WT, and vice versa (Figure 1e and 1f). ese ndings indicate 
that many genes that were up-/downregulated by wildtype ZNF408 can be de-
regulated due to the p.His455Tyr mutation, suggesting that MUT can disrupt the 
regulation of gene expression which is controlled by WT.
To further focus on the mechanisms that are disrupted by MUT, we focused on 
genes whose expression is deregulated by MUT. In total, there were 122 genes that 
were exclusively upregulated by WT as compared to NT, but downregulated by 
MUT as compared to WT (WT > MUT, Table S2, Figure 2a and 2c), while there 
were 102 genes that were uniquely downregulated by WT as compared to NT, but 
upregulated by MUT as compared to WT (WT < MUT, Table S3, Figure 2b and 
2d). Some of these genes were regulated in opposite direction by WT and MUT. 
For instance, HIST1H1D and HIST1H3C were upregulated by WT as compared 
to NT, but downregulated by MUT as compared to NT. Another example is 
VCAM1, which is downregulated by WT as compared to NT, but upregulated by 
MUT as compared to NT. Consistently, these deregulated genes were similar to 
the genes that mark the dierence on the PC2 axis in the PCA analysis (Table 
S4), further highlighting the fact that MUT can disrupt the regulation of these 
genes. e GO terms enriched for these genes were similar to those enriched 
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in the pairwise comparisons. For instance, nucleosome assembly and protein 
heterotetramerisation, which are relevant to chromatin organization and 
remodeling, were enriched for genes upregulated by WT (Figure 2e). Likewise, 
terms relevant to the development of vasculature were again enriched for genes 
downregulated by WT. Besides response to hypoxia and cell adhesion, the term 
angiogenesis was also enriched in this set of genes (Figure 2f), and included CTGF, 
COL8A1, ANGPT2, MMP2, FN1 and TGFB2. ese data provide novel insights 
into the function of ZNF408, probably in chromatin organization and remodeling, 
and also conrm our previous ndings of its role in vasculature development.
Given the fact that ZNF408 is mutated in FEVR, we further focused on genes 
that are relevant to vasculature development. Quantitative PCR (qPCR) was 
performed to conrm the expression pattern of 15 genes known to be associated 
with vasculature development including HMOX1, CTGF, ITGA4, ANGPT2, and 
MMP2 (Figure S2). e dierence in expression level between WT and MUT was 
validated for all of them, demonstrating the reliability of the RNA-Seq data. 
2.3.3 ZNF408 p.His455Tyr has reduced DNA-binding ability
e data obtained from the transcriptome analysis indicate a regulatory role 
for ZNF408 in the development of vasculature. Due to the presence of ten zinc 
nger domains in ZNF408, we hypothesized that this protein regulates gene 
expression by binding to regulatory genomic regions. erefore, a chromatin 
immunoprecipitation followed by high-throughput sequencing (ChIP-Seq 
experiment was performed. HEK293T cells were transfected with HA-tagged 
wild-type and p.His455Tyr mutant ZNF408 and the immunoprecipitation was 
performed using antibodies targeting either the HA-tag or the ZNF408 protein 
(Figure 3a). ere were 1,548 and 3,074 binding sites detected for wild-type 
ZNF408, while there were only 56 and 58 binding sites detected for p.His455Tyr 
ZNF408 in the HA-ChIP and ZNF408-ChIP, respectively. e overlapping 
binding sites between HA-ChIP and ZNF408-ChIP were considered the most 
reliable, which were 730 for wild-type ZNF408 and 10 for p.His455Tyr ZNF408. 
Interestingly, these results showed that p.His455Tyr ZNF408 has remarkably less 
binding sites compared to wild-type ZNF408 (Figure 3b), examples of which are 
shown for ANXA5, GPR180, and LZTS2 (Figure S3a). To validate the ChIP-Seq 
results, the identied regulatory regions were cloned upstream of the luciferase 
sequence in the pGL3-Enhancer vector. e overexpression of these constructs, 
together with constructs encoding wild-type or p.His455Tyr ZNF408, showed 
7-5 Dyah Karjosukarso.indd   56 17-05-19   12:18
A mutation in ZNF408 deregulates genes expression
57
2
activation of luciferase gene transcription by wild-type ZNF408, but not by 
p.His455Tyr ZNF408 (Figure S3b), thereby conrming the reduced DNA-binding 
ability of p.His455Tyr that was observed in the ChIP-Seq experiment. 
Figure 1. Overexpression of ZNF408 p.His455Tyr (p.H455Y) resulted in absence of capillary-like 
structures in tube-formation assay and disrupts the normal gene expression regulated by wild-type 
ZNF408. A) Lentiviral constructs for wild-type and p.His455Tyr mutant ZNF408 overexpression. LTR: long 
terminal repeats, Tet: tetracycline-inducible promoter, WPRE: woodchuck hepatitis virus post-
transcriptional regulatory element, SV40: Simian virus 40, BSD: blasticidin resistance gene. B) Schematic 
illustration of the experimental setup. NT: non-transduced HUVEC, WT: HUVEC transduced with wild-
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type ZNF408, and MUT: HUVEC transduced with mutant ZNF408. ZNF408 overexpression was induced 
by doxycycline. C) Fluorescent images of the capillary-like structures formed by NT and WT cells, but not 
MUT cells in an in vitro tube formation assay. Scale bars = 1000 µm. D) Principal component analysis of the 
transcriptome data. Two biological replicates were analysed in each condition. E) and F) MA-plot of the 
dierential expression analysis, comparing WT to MUT and WT to NT, respectively. Red dots represent 
genes dierentially expressed between conditions, black dots represent no dierence in expression. e 
number of genes with signicant dierence in expression is depicted on the corner of the plot. e top 10 
biological process GO-terms associated to genes belonging to the upper and lower panel of the MA-plot are 
depicted above and below the MA-plot, respectively. e p-values were adjusted using the Benjamini-
Hochberg method. 
Figure 2. p.His455Tyr ZNF408 deregulates the expression of some genes. A) Venn diagrams showing the 
overlap of genes that are exclusively upregulated  in WT compared to NT (WT > NT) and downregulated in 
MUT compared to WT (WT > MUT) and B) Venn diagrams showing the overlap of genes that are exclusively 
downregulated in WT compared to NT (WT < NT) and upregulated in MUT compared to WT (WT < 
MUT). C) and D) Heatmap of the expression of these genes described in (A) and (B), respectively. e 
z-score was calculated based on the FPKM values of these genes. E) and F) e enriched biological process 
GO-terms for the genes described in (A) and (B), respectively. e p-values were adjusted using the 
Benjamini-Hochberg method.
e binding sites of wild-type ZNF408 were predominantly located around 
the transcription start site (Figure 3c) and associated with 778 genes (Dataset 
S4). Gene ontology analysis showed that these genes are involved in diverse 
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biological processes, such as nucleosome assembly, regulation of gene expression, 
megakaryocyte dierentiation, and protein processing (Figure 3d).  Despite the 
clear loss of binding demonstrated by p.His455Tyr ZNF408, only 15 of these 
genes are dierentially regulated by wild-type and p.His455Tyr ZNF408 in 
HUVEC (Table S5). Two of these 15 genes, HMOX1 and ITGA4, are involved in 
biological processes relevant to the development of vasculature. Intriguingly, gene 
expression analysis showed that wild-type ZNF408 upregulated the expression of 
HMOX1 while downregulating that of ITGA4, processes that were reversed by the 
p.His455Tyr mutation (Figure S2). ZNF408 binds to a region around 8 kb upstream 
the transcription start site (TSS) of HMOX1, whereas it binds approximately 350 
bp downstream of the TSS in ITGA4 (Figure S4a and S4b). Cloning of these regions 
upstream of luciferase sequence followed by transactivation assay in HEK293T 
cells validated direct binding of wild-type ZNF408 to the ITGA4 TSS (Figure S4c 
and S4d). 
Figure 3. ZNF408 p.His455Tyr has reduced DNA-binding ability. A) Schematic illustration of the 
experimental setup. NT: non-transduced HEK293T, WT: HEK293T transfected with wild-type ZNF408, 
and MUT: HEK293T transfected with mutant ZNF408. B) Number of peaks detected in ChIP using HA 
antibody, ZNF408 antibody and the overlap of both. C) e distance of the overlapping peaks to transcription 
start site (TSS). D) e top 10 biological process GO-terms of genes associated with ZNF408 binding sites. 
e p-values are adjusted with false discovery rate (FDR) method. 
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2.4 Discussion
In this study, the role of ZNF408 in the development of vasculature was investigated. 
An in vitro model of ZNF408-associated FEVR was generated by overexpressing 
wild-type or p.His455Tyr mutant ZNF408 in HUVEC. e overexpression of 
p.His455Tyr ZNF408 disrupted the ability of HUVEC to form a capillary-like 
network in vitro, which mimics the aberrant retinal vasculature development 
observed in FEVR patients. Transcriptome analyses of the cellular models 
showed that the mutation altered the normal gene expression regulated by wild-
type ZNF408, which may underlie the observed cellular phenotype. Chromatin 
immunoprecipitation in HEK293T cells showed that the p.His455Tyr mutation 
reduced the DNA-binding ability of mutant ZNF408. 
e results obtained in this study suggest a role of ZNF408 in various biological 
processes. Nucleosome assembly and protein heterotetramerization are two terms 
that were highly enriched for genes upregulated by wild-type ZNF408. e genes 
associated with these terms are mainly encoding for histones H1 and H2, implying 
a role for ZNF408 in chromatin remodeling. Interestingly, the term nucleosome 
assembly was also highly enriched for the genes identied in the ChIP-Seq 
experiment and is mainly associated with genes encoding histone H1, H2, and 
H3. Although little overlap was observed between genes identied by ChIP-Seq 
and the transcriptome analysis, our results suggest the involvement of ZNF408 
in chromatin remodeling, which may directly or indirectly contribute to the 
observed vascular phenotype. 
Response to hypoxia, cell adhesion, and most importantly angiogenesis are 
processes that are directly relevant to the development of vasculature. Genes related 
to these terms were downregulated by wild-type ZNF408, which was deregulated 
by p.His455Tyr ZNF408. Given that the overexpression of wild-type ZNF408 
did not inhibit in vitro tube formation, we hypothesize that wild-type ZNF408 
promotes the vasculature development by downregulating genes inhibiting 
angiogenesis, explaining why reversal of this process by p.His455Tyr ZNF408 led 
to a disruption of in vitro tube formation. Indeed, based on literature, some of the 
genes associated with these terms (e.g. CTGF and ANGPT2), are proposed to act 
as angiogenesis inhibitors in some circumstances [33, 34].  
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Hypoxia has been widely described as one of the inducers of angiogenesis, 
including in the retina [35]. Hypoxic retinal astrocytes in avascular areas express 
the vascular endothelial growth factor (VEGF) and can direct endothelial cells to 
a specic site to form a vascular network [36, 37]. e downregulation of genes 
associated to a response to hypoxia by ZNF408 implies a role for this protein in 
regulating this response, albeit via an unknown mechanism. e de-regulation 
of these genes by p.His455Tyr ZNF408 suggests a prevention of compensatory 
hypoxia-induced angiogenesis in FEVR patients, despite the presence of an 
avascular peripheral retina that would normally induce hypoxia.
Since ZNF408 is predicted to have ten zinc nger domains, we hypothesized 
that it regulates gene expression by binding to genomic regulatory regions and 
therefore, performed ChIP-Seq experiment to determine ZNF408 binding sites. 
Relatively a small number of peaks were detected in the ChIP-Seq experiment. 
is, together with the dierence in cellular systems used - HEK293T in ChIP-Seq 
experiment and HUVEC in transcriptome analysis -  may contribute to the little 
overlap with the dierentially expressed genes. e small number of peaks also 
suggests that ZNF408 does not bind directly to DNA to regulate gene expression. 
Despite DNA binding being the primary role of many zinc nger domains, 
binding activity to other ligands such as RNA and protein have been described 
as well [38, 39]. Moreover, ZNF408 belongs to the PRDM family. Although some 
members of this family have been shown to bind DNA directly, other members of 
the family are known to regulate gene expression either by acting as direct histone 
methyltransferase or by recruiting other histone modifying enzymes. PRDM 
family proteins have also been shown to bind to transcription factors to target 
gene promoters or to act as non-DNA binding cofactors [17, 18]. ese not only 
further suggest the role of ZNF408 in chromatin remodeling, but also support 
the hypothesis that ZNF408 acts in concert with other molecules to regulate gene 
expression instead of directly binding to its target genes. Further investigation on 
ZNF408 interacting partners will enable a more detailed understanding of the 
mechanism by which this protein regulates gene expression.
e data obtained in our ChIP-Seq experiment showed ZNF408 binding sites 
near two dierentially regulated genes which are relevant to the development of 
vasculature, namely HMOX1 and ITGA4. HMOX1 encodes for heme oxygenase 
1 (HO-1), which is an enzyme that catalyzes the conversion of heme into carbon 
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monoxide, free iron, and biliverdin. HO-1 has a dual role in the development of 
blood vessels, in which its activation is required in vascular endothelial growth 
factor (VEGF)-induced angiogenesis, while its inhibition promotes inammatory 
angiogenesis (reviewed in [40, 41]). Overexpression of wild-type ZNF408 in 
HUVEC resulted in an upregulation of HMOX1. Interestingly, overexpression of 
HMOX1 inhibits the expression of VCAM-1, a cell adhesion molecule that, together 
with its receptor α4 integrin (the protein encoded by ITGA4), mediates TNFα-
induced angiogenesis [40, 42]. Induction of VCAM-1 expression by TNFα during 
inammation triggers leukocyte migration through the cell junctions, which 
subsequently may lead to endothelial cell barrier breakdown [43, 44]. Blockade 
of α4 integrin has been shown to reduce leukocyte adhesion, and thereby prevent 
vascular leakage in a diabetic retinopathy model [45]. e overexpression of wild-
type ZNF408 also resulted in a downregulation of ITGA4, VCAM1, and of genes 
associated to leukocyte migration, whilst their expression was de-regulated by the 
p.His455Tyr mutation. is suggests an involvement of ZNF408 in protecting the 
endothelial cell barrier, thereby preventing vascular leakage. Additionally, binding 
of ZNF408 to the proximity of ITGA4, but not HMOX1, was further validated by a 
transactivation assay in HEK293T cells. is indicates that ZNF408 represses the 
expression of ITGA4 by binding directly to its TSS, whereas HMOX1 activation is 
more likely due to an indirect eect of ZNF408 overexpression. 
Mutations in ZNF408 have also been reported in retinitis pigmentosa (RP), 
another type of inherited visual impairment in which the patients suer from 
photoreceptor degeneration [46]. Immunohistochemistry revealed that ZNF408 
is expressed in both retinal vasculature as well as the photoreceptor layer of 
the human retina [46]. e hypothesis that ZNF408 works together with other 
molecules to regulate gene expression may contribute to distinct phenotypes that 
can result from dierent ZNF408 mutations. However, it remains unclear what 
determines the exact outcome of the dierent mutations, as those reported in both 
FEVR and RP are spread throughout the gene [10, 46-49], implying that there 
is not yet a clear correlation between the exact position of the mutation and the 
corresponding phenotype.
In summary, the results obtained in this study indicate that ZNF408 is involved 
in the regulation of genes involved in the development of vasculature as well 
as other biological processes. Our data also imply that ZNF408 mainly acts in 
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concert with other molecules to regulate gene expression. is process is clearly 
disrupted by the FEVR-associated p.His455Tyr mutation, leading to the observed 
cellular phenotype, and thereby increases our understanding on the molecular 
mechanisms underlying ZNF408-associated vitreoretinopathy. 
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Supplementary materials
Figure S1. Stable cells validation and the eect of wild-type and p.His455Tyr ZNF408 overexpression to 
global transcriptome. A) Validation of the generated stable cells at the genomic DNA level. e c.1363C>T 
(p.His455Tyr) mutation is highlighted in yellow on the chromatogram. e presence of both endogenous 
and exogenous ZNF408 results in a heterozygous peak. B) Measurement of ZNF408 overexpression at RNA 
level by qPCR. Two biological replicates were tested separately (denoted as 1 and 2) and the depicted 
expression is relative to the housekeeping gene (GUSB). Primers targeting HA-ZNF408 transgene (upper 
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panel) and endogenous ZNF408 (lower panel) were used. C) Western blot analysis of ZNF408 overexpression. 
WT cells were induced with dierent doses of doxycycline to determine the dose required to have equal 
expression level of wild-type and p.His455Tyr ZNF408 protein. D) Heatmap of dierentially expressed 
genes between the three conditions. Two biological replicates of each condition were included in the 
analysis. e z-score was calculated from the FPKM value of each gene. E) MA-plot of the dierential 
expression analysis, comparing MUT to NT. Red dots represent genes with dierential expression between 
the two conditions compared, black dots represent no dierence in expression. e number of genes with 
signicant dierence in expression is depicted on the corner of the plot. e top 10 biological process GO-
terms of genes belonging to the upper and lower part of the MA-plot are depicted above and below the 
MA-plot, respectively. e p-values were adjusted using the Benjamini-Hochberg method.
Figure S2. e expression of genes relevant to angiogenesis process detected by RNA-Seq (A and B) and 
qPCR (C and D). e expression of genes detected by RNA-Seq is depicted in FPKM values relative to NT 
condition (NT = 1). e gene expression detected by qPCR is also shown relative to NT condition (NT = 1). 
Error bars in c) and d) represent standard deviation of three biological replicates. Signicance is illustrated 
with *(p-value < 0.05). 
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Figure S3. Validation of p.His455Tyr ZNF408 reduced DNA-binding ability by transactivation assay. A) 
Screenshot of UCSC Genome Browser track of example ChIP peaks. B) Fold-activation of transcription 
detected in luciferase-based transactivation assay. e fold-activation of WT and MUT is relative to mock. 
Error bars denote standard deviation of three biological replicates. Signicance is illustrated with * (p-value 
< 0.05). 
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Figure S4. Validation of ZNF408 binding to a locus near HMOX1 and ITGA4. A) and B) Screenshot of 
UCSC Genome Browser track of wild-type ZNF408 binding in the proximity of HMOX1 and ITGA4, 
respectively. Antibody targeting ZNF408 was used for immunoprecipitation. Error bars represent standard 
deviation of two biological replicates. C) and D) Fold-activation of transcription detected in luciferase-
based transactivation assay. e fold-activation of WT and MUT is relative to mock. Error bars denote 
standard deviation of three biological replicates. Signicance is illustrated with * (p-value < 0.05).
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Table S1 Primer list 
Target Sequence (5’- 3’)
qPCR_LYVE1_Forward TTTGGAAGGTTCCAGTGAGC
qPCR_LYVE1_Reverse GAATATGGGATCTTTGGTGGTG
qPCR_HMOX1_Forward CTTTCAGAAGGGCCAGGTG
qPCR_HMOX1_Reverse GTAGACAGGGGCGAAGACTG
qPCR_CLDN5_Forward CCTTCCTGGACCACAACATC
qPCR_CLDN5_Reverse ACCGAGTCGTACACTTTGCAC
qPCR_ALDH1A2_Forward ATGATATGCGGATTGCCAAG
qPCR_ALDH1A2_Reverse CAGCTGCTACGAGTCCAAAG
qPCR_KHDRBS3_Forward TGAAGCTGGGACAGAAAGTG
qPCR_KHDRBS3_Reverse AACCTTTCCCAAGGATGGAC
qPCR_FILIP1L_Forward AACGCTGGTATCATGGCTGAA
qPCR_FILIP1L_Reverse ATCTCTTGCACTGCTCCTCCATT
qPCR_COL8A1_Forward TGGCAAAGAGTATCCACACC
qPCR_COL8A1_Reverse TTGTTCCCCTCGTAAACTGG
qPCR_CTGF_Forward GCAGGCTAGAGAAGCAGAGC
qPCR_CTGF_Reverse TGGAGATTTTGGGAGTACGG
qPCR_EDN1_Forward ACTTCTGCCACCTGGACATC
qPCR_EDN1_Reverse GGCATCTATTTTCACGGTCTG
qPCR_ANGPT2_Forward AGGGACAAACCTGTTGAACC
qPCR_ANGPT2_Reverse TTGTCGAGAGGGAGTGTTCC
qPCR_ITGA4_Forward ACCTCAATGCAGATGGCTTC
qPCR_ITGA4_Reverse ACGAGGTTTGTTTCCATTGC
qPCR_MMP2_Forward GAGAAGGATGGCAAGTACGG
qPCR_MMP2_Reverse CATAGGATGTGCCCTGGAAG
qPCR_PLSCR4_Forward ACAGCCTGCAGGTGAAATG
qPCR_PLSCR4_Reverse TGGGTAGCCAGTAGGTGGAG
qPCR_TGFB2_Forward AGCCAGAGTGCCTGAACAAC
qPCR_TGFB2_Reverse ACATCGAAGGAGAGCCATTC
qPCR_VCAM1_Forward GGCAGGCTGTAAAAGAATTGC
qPCR_VCAM1_Reverse TTCTTGCAGCTTTGTGGATG
qPCR_GUSB_Forward AGAGTGGTGCTGAGGATTGG
qPCR_GUSB_Reverse CCCTCATGCTCTAGCGTGTC
gDNA_ZNF408_Forward CCTGGCCAAGAAGTTACACAG
gDNA_ZNF408_Reverse TTTCTCCTGTATGGAGCCTCA
qPCR_ZNF408_Forward GAGGAGTCTGCCTCCAAGG
qPCR_ZNF408_Reverse CCAGCCAGAACTCTGCTCAC
qPCR_HA-ZNF408_Forward TTACGATGTACCGGATTACGC
qPCR_HA-ZNF408_Reverse CGGAAGGGTTCCATCCTAAG
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Table S2 Genes that are upregulated in WT, but not in MUT
Ensembl ID Symbol Ensembl ID Symbol Ensembl ID Symbol
ENSG00000135451 TROAP ENSG00000276410 HIST1H2BB ENSG00000185130 HIST1H2BL
ENSG00000197182 MIR4763 ENSG00000100292 HMOX1 ENSG00000274290 HIST1H2BE
ENSG00000127528 KLF2 ENSG00000184270 HIST2H2AB ENSG00000275713 HIST1H2BH
ENSG00000013810 TACC3 ENSG00000079616 KIF22 ENSG00000278588 HIST1H2BI
ENSG00000233922 LOC105372840 ENSG00000171345 KRT19 ENSG00000111665 CDCA3
ENSG00000133800 LYVE1 ENSG00000197182 MIRLET7BHG ENSG00000274641 HIST1H2BO
ENSG00000122952 ZWINT ENSG00000197182 MIRLET7A3 ENSG00000275714 HIST1H3A
ENSG00000146670 CDCA5 ENSG00000197182 MIRLET7B ENSG00000278272 HIST1H3C
ENSG00000104147 OIP5 ENSG00000164109 MAD2L1 ENSG00000275379 HIST1H3I
ENSG00000162639 HENMT1 ENSG00000073111 MCM2 ENSG00000273983 HIST1H3G
ENSG00000163923 RPL39L ENSG00000100297 MCM5 ENSG00000197153 HIST1H3J
ENSG00000197837 HIST4H4 ENSG00000166508 MCM7 ENSG00000278828 HIST1H3H
ENSG00000181885 CLDN7 ENSG00000085840 ORC1 ENSG00000274267 HIST1H3B
ENSG00000165071 TMEM71 ENSG00000131153 GINS2 ENSG00000278637 HIST1H4A
ENSG00000188643 S100A16 ENSG00000197594 ENPP1 ENSG00000197061 HIST1H4C
ENSG00000101331 CCM2L ENSG00000166851 PLK1 ENSG00000158406 HIST1H4H
ENSG00000161888 SPC24 ENSG00000102575 ACP5 ENSG00000167747 C19orf48
ENSG00000186281 GPAT2 ENSG00000129195 FAM64A ENSG00000274997 HIST1H2AH
ENSG00000123977 DAW1 ENSG00000134690 CDCA8 ENSG00000118640 VAMP8
ENSG00000204161 C10orf128 ENSG00000105011 ASF1B ENSG00000157873 TNFRSF14
ENSG00000130511 SSBP4 ENSG00000035499 DEPDC1B ENSG00000128918 ALDH1A2
ENSG00000140873 ADAMTS18 ENSG00000163638 ADAMTS9 ENSG00000134057 CCNB1
ENSG00000090776 EFNB1 ENSG00000171848 RRM2 ENSG00000277775 HIST1H3F
ENSG00000175899 A2M ENSG00000127586 CHTF18 ENSG00000196787 HIST1H2AG
ENSG00000163584 RPL22L1 ENSG00000186283 TOR3A ENSG00000124635 HIST1H2BJ
ENSG00000144554 FANCD2 ENSG00000110080 ST3GAL4 ENSG00000119333 WDR34
ENSG00000184232 OAF ENSG00000183598 HIST2H3D ENSG00000162063 CCNF
ENSG00000161513 FDXR ENSG00000252481 SCARNA13 ENSG00000110711 AIP
ENSG00000168496 FEN1 ENSG00000159167 STC1 ENSG00000178999 AURKB
ENSG00000001561 ENPP4 ENSG00000137310 TCF19 ENSG00000071539 TRIP13
ENSG00000100304 TTLL12 ENSG00000270141 TERC ENSG00000158859 ADAMTS4
ENSG00000179604 CDC42EP4 ENSG00000167900 TK1 ENSG00000100034 PPM1F
ENSG00000186994 KANK3 ENSG00000184113 CLDN5 ENSG00000135476 ESPL1
ENSG00000164087 POC1A ENSG00000176890 TYMS ENSG00000007312 CD79B
ENSG00000107719 PALD1 ENSG00000100162 CENPM ENSG00000166803 KIAA0101
ENSG00000161800 RACGAP1 ENSG00000131652 THOC6 ENSG00000117399 CDC20
ENSG00000276043 UHRF1 ENSG00000171241 SHCBP1 ENSG00000100918 REC8
ENSG00000160447 PKN3 ENSG00000276180 HIST1H4I ENSG00000198327 NA
ENSG00000124575 HIST1H1D ENSG00000093009 CDC45 ENSG00000124529 NA
ENSG00000184357 HIST1H1B ENSG00000196747 HIST1H2AI ENSG00000259001 NA
ENSG00000277075 HIST1H2AE ENSG00000276903 HIST1H2AL ENSG00000267325 NA
ENSG00000164032 H2AFZ ENSG00000278463 HIST1H2AB
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Table S3 Genes that are downregulated in WT, but not in MUT 
Ensembl ID Symbol Ensembl ID Symbol Ensembl ID Symbol
ENSG00000227124 ZNF717 ENSG00000115457 IGFBP2 ENSG00000169439 SDC2
ENSG00000139187 KLRG1 ENSG00000163453 IGFBP7 ENSG00000154864 PIEZO2
ENSG00000131773 KHDRBS3 ENSG00000122641 INHBA ENSG00000214944 ARHGEF28
ENSG00000168386 FILIP1L ENSG00000117595 IRF6 ENSG00000143429 LOC645166
ENSG00000180787 ZFP3 ENSG00000115232 ITGA4 ENSG00000206432 TMEM200C
ENSG00000144810 COL8A1 ENSG00000206538 VGLL3 ENSG00000196632 WNK3
ENSG00000111799 COL12A1 ENSG00000156466 GDF6 ENSG00000189223 PAX8-AS1
ENSG00000164318 EGFLAM ENSG00000095015 MAP3K1 ENSG00000144681 STAC
ENSG00000139971 C14orf37 ENSG00000170430 MGMT ENSG00000130303 BST2
ENSG00000118523 CTGF ENSG00000087245 MMP2 ENSG00000092969 TGFB2
ENSG00000143869 GDF7 ENSG00000198938 COX3 ENSG00000162692 VCAM1
ENSG00000198947 DMD ENSG00000198727 CYTB ENSG00000147180 ZNF711
ENSG00000183044 ABAT ENSG00000198840 ND3 ENSG00000075785 RAB7A
ENSG00000078401 EDN1 ENSG00000086991 NOX4 ENSG00000129680 MAP7D3
ENSG00000123572 NRK ENSG00000124785 NRN1 ENSG00000175471 MCTP1
ENSG00000225383 SFTA1P ENSG00000154678 PDE1C ENSG00000122786 CALD1
ENSG00000148218 ALAD ENSG00000184588 PDE4B ENSG00000138759 FRAS1
ENSG00000165092 ALDH1A1 ENSG00000057294 PKP2 ENSG00000118473 SGIP1
ENSG00000177409 SAMD9L ENSG00000128567 PODXL ENSG00000184384 MAML2
ENSG00000083857 FAT1 ENSG00000170891 CYTL1 ENSG00000154556 SORBS2
ENSG00000184254 ALDH1A3 ENSG00000196368 NUDT11 ENSG00000102802 MEDAG
ENSG00000146555 SDK1 ENSG00000022556 NLRP2 ENSG00000180543 TSPYL5
ENSG00000189134 NKAPL ENSG00000198185 ZNF334 ENSG00000138735 PDE5A
ENSG00000179399 GPC5 ENSG00000114698 PLSCR4 ENSG00000133101 CCNA1
ENSG00000162631 NTNG1 ENSG00000134247 PTGFRN ENSG00000003096 KLHL13
ENSG00000115414 FN1 ENSG00000095303 PTGS1 ENSG00000162614 NEXN
ENSG00000118407 FILIP1 ENSG00000136383 ALPK3 ENSG00000128487 SPECC1
ENSG00000118946 PCDH17 ENSG00000138771 SHROOM3 ENSG00000170160 CCDC144A
ENSG00000177990 DPY19L2 ENSG00000105426 PTPRS ENSG00000184867 ARMCX2
ENSG00000091879 ANGPT2 ENSG00000148143 ZNF462 ENSG00000228495 NA
ENSG00000095951 HIVEP1 ENSG00000169213 RAB3B ENSG00000205664 NA
ENSG00000180806 HOXC9 ENSG00000114200 BCHE ENSG00000226702 NA
ENSG00000147036 LANCL3 ENSG00000074527 NTN4 ENSG00000237973 NA
ENSG00000140443 IGF1R ENSG00000126950 TMEM35A ENSG00000254635 NA
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Table S4 Top 1000 genes on principal component 1 and 2 axis
Principal Component 1 Principal Component 2
Ensembl ID Symbol Ensembl ID Symbol
ENSG00000170558 CDH2 ENSG00000170558 CDH2
ENSG00000234420 ZNF37BP ENSG00000136560 TANK
ENSG00000204767 FAM196B ENSG00000198865 CCDC152
ENSG00000221676 RNU6ATAC ENSG00000255737 AGAP2-AS1
ENSG00000234456 MAGI2-AS3 ENSG00000205078 SYCE1L
ENSG00000204520 MICA ENSG00000227124 ZNF717
ENSG00000113810 SMC4 ENSG00000221676 RNU6ATAC
ENSG00000025434 NR1H3 ENSG00000135451 TROAP
ENSG00000254986 DPP3 ENSG00000260260 SNHG19
ENSG00000113163 COL4A3BP ENSG00000025434 NR1H3
ENSG00000140937 CDH11 ENSG00000230630 DNM3OS
ENSG00000241553 ARPC4 ENSG00000184281 TSSC4
ENSG00000140391 TSPAN3 ENSG00000140937 CDH11
ENSG00000188042 ARL4C ENSG00000140945 CDH13
ENSG00000122644 ARL4A ENSG00000127914 AKAP9
ENSG00000073910 FRY ENSG00000245648 LOC101928100
ENSG00000139679 LPAR6 ENSG00000235448 LURAP1L-AS1
ENSG00000245648 LOC101928100 ENSG00000123136 DDX39A
ENSG00000227517 LINC01483 ENSG00000139187 KLRG1
ENSG00000235448 LURAP1L-AS1 ENSG00000128606 LRRC17
ENSG00000064989 CALCRL ENSG00000070404 FSTL3
ENSG00000105810 CDK6 ENSG00000123080 CDKN2C
ENSG00000105355 PLIN3 ENSG00000100526 CDKN3
ENSG00000136158 SPRY2 ENSG00000264462 MIR3648-2
ENSG00000124762 CDKN1A ENSG00000107833 NPM3
ENSG00000131477 RAMP2 ENSG00000127528 KLF2
ENSG00000111276 CDKN1B ENSG00000164442 CITED2
ENSG00000070404 FSTL3 ENSG00000075213 SEMA3A
ENSG00000103266 STUB1 ENSG00000188229 TUBB4B
ENSG00000147889 CDKN2A ENSG00000101335 MYL9
ENSG00000147883 CDKN2B ENSG00000064225 ST3GAL6
ENSG00000174130 TLR6 ENSG00000080986 NDC80
ENSG00000154258 ABCA9 ENSG00000104324 CPQ
ENSG00000264462 MIR3648-2 ENSG00000134215 VAV3
ENSG00000141338 ABCA8 ENSG00000130204 TOMM40
ENSG00000164442 CITED2 ENSG00000013810 TACC3
ENSG00000124406 ATP8A1 ENSG00000250508 LOC105369364
ENSG00000101335 MYL9 ENSG00000233922 LOC105372840
ENSG00000080986 NDC80 ENSG00000105404 RABAC1
ENSG00000104324 CPQ ENSG00000184990 SIVA1
ENSG00000137693 YAP1 ENSG00000086504 MRPL28
ENSG00000134375 TIMM17A ENSG00000135624 CCT7
ENSG00000106400 ZNHIT1 ENSG00000115163 CENPA
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Table S4 continued
Principal Component 1 Principal Component 2
Ensembl ID Symbol Ensembl ID Symbol
ENSG00000131236 CAP1 ENSG00000183751 TBL3
ENSG00000107175 CREB3 ENSG00000076382 SPAG5
ENSG00000108828 VAT1 ENSG00000113356 POLR3G
ENSG00000257219 LOC105369848 ENSG00000133110 POSTN
ENSG00000254486 LOC105376554 ENSG00000111247 RAD51AP1
ENSG00000136938 ANP32B ENSG00000131773 KHDRBS3
ENSG00000151640 DPYSL4 ENSG00000048740 CELF2
ENSG00000184470 TXNRD2 ENSG00000051341 POLQ
ENSG00000138778 CENPE ENSG00000142731 PLK4
ENSG00000113356 POLR3G ENSG00000132970 WASF3
ENSG00000265972 TXNIP ENSG00000173083 HPSE
ENSG00000117724 CENPF ENSG00000183207 RUVBL2
ENSG00000133110 POSTN ENSG00000133800 LYVE1
ENSG00000167642 SPINT2 ENSG00000148671 ADIRF
ENSG00000253522 MIR3142HG ENSG00000143554 SLC27A3
ENSG00000077514 POLD3 ENSG00000142945 KIF2C
ENSG00000185737 NRG3 ENSG00000175602 CCDC85B
ENSG00000132970 WASF3 ENSG00000099203 TMED1
ENSG00000170271 FAXDC2 ENSG00000123124 WWP1
ENSG00000173083 HPSE ENSG00000175063 UBE2C
ENSG00000125966 MMP24 ENSG00000164283 ESM1
ENSG00000104356 POP1 ENSG00000070778 PTPN21
ENSG00000213190 MLLT11 ENSG00000138080 EMILIN1
ENSG00000136026 CKAP4 ENSG00000053254 FOXN3
ENSG00000118508 RAB32 ENSG00000122952 ZWINT
ENSG00000139278 GLIPR1 ENSG00000169306 IL1RAPL1
ENSG00000243244 STON1 ENSG00000173598 NUDT4
ENSG00000080561 MID2 ENSG00000168309 FAM107A
ENSG00000119397 CNTRL ENSG00000170955 PRKCDBP
ENSG00000091428 RAPGEF4 ENSG00000168386 FILIP1L
ENSG00000276023 DUSP14 ENSG00000222041 CYTOR
ENSG00000162616 DNAJB4 ENSG00000135324 MRAP2
ENSG00000164283 ESM1 ENSG00000137491 SLCO2B1
ENSG00000150687 PRSS23 ENSG00000146670 CDCA5
ENSG00000138738 PRDM5 ENSG00000104147 OIP5
ENSG00000138080 EMILIN1 ENSG00000138435 CHRNA1
ENSG00000026950 BTN3A1 ENSG00000247596 TWF2
ENSG00000136504 KAT7 ENSG00000162639 HENMT1
ENSG00000164985 PSIP1 ENSG00000207445 SNORD15B
ENSG00000160326 SLC2A6 ENSG00000164796 CSMD3
ENSG00000090376 IRAK3 ENSG00000156804 FBXO32
ENSG00000139629 GALNT6 ENSG00000157657 ZNF618
ENSG00000166073 GPR176 ENSG00000144741 SLC25A26
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Table S4 continued
Principal Component 1 Principal Component 2
Ensembl ID Symbol Ensembl ID Symbol
ENSG00000168386 FILIP1L ENSG00000164932 CTHRC1
ENSG00000222041 CYTOR ENSG00000150551 LYPD1
ENSG00000135324 MRAP2 ENSG00000183617 MRPL54
ENSG00000161013 MGAT4B ENSG00000163923 RPL39L
ENSG00000011009 LYPLA2 ENSG00000132622 HSPA12B
ENSG00000105669 COPE ENSG00000156398 SFXN2
ENSG00000138435 CHRNA1 ENSG00000197837 HIST4H4
ENSG00000074416 MGLL ENSG00000151136 BTBD11
ENSG00000247596 TWF2 ENSG00000151572 ANO4
ENSG00000164796 CSMD3 ENSG00000180787 ZFP3
ENSG00000166897 ELFN2 ENSG00000202198 RN7SK
ENSG00000164484 TMEM200A ENSG00000161677 JOSD2
ENSG00000079156 OSBPL6 ENSG00000161618 ALDH16A1
ENSG00000156804 FBXO32 ENSG00000164692 COL1A2
ENSG00000178695 KCTD12 ENSG00000168542 COL3A1
ENSG00000164849 GPR146 ENSG00000187498 COL4A1
ENSG00000157107 FCHO2 ENSG00000183856 IQGAP3
ENSG00000186446 ZNF501 ENSG00000134871 COL4A2
ENSG00000164932 CTHRC1 ENSG00000130635 COL5A1
ENSG00000166265 CYYR1 ENSG00000163092 XIRP2
ENSG00000150551 LYPD1 ENSG00000144810 COL8A1
ENSG00000135842 FAM129A ENSG00000111799 COL12A1
ENSG00000132622 HSPA12B ENSG00000065618 COL17A1
ENSG00000131584 ACAP3 ENSG00000175182 FAM131A
ENSG00000131386 GALNT15 ENSG00000164509 IL31RA
ENSG00000106367 AP1S1 ENSG00000164318 EGFLAM
ENSG00000178338 ZNF354B ENSG00000197261 C6orf141
ENSG00000163297 ANTXR2 ENSG00000163751 CPA3
ENSG00000120885 CLU ENSG00000109472 CPE
ENSG00000139263 LRIG3 ENSG00000181885 CLDN7
ENSG00000151136 BTBD11 ENSG00000155975 VPS37A
ENSG00000151572 ANO4 ENSG00000165071 TMEM71
ENSG00000172590 MRPL52 ENSG00000188643 S100A16
ENSG00000139926 FRMD6 ENSG00000101331 CCM2L
ENSG00000167703 SLC43A2 ENSG00000179630 LACC1
ENSG00000161091 MFSD12 ENSG00000139971 C14orf37
ENSG00000169991 IFFO2 ENSG00000216588 IGSF23
ENSG00000197982 C1orf122 ENSG00000161888 SPC24
ENSG00000164692 COL1A2 ENSG00000118523 CTGF
ENSG00000187498 COL4A1 ENSG00000116761 CTH
ENSG00000134871 COL4A2 ENSG00000186281 GPAT2
ENSG00000130635 COL5A1 ENSG00000143869 GDF7
ENSG00000204262 COL5A2 ENSG00000091986 CCDC80
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Table S4 continued
Principal Component 1 Principal Component 2
Ensembl ID Symbol Ensembl ID Symbol
ENSG00000163092 XIRP2 ENSG00000256043 CTSO
ENSG00000162944 RFTN2 ENSG00000180611 MB21D2
ENSG00000197467 COL13A1 ENSG00000163131 CTSS
ENSG00000057019 DCBLD2 ENSG00000137075 RNF38
ENSG00000145247 OCIAD2 ENSG00000122694 GLIPR2
ENSG00000151466 SCLT1 ENSG00000174899 PQLC2L
ENSG00000254535 PABPC4L ENSG00000154639 CXADR
ENSG00000164284 GRPEL2 ENSG00000178343 SHISA3
ENSG00000163751 CPA3 ENSG00000008283 CYB561
ENSG00000180938 ZNF572 ENSG00000051523 CYBA
ENSG00000198832 SELENOM ENSG00000196715 VKORC1L1
ENSG00000125995 ROMO1 ENSG00000184661 CDCA2
ENSG00000152404 CWF19L2 ENSG00000183354 KIAA2026
ENSG00000178882 RFLNA ENSG00000153071 DAB2
ENSG00000167767 KRT80 ENSG00000196352 CD55
ENSG00000198324 FAM109A ENSG00000166750 SLFN5
ENSG00000140511 HAPLN3 ENSG00000167554 ZNF610
ENSG00000038427 VCAN ENSG00000123977 DAW1
ENSG00000159176 CSRP1 ENSG00000173200 PARP15
ENSG00000101439 CST3 ENSG00000178175 ZNF366
ENSG00000216588 IGSF23 ENSG00000204161 C10orf128
ENSG00000196659 TTC30B ENSG00000130511 SSBP4
ENSG00000164733 CTSB ENSG00000140873 ADAMTS18
ENSG00000213160 KLHL23 ENSG00000228716 DHFR
ENSG00000143869 GDF7 ENSG00000147202 DIAPH2
ENSG00000091986 CCDC80 ENSG00000211448 DIO2
ENSG00000180611 MB21D2 ENSG00000075711 DLG1
ENSG00000163131 CTSS ENSG00000198947 DMD
ENSG00000154639 CXADR ENSG00000124721 DNAH8
ENSG00000164463 CREBRF ENSG00000115325 DOK1
ENSG00000051523 CYBA ENSG00000183044 ABAT
ENSG00000153721 CNKSR3 ENSG00000113070 HBEGF
ENSG00000171115 GIMAP8 ENSG00000107404 DVL1
ENSG00000168672 FAM84B ENSG00000213694 S1PR3
ENSG00000176853 FAM91A1 ENSG00000078401 EDN1
ENSG00000153071 DAB2 ENSG00000136160 EDNRB
ENSG00000176438 SYNE3 ENSG00000247077 PGAM5
ENSG00000176435 CLEC14A ENSG00000237624 OXCT2P1
ENSG00000167657 DAPK3 ENSG00000090776 EFNB1
ENSG00000159640 ACE ENSG00000125266 EFNB2
ENSG00000179144 GIMAP7 ENSG00000106780 MEGF9
ENSG00000181444 ZNF467 ENSG00000165244 ZNF367
ENSG00000213203 GIMAP1 ENSG00000203805 PLPP4
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Table S4 continued
Principal Component 1 Principal Component 2
Ensembl ID Symbol Ensembl ID Symbol
ENSG00000172893 DHCR7 ENSG00000161996 WDR90
ENSG00000211448 DIO2 ENSG00000175899 A2M
ENSG00000075711 DLG1 ENSG00000163584 RPL22L1
ENSG00000124721 DNAH8 ENSG00000185909 KLHDC8B
ENSG00000013563 DNASE1L1 ENSG00000159314 ARHGAP27
ENSG00000197102 DYNC1H1 ENSG00000169689 CENPX
ENSG00000119772 DNMT3A ENSG00000169683 LRRC45
ENSG00000197635 DPP4 ENSG00000074800 ENO1
ENSG00000157514 TSC22D3 ENSG00000123572 NRK
ENSG00000134769 DTNA ENSG00000145242 EPHA5
ENSG00000113070 HBEGF ENSG00000225383 SFTA1P
ENSG00000120129 DUSP1 ENSG00000157554 ERG
ENSG00000133740 E2F5 ENSG00000148218 ALAD
ENSG00000078401 EDN1 ENSG00000173153 ESRRA
ENSG00000111752 PHC1 ENSG00000182197 EXT1
ENSG00000125266 EFNB2 ENSG00000165092 ALDH1A1
ENSG00000106546 AHR ENSG00000144554 FANCD2
ENSG00000111145 ELK3 ENSG00000078098 FAP
ENSG00000158711 ELK4 ENSG00000177409 SAMD9L
ENSG00000169621 APLF ENSG00000083857 FAT1
ENSG00000154240 CEP112 ENSG00000107731 UNC5B
ENSG00000134531 EMP1 ENSG00000184254 ALDH1A3
ENSG00000213853 EMP2 ENSG00000184232 OAF
ENSG00000142227 EMP3 ENSG00000172738 TMEM217
ENSG00000170006 TMEM154 ENSG00000160813 PPP1R35
ENSG00000112297 AIM1 ENSG00000106009 BRAT1
ENSG00000106991 ENG ENSG00000146555 SDK1
ENSG00000183323 CCDC125 ENSG00000189134 NKAPL
ENSG00000116016 EPAS1 ENSG00000166924 NYAP1
ENSG00000145242 EPHA5 ENSG00000161513 FDXR
ENSG00000151491 EPS8 ENSG00000168496 FEN1
ENSG00000213462 ERV3-1 ENSG00000138675 FGF5
ENSG00000173153 ESRRA ENSG00000179399 GPC5
ENSG00000182197 EXT1 ENSG00000087303 NID2
ENSG00000164251 F2RL1 ENSG00000158186 MRAS
ENSG00000068366 ACSL4 ENSG00000162631 NTNG1
ENSG00000078098 FAP ENSG00000001561 ENPP4
ENSG00000169710 FASN ENSG00000135299 ANKRD6
ENSG00000083857 FAT1 ENSG00000141337 ARSG
ENSG00000183621 ZNF438 ENSG00000118985 ELL2
ENSG00000069122 ADGRF5 ENSG00000129116 PALLD
ENSG00000172738 TMEM217 ENSG00000020577 SAMD4A
ENSG00000180537 RNF182 ENSG00000187239 FNBP1
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Table S4 continued
Principal Component 1 Principal Component 2
Ensembl ID Symbol Ensembl ID Symbol
ENSG00000164651 SP8 ENSG00000102935 ZNF423
ENSG00000146555 SDK1 ENSG00000123200 ZC3H13
ENSG00000005108 THSD7A ENSG00000082397 EPB41L3
ENSG00000180354 MTURN ENSG00000100304 TTLL12
ENSG00000161040 FBXL13 ENSG00000107104 KANK1
ENSG00000153993 SEMA3D ENSG00000137573 SULF1
ENSG00000138685 FGF2 ENSG00000160796 NBEAL2
ENSG00000138675 FGF5 ENSG00000171735 CAMTA1
ENSG00000149925 ALDOA ENSG00000049759 NEDD4L
ENSG00000105967 TFEC ENSG00000131018 SYNE1
ENSG00000135315 CEP162 ENSG00000115414 FN1
ENSG00000071246 VASH1 ENSG00000121152 NCAPH
ENSG00000107890 ANKRD26 ENSG00000169946 ZFPM2
ENSG00000169760 NLGN1 ENSG00000127603 MACF1
ENSG00000096060 FKBP5 ENSG00000179604 CDC42EP4
ENSG00000064932 SBNO2 ENSG00000011454 RABGAP1
ENSG00000138722 MMRN1 ENSG00000133265 HSPBP1
ENSG00000118985 ELL2 ENSG00000130147 SH3BP4
ENSG00000107984 DKK1 ENSG00000123892 RAB38
ENSG00000054598 FOXC1 ENSG00000128228 SDF2L1
ENSG00000085831 TTC39A ENSG00000125848 FLRT3
ENSG00000020577 SAMD4A ENSG00000198691 ABCA4
ENSG00000187239 FNBP1 ENSG00000102384 CENPI
ENSG00000150907 FOXO1 ENSG00000180071 ANKRD18A
ENSG00000102935 ZNF423 ENSG00000126709 IFI6
ENSG00000151702 FLI1 ENSG00000143469 SYT14
ENSG00000109436 TBC1D9 ENSG00000186994 KANK3
ENSG00000010327 STAB1 ENSG00000141424 SLC39A6
ENSG00000011523 CEP68 ENSG00000130520 LSM4
ENSG00000019144 PHLDB1 ENSG00000117308 GALE
ENSG00000137573 SULF1 ENSG00000108479 GALK1
ENSG00000054654 SYNE2 ENSG00000185432 METTL7A
ENSG00000037280 FLT4 ENSG00000205356 TECPR1
ENSG00000186866 POFUT2 ENSG00000164087 POC1A
ENSG00000064999 ANKS1A ENSG00000196155 PLEKHG4
ENSG00000131018 SYNE1 ENSG00000197555 SIPA1L1
ENSG00000103187 COTL1 ENSG00000152217 SETBP1
ENSG00000107130 NCS1 ENSG00000198624 CCDC69
ENSG00000154262 ABCA6 ENSG00000181722 ZBTB20
ENSG00000154589 LY96 ENSG00000119403 PHF19
ENSG00000103066 PLA2G15 ENSG00000137507 LRRC32
ENSG00000117758 STX12 ENSG00000161956 SENP3
ENSG00000185022 MAFF ENSG00000154027 AK5
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Table S4 continued
Principal Component 1 Principal Component 2
Ensembl ID Symbol Ensembl ID Symbol
ENSG00000125848 FLRT3 ENSG00000131979 GCH1
ENSG00000099968 BCL2L13 ENSG00000135441 BLOC1S1
ENSG00000137409 MTCH1 ENSG00000100558 PLEK2
ENSG00000110218 PANX1 ENSG00000099800 TIMM13
ENSG00000172031 EPHX4 ENSG00000134809 TIMM10
ENSG00000126709 IFI6 ENSG00000238578 SNORD4A
ENSG00000184465 WDR27 ENSG00000225091 SNORA71A
ENSG00000137700 SLC37A4 ENSG00000204136 GGTA1P
ENSG00000166046 TCP11L2 ENSG00000200959 SNORA74A
ENSG00000143469 SYT14 ENSG00000200156 RNU5B-1
ENSG00000184005 ST6GALNAC3 ENSG00000070756 PABPC1
ENSG00000165072 MAMDC2 ENSG00000143322 ABL2
ENSG00000172159 FRMD3 ENSG00000265107 GJA5
ENSG00000172260 NEGR1 ENSG00000148677 ANKRD1
ENSG00000151014 NOCT ENSG00000105327 BBC3
ENSG00000198792 TMEM184B ENSG00000050165 DKK3
ENSG00000185432 METTL7A ENSG00000107719 PALD1
ENSG00000196155 PLEKHG4 ENSG00000118407 FILIP1
ENSG00000143641 GALNT2 ENSG00000250510 GPR162
ENSG00000170011 MYRIP ENSG00000146072 TNFRSF21
ENSG00000198795 ZNF521 ENSG00000150593 PDCD4
ENSG00000066279 ASPM ENSG00000118946 PCDH17
ENSG00000104951 IL4I1 ENSG00000102359 SRPX2
ENSG00000132424 PNISR ENSG00000154553 PDLIM3
ENSG00000020181 ADGRA2 ENSG00000078053 AMPH
ENSG00000197324 LRP10 ENSG00000178445 GLDC
ENSG00000138604 GLCE ENSG00000137502 RAB30
ENSG00000152217 SETBP1 ENSG00000108106 UBE2S
ENSG00000109046 WSB1 ENSG00000244509 APOBEC3C
ENSG00000137507 LRRC32 ENSG00000136717 BIN1
ENSG00000066735 KIF26A ENSG00000211450 SELENOH
ENSG00000157214 STEAP2 ENSG00000250303 LOC283140
ENSG00000134242 PTPN22 ENSG00000149380 P4HA3
ENSG00000154217 PITPNC1 ENSG00000165434 PGM2L1
ENSG00000092621 PHGDH ENSG00000177990 DPY19L2
ENSG00000146021 KLHL3 ENSG00000255874 LINC00346
ENSG00000154027 AK5 ENSG00000139508 SLC46A3
ENSG00000177628 GBA ENSG00000154188 ANGPT1
ENSG00000114480 GBE1 ENSG00000154874 CCDC144B
ENSG00000152137 HSPB8 ENSG00000224877 NDUFAF8
ENSG00000106852 LHX6 ENSG00000227195 MIR663AHG
ENSG00000187210 GCNT1 ENSG00000091879 ANGPT2
ENSG00000172927 MYEOV ENSG00000144792 ZNF660
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Table S4 continued
Principal Component 1 Principal Component 2
Ensembl ID Symbol Ensembl ID Symbol
ENSG00000185352 HS6ST3 ENSG00000099875 MKNK2
ENSG00000204136 GGTA1P ENSG00000233276 GPX1
ENSG00000200959 SNORA74A ENSG00000115290 GRB14
ENSG00000099998 GGT5 ENSG00000102760 RGCC
ENSG00000164647 STEAP1 ENSG00000168701 TMEM208
ENSG00000196511 TPK1 ENSG00000120217 CD274
ENSG00000265107 GJA5 ENSG00000161800 RACGAP1
ENSG00000148677 ANKRD1 ENSG00000276043 UHRF1
ENSG00000078081 LAMP3 ENSG00000163739 CXCL1
ENSG00000114861 FOXP1 ENSG00000025770 NCAPH2
ENSG00000050165 DKK3 ENSG00000164116 GUCY1A3
ENSG00000102393 GLA ENSG00000061918 GUCY1B3
ENSG00000198075 SULT1C4 ENSG00000121957 GPSM2
ENSG00000102359 SRPX2 ENSG00000160447 PKN3
ENSG00000130768 SMPDL3B ENSG00000136732 GYPC
ENSG00000108106 UBE2S ENSG00000197019 SERTAD1
ENSG00000250303 LOC283140 ENSG00000089486 CDIP1
ENSG00000171435 KSR2 ENSG00000123636 BAZ2B
ENSG00000139508 SLC46A3 ENSG00000147010 SH3KBP1
ENSG00000099814 CEP170B ENSG00000187837 HIST1H1C
ENSG00000166450 PRTG ENSG00000124575 HIST1H1D
ENSG00000180229 HERC2P3 ENSG00000184357 HIST1H1B
ENSG00000154188 ANGPT1 ENSG00000277075 HIST1H2AE
ENSG00000186665 C17orf58 ENSG00000188486 H2AFX
ENSG00000154874 CCDC144B ENSG00000164032 H2AFZ
ENSG00000196268 ZNF493 ENSG00000158373 HIST1H2BD
ENSG00000267519 LOC284454 ENSG00000276410 HIST1H2BB
ENSG00000227195 MIR663AHG ENSG00000124610 HIST1H1A
ENSG00000198719 DLL1 ENSG00000099937 SERPIND1
ENSG00000180376 CCDC66 ENSG00000000971 CFH
ENSG00000249464 LINC01091 ENSG00000013016 EHD3
ENSG00000126882 FAM78A ENSG00000177374 HIC1
ENSG00000233276 GPX1 ENSG00000095951 HIVEP1
ENSG00000081087 OSTM1 ENSG00000231389 HLA-DPA1
ENSG00000087884 AAMDC ENSG00000223865 HLA-DPB1
ENSG00000102760 RGCC ENSG00000138356 AOX1
ENSG00000163884 KLF15 ENSG00000072571 HMMR
ENSG00000166825 ANPEP ENSG00000100292 HMOX1
ENSG00000120217 CD274 ENSG00000129514 FOXA1
ENSG00000163739 CXCL1 ENSG00000184270 HIST2H2AB
ENSG00000213366 GSTM2 ENSG00000107282 APBA1
ENSG00000100027 YPEL1 ENSG00000180806 HOXC9
ENSG00000164116 GUCY1A3 ENSG00000126457 PRMT1
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ENSG00000061918 GUCY1B3 ENSG00000086696 HSD17B2
ENSG00000106266 SNX8 ENSG00000089685 BIRC5
ENSG00000197019 SERTAD1 ENSG00000135914 HTR2B
ENSG00000124593 PRICKLE4 ENSG00000090339 ICAM1
ENSG00000089486 CDIP1 ENSG00000108622 ICAM2
ENSG00000147650 LRP12 ENSG00000254004 ZNF260
ENSG00000151967 SCHIP1 ENSG00000100036 SLC35E4
ENSG00000189060 H1F0 ENSG00000125968 ID1
ENSG00000187837 HIST1H1C ENSG00000010404 IDS
ENSG00000168298 HIST1H1E ENSG00000205403 CFI
ENSG00000182718 ANXA2 ENSG00000147036 LANCL3
ENSG00000063854 HAGH ENSG00000130203 APOE
ENSG00000099937 SERPIND1 ENSG00000140443 IGF1R
ENSG00000138772 ANXA3 ENSG00000115457 IGFBP2
ENSG00000000971 CFH ENSG00000167779 IGFBP6
ENSG00000213977 TAX1BP3 ENSG00000163453 IGFBP7
ENSG00000127946 HIP1 ENSG00000198931 APRT
ENSG00000164104 HMGB2 ENSG00000115008 IL1A
ENSG00000138356 AOX1 ENSG00000115594 IL1R1
ENSG00000103415 HMOX2 ENSG00000131724 IL13RA1
ENSG00000163412 EIF4E3 ENSG00000122641 INHBA
ENSG00000180806 HOXC9 ENSG00000163083 INHBB
ENSG00000115756 HPCAL1 ENSG00000117595 IRF6
ENSG00000086696 HSD17B2 ENSG00000115232 ITGA4
ENSG00000090339 ICAM1 ENSG00000138448 ITGAV
ENSG00000148488 ST8SIA6 ENSG00000259207 ITGB3
ENSG00000197841 ZNF181 ENSG00000132470 ITGB4
ENSG00000185860 CCDC190 ENSG00000105855 ITGB8
ENSG00000165949 IFI27 ENSG00000182118 FAM89A
ENSG00000122483 CCDC18 ENSG00000135976 ANKRD36
ENSG00000162687 KCNT2 ENSG00000069020 MAST4
ENSG00000176771 NCKAP5 ENSG00000157404 KIT
ENSG00000234284 ZNF879 ENSG00000237649 KIFC1
ENSG00000188107 EYS ENSG00000079616 KIF22
ENSG00000157593 SLC35B2 ENSG00000186081 KRT5
ENSG00000168528 SERINC2 ENSG00000205420 KRT6A
ENSG00000130203 APOE ENSG00000171401 KRT13
ENSG00000242498 ARPIN ENSG00000203760 CENPW
ENSG00000115457 IGFBP2 ENSG00000171345 KRT19
ENSG00000167779 IGFBP6 ENSG00000175155 YPEL2
ENSG00000163453 IGFBP7 ENSG00000264343 NOTCH2NL
ENSG00000142871 CYR61 ENSG00000168887 C2orf68
ENSG00000198931 APRT ENSG00000206538 VGLL3
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Principal Component 1 Principal Component 2
Ensembl ID Symbol Ensembl ID Symbol
ENSG00000115008 IL1A ENSG00000115963 RND3
ENSG00000115594 IL1R1 ENSG00000130702 LAMA5
ENSG00000185291 IL3RA ENSG00000091136 LAMB1
ENSG00000136244 IL6 ENSG00000058085 LAMC2
ENSG00000168685 IL7R ENSG00000156466 GDF6
ENSG00000169429 CXCL8 ENSG00000182541 LIMK2
ENSG00000240583 AQP1 ENSG00000169756 LIMS1
ENSG00000163083 INHBB ENSG00000079435 LIPE
ENSG00000171105 INSR ENSG00000160789 LMNA
ENSG00000169083 AR ENSG00000113368 LMNB1
ENSG00000005884 ITGA3 ENSG00000197182 MIRLET7BHG
ENSG00000115232 ITGA4 ENSG00000186479 RGS7BP
ENSG00000161638 ITGA5 ENSG00000177570 SAMD12
ENSG00000138448 ITGAV ENSG00000188921 HACD4
ENSG00000259207 ITGB3 ENSG00000182489 XKRX
ENSG00000132470 ITGB4 ENSG00000119681 LTBP2
ENSG00000242372 EIF6 ENSG00000164109 MAD2L1
ENSG00000082781 ITGB5 ENSG00000101846 STS
ENSG00000105855 ITGB8 ENSG00000111885 MAN1A1
ENSG00000184916 JAG2 ENSG00000132561 MATN2
ENSG00000162434 JAK1 ENSG00000103495 MAZ
ENSG00000177606 JUN ENSG00000073111 MCM2
ENSG00000182118 FAM89A ENSG00000104738 MCM4
ENSG00000135976 ANKRD36 ENSG00000100297 MCM5
ENSG00000188157 AGRN ENSG00000076003 MCM6
ENSG00000143603 KCNN3 ENSG00000166508 MCM7
ENSG00000140859 KIFC3 ENSG00000111339 ART4
ENSG00000186081 KRT5 ENSG00000095015 MAP3K1
ENSG00000135480 KRT7 ENSG00000049130 KITLG
ENSG00000171401 KRT13 ENSG00000170430 MGMT
ENSG00000171346 KRT15 ENSG00000002586 CD99
ENSG00000181350 LRRC75A ENSG00000187098 MITF
ENSG00000253368 TRNP1 ENSG00000087245 MMP2
ENSG00000155366 RHOC ENSG00000166670 MMP10
ENSG00000206538 VGLL3 ENSG00000204899 MZT1
ENSG00000115963 RND3 ENSG00000206149 HERC2P9
ENSG00000185896 LAMP1 ENSG00000203995 ZYG11A
ENSG00000058085 LAMC2 ENSG00000215146 LOC441666
ENSG00000156466 GDF6 ENSG00000198899 ATP6
ENSG00000130164 LDLR ENSG00000228253 ATP8
ENSG00000116678 LEPR ENSG00000198804 COX1
ENSG00000100097 LGALS1 ENSG00000198712 COX2
ENSG00000113594 LIFR ENSG00000198938 COX3
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ENSG00000099204 ABLIM1 ENSG00000198727 CYTB
ENSG00000221968 FADS3 ENSG00000100714 MTHFD1
ENSG00000135363 LMO2 ENSG00000198888 ND1
ENSG00000136153 LMO7 ENSG00000198763 ND2
ENSG00000124374 PAIP2B ENSG00000198840 ND3
ENSG00000184305 CCSER1 ENSG00000198886 ND4
ENSG00000186479 RGS7BP ENSG00000212907 ND4L
ENSG00000134013 LOXL2 ENSG00000198786 ND5
ENSG00000163956 LRPAP1 ENSG00000157601 MX1
ENSG00000154102 C16orf74 ENSG00000099860 GADD45B
ENSG00000160285 LSS ENSG00000133026 MYH10
ENSG00000111144 LTA4H ENSG00000176658 MYO1D
ENSG00000119681 LTBP2 ENSG00000157483 MYO1E
ENSG00000226380 MIR29A ENSG00000196586 MYO6
ENSG00000120693 SMAD9 ENSG00000137474 MYO7A
ENSG00000100299 ARSA ENSG00000145555 MYO10
ENSG00000166963 MAP1A ENSG00000117650 NEK2
ENSG00000132561 MATN2 ENSG00000103024 NME3
ENSG00000076706 MCAM ENSG00000164867 NOS3
ENSG00000106511 MEOX2 ENSG00000169418 NPR1
ENSG00000049130 KITLG ENSG00000065057 NTHL1
ENSG00000111341 MGP ENSG00000185483 ROR1
ENSG00000143198 MGST3 ENSG00000115758 ODC1
ENSG00000104763 ASAH1 ENSG00000116213 WRAP73
ENSG00000204516 MICB ENSG00000085840 ORC1
ENSG00000171843 MLLT3 ENSG00000086991 NOX4
ENSG00000196611 MMP1 ENSG00000106366 SERPINE1
ENSG00000166670 MMP10 ENSG00000197632 SERPINB2
ENSG00000157227 MMP14 ENSG00000149269 PAK1
ENSG00000119711 ALDH6A1 ENSG00000204387 C6orf48
ENSG00000182534 MXRA7 ENSG00000173599 PC
ENSG00000015133 CCDC88C ENSG00000169851 PCDH7
ENSG00000206149 HERC2P9 ENSG00000184226 PCDH9
ENSG00000169715 MT1E ENSG00000078674 PCM1
ENSG00000260549 MT1L ENSG00000132646 PCNA
ENSG00000125148 MT2A ENSG00000053372 MRTO4
ENSG00000167508 MVD ENSG00000172889 EGFL7
ENSG00000157601 MX1 ENSG00000109576 AADAT
ENSG00000133026 MYH10 ENSG00000136463 TACO1
ENSG00000092841 MYL6 ENSG00000108798 ABI3
ENSG00000183091 NEB ENSG00000099139 PCSK5
ENSG00000090266 NDUFB2 ENSG00000150048 CLEC1A
ENSG00000129559 NEDD8 ENSG00000171222 SCAND1
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Ensembl ID Symbol Ensembl ID Symbol
ENSG00000111859 NEDD9 ENSG00000167775 CD320
ENSG00000136098 NEK3 ENSG00000113555 PCDH12
ENSG00000186575 NF2 ENSG00000124785 NRN1
ENSG00000143153 ATP1B1 ENSG00000115252 PDE1A
ENSG00000116962 NID1 ENSG00000154678 PDE1C
ENSG00000198805 PNP ENSG00000186642 PDE2A
ENSG00000144061 NPHP1 ENSG00000187688 TRPV2
ENSG00000169418 NPR1 ENSG00000184588 PDE4B
ENSG00000185483 ROR1 ENSG00000075218 GTSE1
ENSG00000111335 OAS2 ENSG00000171425 ZNF581
ENSG00000013297 CLDN11 ENSG00000100311 PDGFB
ENSG00000135124 P2RX4 ENSG00000129048 ACKR4
ENSG00000140564 FURIN ENSG00000013306 SLC25A39
ENSG00000117450 PRDX1 ENSG00000119801 YPEL5
ENSG00000106366 SERPINE1 ENSG00000131153 GINS2
ENSG00000197632 SERPINB2 ENSG00000197594 ENPP1
ENSG00000185630 PBX1 ENSG00000164035 EMCN
ENSG00000142546 NOSIP ENSG00000161980 POLR3K
ENSG00000109618 SEPSECS ENSG00000100625 SIX4
ENSG00000167772 ANGPTL4 ENSG00000178921 PFAS
ENSG00000189159 HN1 ENSG00000135919 SERPINE2
ENSG00000023902 PLEKHO1 ENSG00000105851 PIK3CG
ENSG00000137804 NUSAP1 ENSG00000008710 PKD1
ENSG00000175426 PCSK1 ENSG00000057294 PKP2
ENSG00000154781 CCDC174 ENSG00000117410 ATP6V0B
ENSG00000006327 TNFRSF12A ENSG00000136404 TM6SF1
ENSG00000137877 SPTBN5 ENSG00000166851 PLK1
ENSG00000115252 PDE1A ENSG00000071655 MBD3
ENSG00000182022 CHST15 ENSG00000165240 ATP7A
ENSG00000154678 PDE1C ENSG00000102575 ACP5
ENSG00000100554 ATP6V1D ENSG00000184702 SEPT5
ENSG00000172572 PDE3A ENSG00000172965 MIR4435-2HG
ENSG00000187688 TRPV2 ENSG00000128567 PODXL
ENSG00000196247 ZNF107 ENSG00000062822 POLD1
ENSG00000168077 SCARA3 ENSG00000168002 POLR2G
ENSG00000143476 DTL ENSG00000170891 CYTL1
ENSG00000100311 PDGFB ENSG00000129195 FAM64A
ENSG00000129048 ACKR4 ENSG00000145390 USP53
ENSG00000117543 DPH5 ENSG00000168209 DDIT4
ENSG00000004799 PDK4 ENSG00000085224 ATRX
ENSG00000171314 PGAM1 ENSG00000099364 FBXL19
ENSG00000119630 PGF ENSG00000196544 BORCS6
ENSG00000135919 SERPINE2 ENSG00000186871 ERCC6L
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ENSG00000133056 PIK3C2B ENSG00000059769 DNAJC25
ENSG00000171608 PIK3CD ENSG00000099260 PALMD
ENSG00000067225 PKM ENSG00000146918 NCAPG2
ENSG00000104368 PLAT ENSG00000166912 MTMR10
ENSG00000122861 PLAU ENSG00000105538 RASIP1
ENSG00000011422 PLAUR ENSG00000101695 RNF125
ENSG00000117410 ATP6V0B ENSG00000177692 DNAJC28
ENSG00000136404 TM6SF1 ENSG00000087253 LPCAT2
ENSG00000083444 PLOD1 ENSG00000130748 TMEM160
ENSG00000152952 PLOD2 ENSG00000101220 C20orf27
ENSG00000114554 PLXNA1 ENSG00000143224 PPOX
ENSG00000071655 MBD3 ENSG00000175756 AURKAIP1
ENSG00000008277 ADAM22 ENSG00000185480 PARPBP
ENSG00000141682 PMAIP1 ENSG00000170779 CDCA4
ENSG00000102575 ACP5 ENSG00000137831 UACA
ENSG00000184702 SEPT5 ENSG00000126870 WDR60
ENSG00000108387 SEPT4 ENSG00000072041 SLC6A15
ENSG00000147481 SNTG1 ENSG00000134690 CDCA8
ENSG00000099817 POLR2E ENSG00000074964 ARHGEF10L
ENSG00000170891 CYTL1 ENSG00000138180 CEP55
ENSG00000177700 POLR2L ENSG00000196368 NUDT11
ENSG00000145990 GFOD1 ENSG00000090530 P3H2
ENSG00000052126 PLEKHA5 ENSG00000073711 PPP2R3A
ENSG00000033100 CHPF2 ENSG00000146859 TMEM140
ENSG00000189184 PCDH18 ENSG00000038210 PI4K2B
ENSG00000091127 PUS7 ENSG00000103381 CPPED1
ENSG00000154133 ROBO4 ENSG00000104341 LAPTM4B
ENSG00000168209 DDIT4 ENSG00000123485 HJURP
ENSG00000128917 DLL4 ENSG00000095383 TBC1D2
ENSG00000069812 HES2 ENSG00000065328 MCM10
ENSG00000005469 CROT ENSG00000225470 JPX
ENSG00000164951 PDP1 ENSG00000162545 CAMK2N1
ENSG00000184840 TMED9 ENSG00000169826 CSGALNACT2
ENSG00000178075 GRAMD1C ENSG00000101311 FERMT1
ENSG00000011258 MBTD1 ENSG00000024526 DEPDC1
ENSG00000137960 GIPC2 ENSG00000147642 SYBU
ENSG00000137501 SYTL2 ENSG00000022556 NLRP2
ENSG00000198113 TOR4A ENSG00000165801 ARHGEF40
ENSG00000044459 CNTLN ENSG00000058804 NDC1
ENSG00000118898 PPL ENSG00000198185 ZNF334
ENSG00000101695 RNF125 ENSG00000218336 TENM3
ENSG00000175756 AURKAIP1 ENSG00000105011 ASF1B
ENSG00000141219 C17orf80 ENSG00000042088 TDP1
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Principal Component 1 Principal Component 2
Ensembl ID Symbol Ensembl ID Symbol
ENSG00000160058 BSDC1 ENSG00000140563 MCTP2
ENSG00000072041 SLC6A15 ENSG00000035499 DEPDC1B
ENSG00000134186 PRPF38B ENSG00000112304 ACOT13
ENSG00000090530 P3H2 ENSG00000168078 PBK
ENSG00000172731 LRRC20 ENSG00000197852 FAM212B
ENSG00000137269 LRRC1 ENSG00000156711 MAPK13
ENSG00000115107 STEAP3 ENSG00000145431 PDGFC
ENSG00000147419 CCDC25 ENSG00000183943 PRKX
ENSG00000066027 PPP2R5A ENSG00000112852 PCDHB2
ENSG00000137522 RNF121 ENSG00000147697 GSDMC
ENSG00000133574 GIMAP4 ENSG00000120549 KIAA1217
ENSG00000149923 PPP4C ENSG00000082497 SERTAD4
ENSG00000135002 RFK ENSG00000130962 PRRG1
ENSG00000129534 MIS18BP1 ENSG00000010438 PRSS3
ENSG00000138587 MNS1 ENSG00000202515 VTRNA1-3
ENSG00000152953 STK32B ENSG00000182916 TCEAL7
ENSG00000104341 LAPTM4B ENSG00000176907 C8orf4
ENSG00000163046 ANKRD30BL ENSG00000141994 DUS3L
ENSG00000162545 CAMK2N1 ENSG00000124225 PMEPA1
ENSG00000122862 SRGN ENSG00000240065 PSMB9
ENSG00000110675 ELMOD1 ENSG00000205220 PSMB10
ENSG00000130827 PLXNA3 ENSG00000163808 KIF15
ENSG00000135905 DOCK10 ENSG00000163050 COQ8A
ENSG00000162409 PRKAA2 ENSG00000163638 ADAMTS9
ENSG00000118242 MREG ENSG00000114698 PLSCR4
ENSG00000116871 MAP7D1 ENSG00000090971 NAT14
ENSG00000218336 TENM3 ENSG00000117643 MAN1C1
ENSG00000167601 AXL ENSG00000134247 PTGFRN
ENSG00000171132 PRKCE ENSG00000124212 PTGIS
ENSG00000042317 SPATA7 ENSG00000152253 SPC25
ENSG00000065675 PRKCQ ENSG00000095303 PTGS1
ENSG00000176871 WSB2 ENSG00000073756 PTGS2
ENSG00000186918 ZNF395 ENSG00000128578 STRIP2
ENSG00000005483 KMT2E ENSG00000186260 MKL2
ENSG00000128833 MYO5C ENSG00000196935 SRGAP1
ENSG00000196562 SULF2 ENSG00000183775 KCTD16
ENSG00000145431 PDGFC ENSG00000136383 ALPK3
ENSG00000147697 GSDMC ENSG00000138650 PCDH10
ENSG00000171867 PRNP ENSG00000138771 SHROOM3
ENSG00000120549 KIAA1217 ENSG00000013293 SLC7A14
ENSG00000082497 SERTAD4 ENSG00000105426 PTPRS
ENSG00000088882 CPXM1 ENSG00000073008 PVR
ENSG00000130962 PRRG1 ENSG00000148143 ZNF462
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ENSG00000010438 PRSS3 ENSG00000169213 RAB3B
ENSG00000189056 RELN ENSG00000051180 RAD51
ENSG00000175352 NRIP3 ENSG00000166349 RAG1
ENSG00000111554 MDM1 ENSG00000114200 BCHE
ENSG00000176907 C8orf4 ENSG00000172819 RARG
ENSG00000125912 NCLN ENSG00000113319 RASGRF2
ENSG00000100804 PSMB5 ENSG00000032219 ARID4A
ENSG00000116774 OLFML3 ENSG00000074527 NTN4
ENSG00000099256 PRTFDC1 ENSG00000126950 TMEM35A
ENSG00000240065 PSMB9 ENSG00000114115 RBP1
ENSG00000104047 DTWD1 ENSG00000171791 BCL2
ENSG00000163808 KIF15 ENSG00000049541 RFC2
ENSG00000144476 ACKR3 ENSG00000138835 RGS3
ENSG00000090097 PCBP4 ENSG00000269900 RMRP
ENSG00000175166 PSMD2 ENSG00000283029 RN7SL1
ENSG00000047617 ANO2 ENSG00000149201 CCDC81
ENSG00000101474 APMAP ENSG00000106399 RPA3
ENSG00000115310 RTN4 ENSG00000167526 RPL13
ENSG00000102897 LYRM1 ENSG00000265681 RPL17
ENSG00000139946 PELI2 ENSG00000214026 MRPL23
ENSG00000128203 ASPHD2 ENSG00000128626 MRPS12
ENSG00000124212 PTGIS ENSG00000164684 ZNF704
ENSG00000100626 GALNT16 ENSG00000170889 RPS9
ENSG00000120278 PLEKHG1 ENSG00000171848 RRM2
ENSG00000186260 MKL2 ENSG00000176697 BDNF
ENSG00000168916 ZNF608 ENSG00000197956 S100A6
ENSG00000129422 MTUS1 ENSG00000005187 ACSM3
ENSG00000138411 HECW2 ENSG00000137266 SLC22A23
ENSG00000136383 ALPK3 ENSG00000182492 BGN
ENSG00000144959 NCEH1 ENSG00000196876 SCN8A
ENSG00000092421 SEMA6A ENSG00000108691 CCL2
ENSG00000138134 STAMBPL1 ENSG00000115884 SDC1
ENSG00000110318 CEP126 ENSG00000169439 SDC2
ENSG00000137727 ARHGAP20 ENSG00000154864 PIEZO2
ENSG00000144583 MARCH4 ENSG00000101194 SLC17A9
ENSG00000105559 PLEKHA4 ENSG00000127586 CHTF18
ENSG00000115109 EPB41L5 ENSG00000007908 SELE
ENSG00000116260 QSOX1 ENSG00000174175 SELP
ENSG00000013293 SLC7A14 ENSG00000001617 SEMA3F
ENSG00000153707 PTPRD ENSG00000129595 EPB41L4A
ENSG00000142949 PTPRF ENSG00000123219 CENPK
ENSG00000163661 PTX3 ENSG00000169718 DUS1L
ENSG00000117569 PTBP2 ENSG00000142910 TINAGL1
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ENSG00000073008 PVR ENSG00000109805 NCAPG
ENSG00000137767 SQRDL ENSG00000267313 KC6
ENSG00000128805 ARHGAP22 ENSG00000186283 TOR3A
ENSG00000082126 MPP4 ENSG00000214944 ARHGEF28
ENSG00000128340 RAC2 ENSG00000164736 SOX17
ENSG00000144118 RALB ENSG00000250337 LINC01021
ENSG00000077092 RARB ENSG00000164161 HHIP
ENSG00000113319 RASGRF2 ENSG00000143429 LOC645166
ENSG00000032219 ARID4A ENSG00000206432 TMEM200C
ENSG00000198258 UBL5 ENSG00000235770 LINC00607
ENSG00000122257 RBBP6 ENSG00000176974 SHMT1
ENSG00000101773 RBBP8 ENSG00000136205 TNS3
ENSG00000102317 RBM3 ENSG00000075420 FNDC3B
ENSG00000114115 RBP1 ENSG00000110080 ST3GAL4
ENSG00000110092 CCND1 ENSG00000136830 FAM129B
ENSG00000171552 BCL2L1 ENSG00000180992 MRPL14
ENSG00000116741 RGS2 ENSG00000125901 MRPS26
ENSG00000117152 RGS4 ENSG00000136603 SKIL
ENSG00000129538 RNASE1 ENSG00000105281 SLC1A5
ENSG00000113916 BCL6 ENSG00000125351 UPF3B
ENSG00000149201 CCDC81 ENSG00000125378 BMP4
ENSG00000123395 ATG101 ENSG00000196632 WNK3
ENSG00000156313 RPGR ENSG00000183598 HIST2H3D
ENSG00000164684 ZNF704 ENSG00000153162 BMP6
ENSG00000175634 RPS6KB2 ENSG00000189223 PAX8-AS1
ENSG00000176697 BDNF ENSG00000234912 SNHG20
ENSG00000134243 SORT1 ENSG00000214814 FER1L6
ENSG00000197956 S100A6 ENSG00000173638 SLC19A1
ENSG00000182568 SATB1 ENSG00000103254 FAM173A
ENSG00000204842 ATXN2 ENSG00000108604 SMARCD2
ENSG00000182492 BGN ENSG00000023608 SNAPC1
ENSG00000169432 SCN9A ENSG00000125835 SNRPB
ENSG00000108691 CCL2 ENSG00000172331 BPGM
ENSG00000276409 CCL14 ENSG00000152377 SPOCK1
ENSG00000124875 CXCL6 ENSG00000163554 SPTA1
ENSG00000169439 SDC2 ENSG00000140319 SRP14
ENSG00000124145 SDC4 ENSG00000144681 STAC
ENSG00000154864 PIEZO2 ENSG00000115415 STAT1
ENSG00000132436 FIGNL1 ENSG00000138378 STAT4
ENSG00000007908 SELE ENSG00000252835 SCARNA21
ENSG00000188404 SELL ENSG00000270066 SCARNA2
ENSG00000112378 PERP ENSG00000252481 SCARNA13
ENSG00000155307 SAMSN1 ENSG00000251791 SCARNA6
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ENSG00000135926 TMBIM1 ENSG00000252010 SCARNA5
ENSG00000142910 TINAGL1 ENSG00000212464 SNORA12
ENSG00000015532 XYLT2 ENSG00000206634 SNORA22
ENSG00000115267 IFIH1 ENSG00000238961 SNORA47
ENSG00000178980 SELENOW ENSG00000200354 SNORA71D
ENSG00000214765 SEPT7P2 ENSG00000159167 STC1
ENSG00000154134 ROBO3 ENSG00000109193 SULT1E1
ENSG00000007384 RHBDF1 ENSG00000087586 AURKA
ENSG00000164736 SOX17 ENSG00000130303 BST2
ENSG00000167693 NXN ENSG00000067715 SYT1
ENSG00000235505 LOC643733 ENSG00000149591 TAGLN
ENSG00000118515 SGK1 ENSG00000112592 TBP
ENSG00000166922 SCG5 ENSG00000239039 SNORD13
ENSG00000143429 LOC645166 ENSG00000212232 SNORD17
ENSG00000108854 SMURF2 ENSG00000196628 TCF4
ENSG00000136205 TNS3 ENSG00000137310 TCF19
ENSG00000127080 IPPK ENSG00000185339 TCN2
ENSG00000075420 FNDC3B ENSG00000169679 BUB1
ENSG00000121749 TBC1D15 ENSG00000156970 BUB1B
ENSG00000073849 ST6GAL1 ENSG00000270141 TERC
ENSG00000136830 FAM129B ENSG00000090447 TFAP4
ENSG00000163814 CDCP1 ENSG00000072274 TFRC
ENSG00000112246 SIM1 ENSG00000092969 TGFB2
ENSG00000180992 MRPL14 ENSG00000120708 TGFBI
ENSG00000153044 CENPH ENSG00000106799 TGFBR1
ENSG00000165271 NOL6 ENSG00000137801 THBS1
ENSG00000125351 UPF3B ENSG00000100300 TSPO
ENSG00000164889 SLC4A2 ENSG00000172009 THOP1
ENSG00000214814 FER1L6 ENSG00000035862 TIMP2
ENSG00000090020 SLC9A1 ENSG00000167900 TK1
ENSG00000064651 SLC12A2 ENSG00000120802 TMPO
ENSG00000144136 SLC20A1 ENSG00000184113 CLDN5
ENSG00000174640 SLCO2A1 ENSG00000131747 TOP2A
ENSG00000080503 SMARCA2 ENSG00000146242 TPBG
ENSG00000102010 BMX ENSG00000111669 TPI1
ENSG00000166311 SMPD1 ENSG00000140416 TPM1
ENSG00000117143 UAP1 ENSG00000067445 TRO
ENSG00000114850 SSR3 ENSG00000106804 C5
ENSG00000139618 BRCA2 ENSG00000185561 TLCD2
ENSG00000115415 STAT1 ENSG00000176890 TYMS
ENSG00000138378 STAT4 ENSG00000213967 ZNF726
ENSG00000126561 STAT5A ENSG00000148154 UGCG
ENSG00000252010 SCARNA5 ENSG00000149823 VPS51
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Table S4 continued
Principal Component 1 Principal Component 2
Ensembl ID Symbol Ensembl ID Symbol
ENSG00000206634 SNORA22 ENSG00000162692 VCAM1
ENSG00000201998 SNORA23 ENSG00000140105 WARS
ENSG00000212443 SNORA53 ENSG00000147180 ZNF711
ENSG00000152518 ZFP36L2 ENSG00000167232 ZNF91
ENSG00000109193 SULT1E1 ENSG00000159840 ZYX
ENSG00000109743 BST1 ENSG00000263934 SNORD3A
ENSG00000130303 BST2 ENSG00000144063 MALL
ENSG00000149591 TAGLN ENSG00000214706 IFRD2
ENSG00000197780 TAF13 ENSG00000075785 RAB7A
ENSG00000204219 TCEA3 ENSG00000169282 KCNAB1
ENSG00000212232 SNORD17 ENSG00000089723 OTUB2
ENSG00000005436 GCFC2 ENSG00000173621 LRFN4
ENSG00000169131 ZNF354A ENSG00000100162 CENPM
ENSG00000145022 TCTA ENSG00000110104 CCDC86
ENSG00000003436 TFPI ENSG00000116455 WDR77
ENSG00000072274 TFRC ENSG00000111670 GNPTAB
ENSG00000042832 TG ENSG00000142634 EFHD2
ENSG00000092969 TGFB2 ENSG00000131652 THOC6
ENSG00000120708 TGFBI ENSG00000111058 ACSS3
ENSG00000069702 TGFBR3 ENSG00000119900 OGFRL1
ENSG00000100300 TSPO ENSG00000196159 FAT4
ENSG00000104067 TJP1 ENSG00000129680 MAP7D3
ENSG00000065717 TLE2 ENSG00000173281 PPP1R3B
ENSG00000028137 TNFRSF1B ENSG00000100379 KCTD17
ENSG00000159403 C1R ENSG00000063241 ISOC2
ENSG00000131747 TOP2A ENSG00000175471 MCTP1
ENSG00000146242 TPBG ENSG00000091656 ZFHX4
ENSG00000076554 TPD52 ENSG00000165959 CLMN
ENSG00000140416 TPM1 ENSG00000175213 ZNF408
ENSG00000198467 TPM2 ENSG00000171241 SHCBP1
ENSG00000067445 TRO ENSG00000116771 AGMAT
ENSG00000155657 TTN ENSG00000150636 CCDC102B
ENSG00000137267 TUBB2A ENSG00000136122 BORA
ENSG00000143367 TUFT1 ENSG00000187720 THSD4
ENSG00000117586 TNFSF4 ENSG00000135362 PRR5L
ENSG00000226053 LOC729987 ENSG00000133142 TCEAL4
ENSG00000148154 UGCG ENSG00000092470 WDR76
ENSG00000183255 PTTG1IP ENSG00000149636 DSN1
ENSG00000189180 ZNF33A ENSG00000122786 CALD1
ENSG00000202048 SNORD114-20 ENSG00000137872 SEMA6D
ENSG00000063180 CA11 ENSG00000140451 PIF1
ENSG00000109906 ZBTB16 ENSG00000138759 FRAS1
ENSG00000147394 ZNF185 ENSG00000122490 PQLC1
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Principal Component 1 Principal Component 2
Ensembl ID Symbol Ensembl ID Symbol
ENSG00000149050 ZNF214 ENSG00000278259 MYO19
ENSG00000163879 DNALI1 ENSG00000119242 CCDC92
ENSG00000162511 LAPTM5 ENSG00000156675 RAB11FIP1
ENSG00000263934 SNORD3A ENSG00000046889 PREX2
ENSG00000115275 MOGS ENSG00000138336 TET1
ENSG00000167552 TUBA1A ENSG00000177192 PUS1
ENSG00000121966 CXCR4 ENSG00000111981 ULBP1
ENSG00000169282 KCNAB1 ENSG00000197646 PDCD1LG2
ENSG00000185803 SLC52A2 ENSG00000221963 APOL6
ENSG00000111058 ACSS3 ENSG00000100836 PABPN1
ENSG00000119900 OGFRL1 ENSG00000158555 GDPD5
ENSG00000196159 FAT4 ENSG00000101447 FAM83D
ENSG00000180801 ARSJ ENSG00000167513 CDT1
ENSG00000187240 DYNC2H1 ENSG00000178605 GTPBP6
ENSG00000128915 ICE2 ENSG00000169249 ZRSR2
ENSG00000196449 YRDC ENSG00000276180 HIST1H4I
ENSG00000119514 GALNT12 ENSG00000093009 CDC45
ENSG00000130309 COLGALT1 ENSG00000196747 HIST1H2AI
ENSG00000198517 MAFK ENSG00000275221 HIST1H2AK
ENSG00000175471 MCTP1 ENSG00000276368 HIST1H2AJ
ENSG00000132321 IQCA1 ENSG00000276903 HIST1H2AL
ENSG00000175213 ZNF408 ENSG00000278463 HIST1H2AB
ENSG00000105825 TFPI2 ENSG00000185130 HIST1H2BL
ENSG00000105792 CFAP69 ENSG00000274290 HIST1H2BE
ENSG00000187720 THSD4 ENSG00000275713 HIST1H2BH
ENSG00000104723 TUSC3 ENSG00000278588 HIST1H2BI
ENSG00000133142 TCEAL4 ENSG00000111665 CDCA3
ENSG00000099219 ERMP1 ENSG00000213347 MXD3
ENSG00000121895 TMEM156 ENSG00000129932 DOHH
ENSG00000266714 MYO15B ENSG00000274641 HIST1H2BO
ENSG00000162174 ASRGL1 ENSG00000275714 HIST1H3A
ENSG00000096872 IFT74 ENSG00000278272 HIST1H3C
ENSG00000046889 PREX2 ENSG00000275379 HIST1H3I
ENSG00000005238 FAM214B ENSG00000273983 HIST1H3G
ENSG00000107611 CUBN ENSG00000197153 HIST1H3J
ENSG00000165113 GKAP1 ENSG00000278828 HIST1H3H
ENSG00000114107 CEP70 ENSG00000274267 HIST1H3B
ENSG00000101152 DNAJC5 ENSG00000278637 HIST1H4A
ENSG00000196812 ZSCAN16 ENSG00000126453 BCL2L12
ENSG00000197646 PDCD1LG2 ENSG00000277157 HIST1H4D
ENSG00000128284 APOL3 ENSG00000273542 HIST1H4K
ENSG00000158270 COLEC12 ENSG00000197238 HIST1H4J
ENSG00000205683 DPF3 ENSG00000197061 HIST1H4C
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Table S4 continued
Principal Component 1 Principal Component 2
Ensembl ID Symbol Ensembl ID Symbol
ENSG00000140350 ANP32A ENSG00000158406 HIST1H4H
ENSG00000116667 C1orf21 ENSG00000276966 HIST1H4E
ENSG00000239264 TXNDC5 ENSG00000275126 HIST1H4L
ENSG00000178878 APOLD1 ENSG00000149781 FERMT3
ENSG00000124749 COL21A1 ENSG00000105447 GRWD1
ENSG00000143401 ANP32E ENSG00000126391 FRMD8
ENSG00000140941 MAP1LC3B ENSG00000160072 ATAD3B
ENSG00000062716 VMP1 ENSG00000143341 HMCN1
ENSG00000145349 CAMK2D ENSG00000130307 USHBP1
ENSG00000178922 HYI ENSG00000144354 CDCA7
ENSG00000184260 HIST2H2AC ENSG00000177602 GSG2
ENSG00000275713 HIST1H2BH ENSG00000136492 BRIP1
ENSG00000130300 PLVAP ENSG00000124074 ENKD1
ENSG00000126878 AIF1L ENSG00000064012 CASP8
ENSG00000277157 HIST1H4D ENSG00000140853 NLRC5
ENSG00000149781 FERMT3 ENSG00000169604 ANTXR1
ENSG00000136169 SETDB2 ENSG00000242125 SNHG3
ENSG00000133687 TMTC1 ENSG00000118473 SGIP1
ENSG00000119632 IFI27L2 ENSG00000183011 NAA38
ENSG00000136492 BRIP1 ENSG00000256053 APOPT1
ENSG00000158710 TAGLN2 ENSG00000184384 MAML2
ENSG00000126653 NSRP1 ENSG00000145794 MEGF10
ENSG00000115363 EVA1A ENSG00000154556 SORBS2
ENSG00000169604 ANTXR1 ENSG00000183615 FAM167B
ENSG00000242125 SNHG3 ENSG00000161551 ZNF577
ENSG00000121851 POLR3GL ENSG00000167747 C19orf48
ENSG00000186812 ZNF397 ENSG00000163702 IL17RC
ENSG00000168101 NUDT16L1 ENSG00000176619 LMNB2
ENSG00000122986 HVCN1 ENSG00000185904 LINC00839
ENSG00000168497 SDPR ENSG00000099910 KLHL22
ENSG00000198286 CARD11 ENSG00000135637 CCDC142
ENSG00000166432 ZMAT1 ENSG00000092208 GEMIN2
ENSG00000176014 TUBB6 ENSG00000146374 RSPO3
ENSG00000167553 TUBA1C ENSG00000164099 PRSS12
ENSG00000223749 MIR503HG ENSG00000102802 MEDAG
ENSG00000166387 PPFIBP2 ENSG00000233016 SNHG7
ENSG00000128849 CGNL1 ENSG00000196507 TCEAL3
ENSG00000129474 AJUBA ENSG00000274997 HIST1H2AH
ENSG00000149150 SLC43A1 ENSG00000197903 HIST1H2BK
ENSG00000196507 TCEAL3 ENSG00000180543 TSPYL5
ENSG00000144283 PKP4 ENSG00000105499 PLA2G4C
ENSG00000108797 CNTNAP1 ENSG00000162407 PLPP3
ENSG00000171617 ENC1 ENSG00000113739 STC2
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Principal Component 1 Principal Component 2
Ensembl ID Symbol Ensembl ID Symbol
ENSG00000143127 ITGA10 ENSG00000138735 PDE5A
ENSG00000170915 PAQR8 ENSG00000118640 VAMP8
ENSG00000143013 LMO4 ENSG00000068001 HYAL2
ENSG00000087842 PIR ENSG00000159228 CBR1
ENSG00000130589 HELZ2 ENSG00000159231 CBR3
ENSG00000133739 LRRCC1 ENSG00000143537 ADAM15
ENSG00000150764 DIXDC1 ENSG00000157873 TNFRSF14
ENSG00000134107 BHLHE40 ENSG00000128918 ALDH1A2
ENSG00000105499 PLA2G4C ENSG00000138074 SLC5A6
ENSG00000162407 PLPP3 ENSG00000106052 TAX1BP1
ENSG00000079102 RUNX1T1 ENSG00000145386 CCNA2
ENSG00000196139 AKR1C3 ENSG00000133101 CCNA1
ENSG00000117533 VAMP4 ENSG00000134057 CCNB1
ENSG00000162734 PEA15 ENSG00000118971 CCND2
ENSG00000068001 HYAL2 ENSG00000277775 HIST1H3F
ENSG00000121858 TNFSF10 ENSG00000196787 HIST1H2AG
ENSG00000143537 ADAM15 ENSG00000124635 HIST1H2BJ
ENSG00000168615 ADAM9 ENSG00000184897 H1FX
ENSG00000141655 TNFRSF11A ENSG00000168010 ATG16L2
ENSG00000115604 IL18R1 ENSG00000119333 WDR34
ENSG00000196468 FGF16 ENSG00000162063 CCNF
ENSG00000137563 GGH ENSG00000120337 TNFSF18
ENSG00000171388 APLN ENSG00000186193 SAPCD2
ENSG00000176170 SPHK1 ENSG00000144824 PHLDB2
ENSG00000133101 CCNA1 ENSG00000238227 C9orf69
ENSG00000118971 CCND2 ENSG00000171004 HS6ST2
ENSG00000067798 NAV3 ENSG00000003096 KLHL13
ENSG00000168010 ATG16L2 ENSG00000110711 AIP
ENSG00000172578 KLHL6 ENSG00000141295 SCRN2
ENSG00000113732 ATP6V0E1 ENSG00000198901 PRC1
ENSG00000120337 TNFSF18 ENSG00000129691 ASH2L
ENSG00000127533 F2RL3 ENSG00000163347 CLDN1
ENSG00000013588 GPRC5A ENSG00000137033 IL33
ENSG00000139597 N4BP2L1 ENSG00000168679 SLC16A4
ENSG00000129691 ASH2L ENSG00000157456 CCNB2
ENSG00000134873 CLDN10 ENSG00000114767 RRP9
ENSG00000163347 CLDN1 ENSG00000174371 EXO1
ENSG00000162595 DIRAS3 ENSG00000162614 NEXN
ENSG00000169744 LDB2 ENSG00000179820 MYADM
ENSG00000258890 CEP95 ENSG00000120334 CENPL
ENSG00000134668 SPOCD1 ENSG00000073803 MAP3K13
ENSG00000137033 IL33 ENSG00000198774 RASSF9
ENSG00000109881 CCDC34 ENSG00000133083 DCLK1
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Table S4 continued
Principal Component 1 Principal Component 2
Ensembl ID Symbol Ensembl ID Symbol
ENSG00000141526 SLC16A3 ENSG00000178999 AURKB
ENSG00000107438 PDLIM1 ENSG00000171451 DSEL
ENSG00000165915 SLC39A13 ENSG00000164611 PTTG1
ENSG00000187051 RPS19BP1 ENSG00000183691 NOG
ENSG00000154359 LONRF1 ENSG00000128487 SPECC1
ENSG00000115602 IL1RL1 ENSG00000017483 SLC38A5
ENSG00000198774 RASSF9 ENSG00000181218 HIST3H2A
ENSG00000262919 FAM58A ENSG00000071539 TRIP13
ENSG00000167874 TMEM88 ENSG00000105676 ARMC6
ENSG00000151276 MAGI1 ENSG00000198542 ITGBL1
ENSG00000008517 IL32 ENSG00000145348 TBCK
ENSG00000183691 NOG ENSG00000101670 LIPG
ENSG00000100784 RPS6KA5 ENSG00000134824 FADS2
ENSG00000196923 PDLIM7 ENSG00000200913 SNORD46
ENSG00000081320 STK17B ENSG00000099337 KCNK6
ENSG00000010278 CD9 ENSG00000118777 ABCG2
ENSG00000178031 ADAMTSL1 ENSG00000172071 EIF2AK3
ENSG00000205038 PKHD1L1 ENSG00000129675 ARHGEF6
ENSG00000134986 NREP ENSG00000158859 ADAMTS4
ENSG00000198542 ITGBL1 ENSG00000154734 ADAMTS1
ENSG00000156787 TBC1D31 ENSG00000112208 BAG2
ENSG00000138398 PPIG ENSG00000130755 GMFG
ENSG00000101670 LIPG ENSG00000138433 CIR1
ENSG00000152465 NMT2 ENSG00000146592 CREB5
ENSG00000110031 LPXN ENSG00000131016 AKAP12
ENSG00000172057 ORMDL3 ENSG00000050344 NFE2L3
ENSG00000118777 ABCG2 ENSG00000174791 RIN1
ENSG00000135218 CD36 ENSG00000104728 ARHGEF10
ENSG00000179841 AKAP5 ENSG00000100034 PPM1F
ENSG00000050438 SLC4A8 ENSG00000110848 CD69
ENSG00000154734 ADAMTS1 ENSG00000135476 ESPL1
ENSG00000130513 GDF15 ENSG00000170160 CCDC144A
ENSG00000138185 ENTPD1 ENSG00000170381 SEMA3E
ENSG00000115129 TP53I3 ENSG00000138593 SECISBP2L
ENSG00000138182 KIF20B ENSG00000048052 HDAC9
ENSG00000146592 CREB5 ENSG00000007312 CD79B
ENSG00000131016 AKAP12 ENSG00000166803 KIAA0101
ENSG00000026508 CD44 ENSG00000126787 DLGAP5
ENSG00000050344 NFE2L3 ENSG00000184867 ARMCX2
ENSG00000187608 ISG15 ENSG00000198826 ARHGAP11A
ENSG00000135968 GCC2 ENSG00000170312 CDK1
ENSG00000085063 CD59 ENSG00000165304 MELK
ENSG00000158417 EIF5B ENSG00000101003 GINS1
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Principal Component 1 Principal Component 2
Ensembl ID Symbol Ensembl ID Symbol
ENSG00000135404 CD63 ENSG00000094804 CDC6
ENSG00000106443 PHF14 ENSG00000159164 SV2A
ENSG00000110848 CD69 ENSG00000117399 CDC20
ENSG00000065308 TRAM2 ENSG00000164045 CDC25A
ENSG00000166037 CEP57 ENSG00000101224 CDC25B
ENSG00000048052 HDAC9 ENSG00000158402 CDC25C
ENSG00000110651 CD81 ENSG00000181634 TNFSF15
ENSG00000158691 ZSCAN12 ENSG00000100918 REC8
ENSG00000130052 STARD8 ENSG00000231711 NA
ENSG00000177697 CD151 ENSG00000257732 NA
ENSG00000198853 RUSC2 ENSG00000259001 NA
ENSG00000065609 SNAP91 ENSG00000266037 NA
ENSG00000159164 SV2A ENSG00000233452 NA
ENSG00000162413 KLHL21 ENSG00000132967 NA
ENSG00000242802 AP5Z1 ENSG00000261269 NA
ENSG00000241399 CD302 ENSG00000261295 NA
ENSG00000013364 MVP ENSG00000263426 NA
ENSG00000181634 TNFSF15 ENSG00000263740 NA
ENSG00000100918 REC8 ENSG00000280079 NA
ENSG00000118412 CASP8AP2 ENSG00000281508 NA
ENSG00000232533 NA ENSG00000200087 NA
ENSG00000233117 NA ENSG00000197083 NA
ENSG00000260604 NA ENSG00000200312 NA
ENSG00000233452 NA ENSG00000220785 NA
ENSG00000171889 NA ENSG00000233117 NA
ENSG00000140181 NA ENSG00000175746 NA
ENSG00000279095 NA ENSG00000267325 NA
ENSG00000235385 NA ENSG00000222489 NA
ENSG00000266037 NA ENSG00000124529 NA
ENSG00000257605 NA ENSG00000223612 NA
ENSG00000248187 NA ENSG00000229855 NA
ENSG00000228742 NA ENSG00000244642 NA
ENSG00000175746 NA ENSG00000254635 NA
ENSG00000273038 NA ENSG00000210082 NA
ENSG00000253177 NA ENSG00000226476 NA
ENSG00000225840 NA ENSG00000226702 NA
ENSG00000276107 NA ENSG00000226958 NA
ENSG00000263426 NA ENSG00000265150 NA
ENSG00000198327 NA ENSG00000197927 NA
ENSG00000226958 NA ENSG00000214176 NA
ENSG00000244398 NA ENSG00000205664 NA
ENSG00000282057 NA ENSG00000228495 NA
ENSG00000259345 NA ENSG00000276107 NA
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Principal Component 1 Principal Component 2
Ensembl ID Symbol Ensembl ID Symbol
ENSG00000257732 NA ENSG00000198327 NA
ENSG00000228495 NA ENSG00000276232 NA
ENSG00000230257 NA ENSG00000140181 NA
ENSG00000215386 NA ENSG00000237039 NA
ENSG00000231991 NA ENSG00000230606 NA
ENSG00000207344 NA ENSG00000197846 NA
ENSG00000168405 NA ENSG00000237973 NA
ENSG00000226476 NA ENSG00000260604 NA
ENSG00000269378 NA ENSG00000239437 NA
ENSG00000165121 NA ENSG00000235385 NA
ENSG00000231503 NA ENSG00000248187 NA
Table S5 Genes identied in HEK293T ChIP which are dierentially regulated by WT and MUT
Symbol Ensembl ID
FPKM
NT WT MUT
HMOX1 ENSG00000100292 30.30 47.97 25.07
HIST2H2AB ENSG00000184270 18.69 29.63 13.29
CDCA8 ENSG00000134690 7.67 12.05 6.36
HIST1H2BL ENSG00000185130 59.24 103.33 31.13
HIST1H2BO ENSG00000274641 82.49 137.69 72.48
HIST1H3J ENSG00000197153 50.04 114.55 49.60
HIST1H4C ENSG00000197061 75.85 196.47 58.17
HIST1H4H ENSG00000158406 220.72 349.98 154.04
HIST1H2AH ENSG00000274997 43.53 96.02 40.45
HIST1H2BJ ENSG00000124635 137.43 346.42 127.87
WDR34 ENSG00000119333 8.97 15.29 8.18
AURKB ENSG00000178999 9.62 17.80 9.65
GPC5 ENSG00000179399 4.20 2.08 4.70
ITGA4 ENSG00000115232 2.48 0.95 25.38
NEXN ENSG00000162614 22.82 5.78 13.77
Dataset S1 Pairwise comparison of WT and MUT (Excel le, not included)
Dataset S2 Pairwise comparison of NT and WT (Excel le, not included)
Dataset S3 Pairwise comparison of NT and MUT (Excel le, not included)
Dataset S4 Genes located near the binding sites of ZNF408 (Excel le, not included)
All datasets are available upon request (contact: dyah.karjosukarso@radboudumc.nl).
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Abstract
Familial exudative vitreoretinopathy (FEVR) is an inherited retinal disease in 
which the retinal vasculature is aected. Patients with FEVR typically lack or 
have abnormal vasculature in the peripheral retina, the outcome of which can 
range from mild visual impairment to complete blindness. A missense mutation 
(p.His455Tyr) in ZNF408 was identied in an autosomal dominant FEVR family. 
Since little is known about the molecular role of ZNF408 and how its defect leads 
to the clinical features of FEVR, we generated two homozygous truncated znf408 
zebrash models as well as one heterozygous and one homozygous missense 
znf408 model in which the human p.His455Tyr mutation is mimicked, using 
CRISPR/Cas9 technology. Intriguingly, all three znf408-mutant zebrash strains 
demonstrated progressive retinal vascular pathology, initially characterized by a 
decient hyaloid vessel development at 5 dpf leading to vascular insuciency in 
the retina. e generation of stable mutant lines allowed long-term follow up study 
which showed ectopic retinal vascular hyper-sprouting at 90 dpf and extensive 
vascular leakage at 180 dpf. Together, our data demonstrate an important role for 
znf408 in the development and maintenance of the vascular system within the 
retina. 
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3.1 Introduction
Vasculature defects in the retina are one of the leading causes of visual impairment 
[1]. Dierent developmental vision disorders resulting from retinal vasculature 
defects have been described, such as familial exudative vitreoretinopathy (FEVR), 
Norrie disease, persistent fetal vasculature, and retinopathy of prematurity (ROP), 
some of which have overlapping features [2]. FEVR is a rare inherited disorder 
which is hallmarked by an abnormal development of the vasculature in the 
peripheral retina. e clinical features of FEVR are heterogeneous, varying from 
normal vision to complete blindness [2]. Besides its diverse clinical manifestations, 
FEVR is also a genetically heterogeneous disorder. Defects in FZD4, LRP5, NDP, 
and TSPAN12 are classically associated with FEVR. ese genes, as well as the 
mutations they harbor, have been thoroughly investigated, both in vitro and in vivo 
(reviewed in [2, 3]). Recent genetic studies discovered more genes to be associated 
with FEVR, such as ZNF408 [4], RCBTB1 [5] and CTNNB1 [6, 7].
A missense mutation in ZNF408 (c.1363C>T, p.His455Tyr, NM_024741) was 
identied in a large autosomal dominant FEVR family [4]. We demonstrated that 
the encoded protein, ZNF408, is localized in the nucleus and the mutation caused 
mislocalization of ZNF408 to the cytoplasm [4]. Furthermore, morpholino-
induced transient knockdown of znf408 in zebrash led to abnormal development 
of eye and trunk vasculature [4], suggesting it plays an important role in the 
development of the vasculature. However, it remains unclear what the exact role 
of ZNF408 is in this process, as well as how its defect results in abnormal retinal 
vasculature development that leads to visual impairment.
In the recent years, zebrash has become more and more popular as a model 
organism to study disease mechanisms. Besides its easy maintenance and relatively 
low costs, 84% of known human disease-associated genes have an orthologue in this 
model [8]. Vision-related disorders are among the wide variety of human diseases 
that have been studied in zebrash. e zebrash retina has a layered structure 
which is highly similar to the human retina. Since zebrash are diurnal organisms, 
their cone density is also close to that of the human retina [9]. Furthermore, the 
zebrash retina is supplied by a choroidal and a retinal vasculature, the latter being 
derived from the hyaloid vasculature, comparable to the retinal vasculature in 
humans [10-12]. Finally, the availability of transgenic zebrash lines expressing 
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uorescent reporters in the cells which constitute the blood vessels, such as 
Tg(i1:GFP) [13] and Tg(k1:GFP) [14], adds an extra advantage in its application 
to studies of vascular-related disorders. 
Although a previous morpholino-mediated knockdown study has shown that 
znf408 is crucial in the development of eye and trunk vasculature in zebrash [4], 
the specicity of morpholinos has been debated over the recent years [15-17]. 
Moreover, transient knock-down merely allows short-term investigation during 
early development. Finally, only the eect of an insucient amount of a protein 
of interest could be observed in such knock-down studies, which is not always 
completely relevant for diseases inherited in an autosomal dominant manner, such 
as FEVR. To further study the role of ZNF408 in the vasculature development in 
vivo, we generated two homozygous zebrash models with a frameshi mutation 
in znf408 (znf408rmc103/rmc103 and znf408rmc104/rmc104), as well as one heterozygous 
and one homozygous missense znf408 model in which the human p.His455Tyr 
mutation is mimicked (znf408rmc105/+ and znf408rmc105/rmc105), using CRISPR/Cas9 
technology. is study was designed in order to determine the eect of absence 
(or truncation) of znf408 as well as the eect of a specic amino acid substitution 
such as observed in FEVR patients, which may or may not dier from the eect of 
znf408 knockdown. Furthermore, the generation of stable mutant zebrash lines 
would allow us to study and compare the eect of the mutations from larval stage 
up to adult stage, while the previous knockdown study only allowed observation 
at larval stage. We found that both the absence of znf408 as well as the presence of 
znf408 harboring the human FEVR-mutation resulted in impaired development 
of the hyaloid vasculature, followed by subsequent hyper-sprouting and structural 
destabilization of retinal vessels in the periphery of the optic disc culminating 
in extensive retinal vascular leakage at 180 days post fertilization (dpf). ese 
phenotypes accurately recapitulate the disease history of FEVR in human patients, 
suggesting that the zebrash mutants developed here could be exploited for 
developing an improved understanding of FEVR.  
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3.2 Materials and Methods
3.2.1 Ethics statement
Zebrash experiments were approved by the local Animal Experimentation 
Committee (RU-DEC-2016-0991 and N89/15) and were performed according to 
the Dutch law (Wet op Dierproven 1996), the Swedish guidelines for laboratory 
animal research, and European regulations (Directive 86/609/EEC).
3.2.2 Zebrafish husbandry
Tupfel long n (TLF) and Tg(k1:GFP) zebrash were maintained under standard 
conditions following institutional and international guidelines. Zebrash eggs 
were obtained from natural spawning. 
3.2.3 CRISPR/Cas9 design
e zebrash znf408 protein sequence was aligned with the human ZNF408 
protein using AlignX in VectorNTI soware package, to determine the position 
of the fourth zinc nger domain in zebrash znf408 (Figure S1). Subsequently, 
guide RNAs (gRNAs) targeting the nucleotide sequences around the fourth zinc 
nger domain (Figure 1a) were designed using Chopchop soware (https://
chopchop.rc.fas.harvard.edu/) and synthesized as previously described by Gagnon 
et al. [18]. A single-stranded DNA (ssDNA) donor template was used to generate 
the mutation that changes one of the histidine residues in the fourth zinc nger 
domain to a tyrosine, similar to the human p.His455Tyr mutation (Figure 1a). 
Next to the intended mutation, the donor template also contained silent mutations 
to avoid recognition by the gRNA (Figure 1a).
3.2.4 Generation of znf408 zebrafish model
To increase the eciency of the homology directed repair mechanism, the non-
homologous end joining repair mechanism was inhibited by a splice-blocking 
morpholino targeting ku70 (5’-AACTTTTTAGGCTCACCTGCATAGT-3’) [19, 
20]. A mix of 1 nl containing donor template (0.3 µM), gRNA (600 pg), Cas9 
protein (5 ng), ku70 morpholino (1.5 ng), phenol-red (0.01%), and KCl 0.2 M was 
injected using a Pneumatic Picopump pv280 (World Precision Instruments) into 
TLF zebrash embryos at a one-cell stage. e injected embyros were grown into 
adulthood at 28°C in E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 
0.33 mM MgSO4, supplemented with 0.01% methylene blue). ree months post-
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fertilization, adult CRISPR-injected sh were in-crossed. e ospring was raised 
and individually genotyped. Subsequently, the appropriate znf408 mutants were 
crossed with Tg(k1:GFP) sh to generate zebrash with modied znf408 and a 
GFP reporter on the blood vessels (Figure 1b). e generated sh were then in-
crossed to generate homozygous models (Figure 1b).
3.2.5 Genotyping
Larvae and adult sh were genotyped by lysing the larvae or the n of the adult 
sh in lysis buer (40 mM NaOH and 0.2 mM EDTA) for 20 minutes at 95°C. For 
PCR amplication targeting the mutated region, 1-4 µl of the ten times diluted 
lysate was used. e primers fw 5’-GTGCACAGAGTGTGGCAAGT-3’ and rev 
5’-CACGTTGGCGAAAACACTTA-3’ were used for genotyping and subsequent 
Sanger sequencing. 
3.2.6 RNA analysis
For each RNA isolation, a pool of 25 zebrash larvae was used. e larvae were 
snap frozen in liquid nitrogen at 2 days post fertilization (dpf) and either stored 
at -80°C or directly used for RNA isolation. e larvae were homogenized in 
Qiazol (Qiagen, Hilden, North Rhein Westphalia, Germany). e homogenized 
larvae were subjected to overnight chloroform:isopropanol precipitation using 
glycogen as a carrier. e precipitated RNA was subsequently puried using 
the Nucleospin RNA kit (Macherey Nagel, Düren, North Rhein Westphalia, 
Germany) following the manufacturer’s instructions. cDNA was synthesized 
from 500-1000 ng RNA using the iScript cDNA (Bio-rad, Hercules, California, 
United States) synthesis kit. e obtained cDNA was used as template for znf408 
amplication using the same primers as used for genotyping. e product 
of this amplication was also Sanger sequenced to ensure that the mutation is 
transcribed into the mRNA. For normalization purposes, actb1 was amplied 
using primers fw 5’-CAACACTTCAGATCACTTCTCAGG-3’ and rev 
5’-CATTCTGCTCAAGGACATTGG-3’. 
3.2.7 Immunohistochemistry
Zebrash larvae at 5 dpf were incubated for 10 minutes in 10% (w/v) sucrose/
PBS solution for cryo-protection, followed by embedding in Optimal Cutting 
Temperature (OCT) reagent and snap freezing in isopentane cooled in a liquid 
nitrogen bath. e cryosections (7 µm) were xed in 4% paraformaldehyde 
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(PFA) for 10 minutes at room temperature followed by permeabilization in 0.01% 
(v/v) Tween 20/PBS for 20 minutes at room temperature. Subsequently, the 
cryosections were blocked in 10% normal goat serum and 2% BSA for 1 hour at 
room temperature. e immunostaining was performed using rabbit anti-ZNF408 
antibody (1:100, Sigma). e sections were washed 3 times 5 minutes with PBS and 
then subjected to secondary antibody and DAPI incubation for 1 hour at room 
temperature. e secondary antibodies used were goat-anti-rabbit Alexa Fluor 
568 (1:800, Molecular Probes, ermo Fisher Scientic, Waltham, Massachusetts, 
United States). Sections were mounted using ProLong Gold (ermo Fisher 
Scientic, Waltham, Massachusetts, United States). Images were taken with Zeiss 
Axio Imager Z2 (Zeiss, Oberkochen, Baden-Württemberg, Germany).
3.2.8 Vascular phenotyping
Vascular density, morphology and leakage was evaluated by confocal microscopy 
in the retina of zebrash larvae at 5 dpf, young adults at 90 dpf or adults at 180 dpf, 
following intravenous or intraperitoneal injection in larvae or adults, respectively, 
of lysine-modied, rhodamine-conjugated dextran at 70 kDa (ermo Scientic, 
Waltham, Massachusetts, United States), 30 minutes prior to euthanasia with 0.04% 
MS-222. Euthanized sh were then xed overnight at 4oC in 4% PFA, enucleation 
was performed and in case of the adult eyes, the cornea, lens and sclera was 
removed as previously described [21, 22]. Tissues were mounted, vitreal side up in 
VectaShield (Vector, Burlingame, California, Unitesd States) and visualized using an 
LSM700 upright confocal microscope (Leica, Wetzlar, Hesse, Germany). Numbers 
of completed and anastomosed vessels or incomplete sprouts were manually 
counted from confocal images of hyaloid/retinal vascular areas of a specied size 
and density was measured as the percentage of green pixels (i.e. endothelial area) in 
the total area. Numbers of completed hyaloid vessels, hyaloid or retinal sprouts and 
the vascular densities were analyzed in a total of 6-10 individual sh per group. e 
plasma content in the tissue was determined as the percentage of leaded dextran 
(i.e. red pixels in dual-color images) in an area of interest. Leakage was determined 
as the plasma content in the tissue divided by the total amount of dextran-
containing plasma in the area (i.e. red plus yellow pixels, the latter representing 
non-leaked, luminal dextran characterized by overlapping green and red signals). 
Plasma tissue content and leakage was analyzed in a total of 5-8 individual sh per 
group. Dierences between the groups were evaluated using ANOVA followed by 
Dunnett’s post-hoc test and p<0.05 was considered signicant.   
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3.2.9 Visual motor response assays
Visual motor response (VMR) assays were performed on zebrash larvae at 5 dpf 
using a DanioVision Observation Chamber (Noldus, Wageningen, Gelderland, 
the Netherlands). e larvae were individually placed in each well of a 48-well 
plate and subjected to 20 minutes habituation in the dark, followed by cycles of 
10 minutes light OFF (dark) and 10 minutes light ON (light) for 4 hours at 28°C. 
For every batch of larvae, the assay was performed once in the morning and once 
in the aernoon using dierent sets of larvae. At least three independent morning 
and aernoon assays were performed for each genotype. Distance moved (DM, in 
mm) and maximum velocity (Vmax, in mm/s) were tracked per larvae per second 
using EthoVision soware (Noldus, Wageningen, Gelderland, the Netherlands). 
Average DM and average Vmax of 24 wild-type larvae were compared to the 
average activity of 24 mutant larvae in each assay. Further, we focused our analysis 
on the startle response of the larvae to drastic light onset (change from light OFF 
to light ON). Delta DM and delta Vmax were calculated for each light onset in 
each assay. Delta DM or delta Vmax was dened as average DM or Vmax at light 
ON+1 sec and light ON+2 sec subtracted by the average DM or Vmax 30 seconds 
prior to light ON. Delta DM and delta Vmax of each light onset from at least 
three morning or aernoon assays were averaged and compared between those 
of wild-type larvae and mutant larvae. A two-tailed unpaired Student’s t-test was 
employed to calculate the signicant dierence between wild-type and mutant 
larvae at each light onset. e obtained p-values were subjected to multiple testing 
corrections using the Benjamini-Hochberg method. All analyses were performed 
using R version 3.3.1.
3.3 Results
CRISPR/Cas9 technology was employed to generate mutant znf408 zebrash 
models. A guide RNA (gRNA) was designed to specically target znf408 around 
the nucleotides coding for the fourth zinc nger domain (Figure 1a). A single-
stranded oligonucleotide containing the intended znf408 c.1282C>T change was 
designed as donor template, anked by 25 nucleotides long homology arms. A 
few silent mutations were inserted in the homology arms to avoid recognition 
by gRNA (Figure 1a). A mixture of gRNA, donor template and Cas9 protein was 
injected into one-cell staged zebrash embryos (F0). Several genotypes were 
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identied in adult F1 sh, including c.1282del (znf408rmc103/+), c.1282_1285del 
(znf408rmc104/+), and c.1282C>T (znf408rmc105/+) (Figure 1b). F1 sh with these 
genotypes were individually crossed with Tg(k1:GFP) sh to generate a zebrash 
line with both modied znf408 and GFP reported on the blood vessels. e 
generated heterozygous sh were crossed with each other to generate homozygous 
sh (Figure 1c) such that both heterozygous mutant (mimicking FEVR) as well as 
homozygous mutant (mimicking retinitis pigmentosa) sh could be studied. RT-
PCR analysis showed that in all znf408 mutant larvae (2 dpf) the mutant mRNAs 
were expressed, indicating that the mutant transcripts do not fully undergo 
nonsense-mediated decay (Figure 2a). 
e c.1282del and c.1282_1285del mutations lead to a frameshi and are 
predicted to generate shorter proteins that are truncated from the fourth zinc 
nger domain onwards, whereas c.1282C>T changes one of the core histidine 
residues in the fourth zinc nger domain to a tyrosine (p.His428Tyr), at the 
orthologous position of the p.His455Tyr mutation in human ZNF408 (Figure 1d). 
In each mutant generated, the predicted fourth zinc nger domain is disrupted 
due to the mutations introduced. We attempted to determine (mutant) znf408 
protein expression, by employing one of the antibodies directed against human 
ZNF408. As demonstrated in Supplemental Figure S1, the region of the epitope is 
not well conserved between human and zebrash proteins, nor should it recognize 
the truncated protein potentially present in the znf408rmc103/rmc103 and znf408rmc104/
rmc104 mutants. Immunohistochemistry of 5 dpf larvae, however, revealed ‘znf408’ 
staining in the outer plexiform layer (OPL), both in the wild-type and in all 
mutant conditions (Supplemental Figure S2), suggesting the observed staining 
is non-specic. Znf408 was not clearly detectable in the eyes of 3 mpf sh by 
immunostaining (Supplemental Figure S3) nor in the eyes of 6 mpf sh (data not 
shown), even though znf408 transcripts were detectable in the eyes of 90 dpf  and 
180 dpf sh (Figure 2b). 
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Figure 1. Generation of  znf408  zebrash models.  A) e 5 exons of zebrash  znf408  are shown. e 
sequences targeted in exon 5 as well as gRNA and donor template sequences are indicated. B) Sequence 
analysis of wild-type, znf408rmc105/rmc105, znf408rmc103/rmc103, and znf408rmc104/rmc104.   C) e crossing of znf408 
mutants with Tg(k1:GFP) line. D) Protein prediction of the znf408 mutants generated by Prosite tool 
(https://prosite.expasy.org/scanprosite/) based on the amino acid sequences. e length of the predicted 
mutant proteins is indicated.
Figure 2. RT-PCR analysis of znf408 transcripts. A) Znf408 is expressed in wild-type and mutant larvae at 
2 dpf. Two biological replicates are shown. B) Znf408 is expressed at 2 dpf and 5 dpf larvae as well as in the 
eye of 3 mpf and 6 mpf wild-type sh. Two biological replicates are shown. 
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Next, to analyze the retinal vascular development, function and pathology in 
larval and adult mutant sh or controls, we injected sh at 5, 90 or 180 dpf with 
uorescently-labeled 70 kDa Dextran, a method commonly used to analyze vascular 
perfusion, permeability and leakage, and investigated the retinal vasculature by 
confocal microscopy. At 5 dpf, we found a signicantly reduced number of hyaloid 
vessels formed in all three homozygous mutant strains, as well as in heterozygous 
missense (znf408rmc105/+) mutants (Figure 3), leading to signicantly reduced 
hyaloid vascular density (Supplemental Figure S4). Ongoing hyaloid angiogenesis 
at these developmental stages was apparent by the presence of several vascular 
sprouts in all groups, but there were no signicant dierences in sprouting across 
the genotypes analyzed (Supplemental Figure S5). e hyaloid vessels that did 
develop, however, were well perfused and did not leak uorescently-labeled 
dextran from the plasma into the tissue (Figure 3a and Supplemental Figure S5). 
In contrast to this early phenotype, homozygous mutant sh at 90 dpf developed 
robust retinal neovascularization as evidenced by widespread ectopic sprouting 
of retinal capillaries (Figures 3a and –c and Supplemental Figure S5). ese new 
sprouts were thin and non-functional and as such did not support perfusion 
(Figure 3a) and did not signicantly increase the density of the retinal vasculature, 
except for the znf408rmc103/rmc103 strain (Supplemental Figure S4). Importantly, the 
vessels were also not leaky at this time point, as no uorescently-labeled dextran 
was found outside the vascular lumen (Figure 3a and Supplemental Figure S5). 
Interestingly, at later stages of disease development represented by 180 dpf sh, 
the unstable and non-perfused sprouts seen in the 90 dpf sh had largely regressed 
(Figure 3a), although a smaller yet statistically signicant number of ectopic 
sprouts still remained (Supplemental Figure S5). e retinal vascular density had, 
however, returned to wildtype levels in the znf408rmc103/rmc103 strain (Supplemental 
Figure S4). Interestingly, at this stage, the retinal vasculature had become extremely 
leaky, as demonstrated by multiple, large edematous pools of uorescently-labeled 
dextran that had accumulated under the inner limiting membrane of the retina, 
especially in the znf408rmc103/rmc103 and znf408rmc104/rmc104 strains (Figures 3a and –d and 
Supplemental Figure S5). Collectively, these ndings demonstrate a progressive 
retinal vascular pathology developing in znf408-mutant zebrash characterized 
by initially impaired hyaloid vessel development, followed by exaggerated retinal 
sprouting and which culminates in robust leakage and retinal edema. Importantly, 
this trajectory closely recapitulates the vascular changes found in patients with 
FEVR.
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Figure 3. Progressive vascular pathology in znf408-mutant zebrash larvae and adults. A) Confocal 
micrographs at 5, 90 or 180 dpf of the hyaloid (5 dpf, top row) or retinal vessels (90 dpf, second row and 180 
dpf, third row) in znf408+/+, znf408rmc105/+, znf408rmc105/rmc105, znf408rmc103/rmc103, and znf408rmc104/rmc104 zebrash 
crossed onto the Tg(k1:GFP) background (vessels shown in green) following injection with rhodamine-
conjugated dextran (plasma shown in red). B) Quantication of the number of hyaloid vessels at 5 dpf from 
the groups shown in a. n=10, ANOVA: p<0.001, Dunnets post hoc: ***:p<0.001. C) Quantication of the 
number of sprouts in the retinal vessels at 90 dpf from the groups shown in a. n=10, ANOVA: p<0.001, 
Dunnets post hoc: ***:p<0.001. D) Quantication of the leaked dextran as a percentage of total dextran in 
the retinal vasculature at 180 dpf from the groups shown in a. n=10, ANOVA: p<0.001, Dunnets post hoc: 
***:p<0.001. 
 
To assess if there is any visual impairment in these zebrash, 5 dpf zebrash 
larvae were subjected to VMR assay. In this assay, 24 wild-type and 24 mutant 
larvae were placed individually in a 48-well plate and were exposed to light and 
dark condition every 10 minutes for 4 hours. e movements of the larvae were 
monitored during the assay, which is measured as distance moved (in mm) and 
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velocity (in mm/s). We focused our analysis on the startle response of the larvae to 
drastic light onset, such as the movement occurring during the switch from dark 
to light. Although, signicant dierences in startle response between wild-type 
and mutant larvae was not observed, there was a trend that the mutant larvae, 
particularly znf408rmc103/rmc103 and znf408rmc105/rmc105 mutants, did not respond to the 
light switch as much as the wild-type larvae (Figure 4). 
Figure 4. Mutant larvae appear to have less visuomotor response towards light. A) A schematic overview 
of the light treatment given to the 5 dpf larvae. Black bars denotes dark (light OFF), while white bars 
illustrates light (light ON) condition. Numbers underneath the bars indicate the duration of the condition 
in minutes. B) Bar graphs showing the startle response of wild-type vs mutant larvae. Startle response is 
stated as delta distance moved (DM, in mm) or delta maximum velocity (Vmax, in mm/s). Delta DM or 
delta Vmax was dened as average DM or Vmax at light ON+1 sec and light ON+2 sec subtracted by the 
average DM or Vmax 30 seconds prior to light ON.
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3.4 Discussion
e identication of a mutation in ZNF408 in an autosomal dominant FEVR 
family followed by further in vitro investigation has indicated its role in the 
development of vasculature [4, 23]. To further study ZNF408 in vivo, we 
generated two truncated (znf408rmc103/rmc103 and znf408rmc104/rmc104) and one missense 
(znf408rmc105/rmc105) zebrash model using CRISPR/Cas9 technology. Mutant 
transcripts were generated and did not seem to fully undergo nonsense-mediated 
decay. Immunohistochemistry analysis failed to reliably detect znf408 in zebrash 
retina, possibly due to the poor conservation between the human and zebrash 
amino acid sequence of ZNF408 in the region of the epitope. Nevertheless, the 
zebrash models we generated clearly showed retinal vascular phenotypes at 5 dpf, 
90 dpf and 180 dpf. 
e presence of a zebrash orthologue for the majority of known human disease 
genes and its genetic versatility render it a suitable animal model to study gene 
function. Moreover, the similarity of its retinal structure to that of humans, and the 
availability of vasculature-specic transgenic reporter lines, allowed observation 
of retinal vasculature development in a disease context, such as intended in this 
study. Although phenotypic discrepancy between morpholino and gene editing 
studies in zebrash has been reported [15-17], this was not the case for znf408. 
At the larval stage, znf408 mutant zebrash showed delayed retinal vasculature 
development, similar to that observed previously in morpholino-mediated 
knockdown experiments [4]. is suggests the specicity of the phenotype 
observed upon znf408 modication with either method. e use of gene editing to 
generate stable znf408 zebrash mutants allowed us to follow-up the phenotypic 
observations to adult stages.
 
All three mutant lines exhibited similar pathological hyaloid or retinal vascular 
features, strongly indicating that these phenotypes were caused by specic 
modication of znf408 function in these strains. In all three strains, hyaloid vessel 
development was stunted, suggesting that znf408 is important for angiogenesis 
specically in the hyaloid vasculature. In juvenile (3 months old) mutants, however, 
ectopic capillary sprouting in the peripheral retina was evident, a phenotype highly 
reminiscent of hypoxia-induced capillary sprouting [21, 22], suggesting that the 
initially under-developed retinal vasculature likely led to retinal hypoxia which 
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in turn drove ectopic capillary sprouting. At 6 months, the immature capillary 
sprouts had regressed but the capillary network remained immature and highly 
leaky. ese phenotypes closely resemble the vascular pathologies seen during 
progression of FEVR in humans, which also begin with a retinal vasculopathy but 
at more advanced stages progress to pathological retinal neovascularization and 
leakage [2, 24]. As such, the functions of znf408 in regulating the zebrash retinal 
vasculature closely recapitulate that seen in humans.
ZNF408 encodes for a protein that belongs to the PRDM (positive regulatory 
domain I-binding factor 1/PRDI-BF1 and retinoblastoma-interacting zinc 
nger protein 1/RIZ1 homology domain containing) family. Such a protein 
typically contains a PRDM domain, which is oen found in a subfamily of SET 
methyltransferases, and multiple adjacent C2H2 zinc nger domains. Members 
of this family have been reported to regulate gene expression either by enzymatic 
activity towards histone modication, or by interacting with other proteins to 
modify gene expression [25, 26]. e C2H2 domains of ZNF408 are conserved 
in several  species (i.e. Homo sapiens, Bos taurus, Canis familiaris, Mus musculus 
and Danio rerio), highlighting their importance. Znf408 mRNA was detectable 
in both truncated lines (znf408rmc103/rmc103 and znf408rmc104/rmc104), suggesting that 
the mutant mRNA did not undergo nonsense-mediated decay, at least not to a 
large extent. erefore, a truncated znf408 may be produced in znf408rmc103/rmc103 
and znf408rmc104/rmc104 zebrash. However, the protein is likely not functioning 
properly due to the disrupted zinc nger domains, hence the retinal vasculature 
phenotype. We have seen in znf408rmc105/+ sh, how even a single amino acid 
change in the fourth C2H2 domain led to the observed phenotype, comparable 
to that observed in all homozygous mutant lines. However, while all mutant lines 
exhibited similar overall phenotypes, subtle dierences in severity were apparent 
at the 5, 90 and 180 dpf timepoints. Whereas heterozygous znf408rmc105/+ mutants 
exhibited impaired hyaloid vessel development that was non-inferior to that 
seen in the homozygous mutants, the heterozygous sh at 90 and 180 dpf were 
not phenotypically dierent from wildtype controls. is suggests that while the 
development of hyaloid vasculature was temporarily delayed in the heterozygous 
znf408rmc105/+ mutants, it likely recovered faster or more fully leading to retinal 
normoxia at 90 dpf compared to the homozygous mutants. Also at 180 dpf, the 
homozygous missense znf408rmc105/rmc105 mutants did not exhibit the same level of 
vascular leakage as in the znf408rmc103/rmc103 and znf408rmc104/rmc104 mutants that are 
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predicted to produce truncated znf408 proteins. is suggests that in zebrash 
znf408 additional vascular functions are associated with the region downstream 
of the fourth zinc nger domain.  
FEVR patients carry the p.His455Tyr mutation in a heterozygous manner [4]. 
In zebrash, we observed a clear phenotypic dierence between znf408rmc105/+ 
and znf408rmc105/rmc105. Such a diference was also noted in the animal models for 
other FEVR genes, such as FZD4, LRP5, and TSPAN12, in which the heterozygous 
knock-out mice did not show (prominent) phenotype, although both heterozygous 
and homozygous mutations in these genes have been reported in FEVR patients 
[2, 27-29]. It is still poorly understood what underlies this dierence. Intriguingly, 
the vascular disruption observed in znf408 mutants seemed to be specic to the 
hyaloid/retinal vasculature. is is in line with other studies demonstrating specic 
requirements for PI3K [30], VEGF-B [31], or Vitamin D [32] in the development 
of the hyaloid vessels in zebrash. e specic role of these signaling pathways 
and whether they constitute dierent points in the same pathway or contribute 
to several independent pathways that converge on regulating retinal vascular 
development is an area of future investigation.
e p.His455Tyr mutation is located within one of the C2H2 domains of ZNF408 
and a previous study has shown that endothelial cells overexpressing p.His455Tyr 
ZNF408 failed to form tube networks in vitro. Subsequent transcriptome analysis 
revealed that ZNF408 regulates the expression of genes involved in the development 
of vasculature, a process that appears to be disrupted by the p.His455Tyr mutation 
[23]. Taking into account the comparable in vitro versus in vivo phenotype, it 
is tempting to hypothesize that znf408 has a similar molecular role in zebrash 
and the phenotype observed is due to gene expression perturbances. Further 
investigation to the transcriptome of the mutant zebrash models may shed further 
light on this. Analysis performed at dierent time points may also deepen our 
insight into the molecular dynamics leading to the unique phenotypes observed 
at the dierent stages. 
We attempted to detect znf408 protein in the zebrash retina by 
immunohistochemistry. Znf408 appeared to localize to the outer plexiform layer 
in the wild-type zebrash larvae. However, a similar signal was also detected in 
znf408rmc103/rmc103 and znf408rmc104/rmc104, although the antibody epitope should not be 
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present in case a truncated znf408 is expressed in the mutant models. Furthermore, 
no reliable signal was obtained in the retina of young adult (three mpf) and adult 
(six mpf) zebrash. Materials only stained with the secondary antibody did not 
give any uorescent signal, indicating that there is no aspecic binding of the 
secondary antibody. In addition, the uorescent signal was only obtained if the 
zebrash materials were not xed prior to cryosectioning. It is possible that there 
is not enough similarity between the epitope of the primary ZNF408 antibody used 
and the zebrash znf408 amino acid sequence. e specicity of the antibody was 
previously tested by immunocytochemistry on a cellular system overexpressing HA-
tagged znf408, and the uorescent signal of the HA-tag and znf408 were overlapping, 
suggesting that the antibody used, in theory, could recognize zebrash znf408, 
albeit overexpressed. Nevertheless, we cannot exclude whether there is any peptide 
in zebrash that resembles the epitope of the primary antibody, hence the signal 
oberved in znf408rmc103/rmc103 and znf408rmc104/rmc104 mutant lines. A primary antibody 
directed specically against zebrash znf408, in combination with blocking peptides, 
will likely yield more reliable results. 
is study corroborates the involvement of ZNF408 in the development of retinal 
vasculature and also in the disease mechanism of FEVR. Intriguingly, in humans, 
bi-allelic loss-of-function mutations in ZNF408 have been reported to underlie 
autosomal recessive retinitis pigmentosa [33, 34]. e loss of function znf408 
zebrash models (as in znf408rmc103/rmc103 and znf408rmc104/rmc104) showed defective 
retinal vasculature development and only mild visual impairment in visuomotor 
assay, particularly if compared to the visual impairment observed in retinitis 
pigmentosa zebrash models [35-37]. One explanation for this is that the visuomotor 
assay we used here is not sensitive enough, and alternatives (e.g. electroretinogram 
recordings, optokinetic response measurements) would be needed. us, it is yet 
to be determined how (predicted) loss of function of znf408 (as in znf408rmc103/rmc103 
and znf408rmc104/rmc104) showed a retinal vasculature phenotype instead of retinitis 
pigmentosa-like symptoms in zebrash. If truncated znf408 is present in znf408rmc103/
rmc103 and znf408rmc104/rmc104, it is well possible that the lost of function to the C-terminal 
did not disrupt photoreceptor function, albeit the apparent vasculature damage. 
Generation of a full znf408 knock-out model, in which the indels are inserted as 
early as possible in znf408 may provide further insight. Moreover, deeper molecular 
studies of our zebrash models by using e.g. transcriptome analysis will likely 
increase our understanding on this apparent discrepancy. 
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In conclusion, we here show that disruption of znf408, as well as the introduction 
of a missense mutation mimicking ZNF408-associated FEVR, in zebrash leads 
to abnormal development and function of the retinal vasculature system. To our 
knowledge, these are the rst stable FEVR models in zebrash and also the rst 
animal models generated to study ZNF408, which can increase our knowledge on 
the development of retinal vasculature in general, and the still largely unknown 
mechanisms on how mutations in ZNF408 can lead to FEVR in humans.
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Figure S1. Sequence alignment of human ZNF408 protein with zebrash znf408 protein. Identical 
residues in all sequences are white on a black background. e predicted domains of ZNF408 protein are 
indicated. e epitope of the ZNF408 antibody used in this manuscript is indicated by orange color and 
underline.
Figure S2. Znf408 is localized in the outer plexiform layer and can be detected in wild-type and mutant 
larvae at 5 dpf. e signal for znf408 is indicated with white arrowheads and the three nuclear layers of the 
retina are denoted. e detection of the signal in the truncated mutant larvae renders the results as doubtful. 
Scale bar is 50 µm.
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Figure S4. Znf408-mutant zebrash larvae have lower density of hyaloid vasculature, compared to the 
wild-type. Quantication of hyaloid and retinal vasculature at 5, 90, and 180 dpf. n=10, ANOVA: p<0.001, 
Dunnets post hoc: ***:p<0.001
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Figure S5.  Quantication of sprouting and leakage in the retinal vessels at 5 dpf, 90 dpf, and 180 dpf. 
Each group has n=5-8, ANOVA: p<0.001, Dunnets post hoc: ***:p<0.001.
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Abstract
Familial exudative vitreoretinopathy (FEVR) is an inherited retinal disorder that is 
primarily characterized by absence or abnormal development of vasculature in the 
peripheral retina. Heterogeneous clinical features and genetic causes have been 
observed in FEVR. Moreover, reduced penetrance has also been reported in up 
to 25% of mutation carriers. Nevertheless, it still largely unknown what causes 
reduced penetrance in FEVR. A mutation in ZNF408 (c.1363C>T, p.His455Tyr) 
was identied in an autosomal dominant FEVR family and non-penetrance of this 
mutation was observed in two unaected individuals. In this study, we performed 
a pilot investigation whether it is possible to generate patient-specic endothelial 
cells from induced pluripotent stem cells (iPSCs) and used the obtained cells 
as in vitro model of FEVR in order to study ZNF408-associated reduced 
penetrance. Primary broblasts cultures were generated from skin biopsies and 
then reprogrammed into iPSCs. Subsequently, the iPSCs were dierentiated to 
endothelial lineage and then characterized by immunostaining, gene expression 
analysis, and in vitro tube formation assay. e obtained endothelial cells from 
controls, patient, and unaected mutant carrier were comparable with respect to 
morphology, expression of endothelial cells markers, as well as their angiogenic 
ability. A trend of lower dierentiation eciency towards endothelial cells was 
observed in both the patient and the unaected mutant carrier, when compared 
to controls. Furthermore, the expression of ZNF408 in the unaected mutant 
carrier was approximately 2-fold lower than in patient and controls. Altogether, 
this pilot study showed that it is possible to generate patient-specic endothelial 
cells and characterize them to study reduced penetrance in FEVR. To this end, 
the experiments performed in this study, however, did not explain the underlying 
cause of reduced penetrance in FEVR.
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4.1 Introduction
Familial exudative vitreoretinopathy (FEVR) was rst described by Criswick and 
Schepens [1]. It is an inherited retinal disorder, which is hallmarked by the absence 
or abnormal development of vasculature in the peripheral retina [2-4]. Various 
clinical features are observed in FEVR patients, whose manifestations can range 
from no visual symptom to complete blindness [5]. Furthermore, it is a genetically 
heterogeneous disorder. Mutations in multiple genes have so far been found to be 
associated with FEVR [6-14].  
Collin et al. reported a mutation in ZNF408 (c.1363C>T, p.His455Tyr) in a large 
autosomal dominant FEVR family [7]. Besides its presence in FEVR patients, 
this mutation was also detected in two unaected family members, suggesting 
reduced penetrance. Both unaected family members inherited the mutation 
from one aected parent and possessed a dierent wild-type allele compared to 
their aected sibling (Figure 1).
Non-penetrance is dened as a state in which the presence of a genotype trait 
does not manifest in the expected phenotype. In FEVR, non-penetrance has been 
observed in up to 25% of mutation carriers [15]. e penetrance of a genetic 
variant can be inuenced by multiple factors, for instance, gene expression levels, 
epigenetic modications, environment, gender, age, allele dosage or modier 
genes [16]. e underlying cause(s) of reduced penetrance in FEVR are still hardly 
understood. 
To investigate the cause of non-penetrance, one would need patient material, 
which has the appropriate genetic background, derived from a relevant tissue. 
Since retinal vasculature is aected in FEVR, we considered endothelial cells as 
a relevant in vitro model. Although it is not possible to directly access retinal 
endothelial cells from FEVR patients, recent advances in cellular technology have 
shown the feasibility of generating patient-specic endothelial cells (ECs) from 
induced pluripotent stem cells (iPSCs), and subsequently employ the generated 
iPSC-derived ECs (iPSC-ECs) to study vascular diseases (reviewed in [17, 18]). 
Moreover, Gu et al. recently showed the application of iPSC-ECs to study reduced 
penetrance observed in familial pulmonary arterial hypertension [19].  
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In this study, we employed iPSC-ECs to study a non-penetrance case observed in 
ZNF408-associated FEVR. Skin biopsy-derived primary broblast cultures were 
obtained from one of the unaected mutation carriers (UMC) and her aected 
sibling (Figure 1). e generated broblasts were reprogrammed to a pluripotent state 
and subsequently, dierentiated into the endothelial lineage. Flow cytometry was 
employed to sort the cells into a homogeneous endothelial cell population and also to 
assess the dierentiation eciency. Furthermore, the characteristics of the obtained 
endothelial cells were examined by immunostaining, gene expression analysis, as well 
as in vitro tube formation assay. e properties of endothelial cells derived from the 
patient and the UMC were compared to each other and also to controls. 
4.2 Materials and Methods
4.2.1 Ethical statement
Written informed consent was obtained from all participants. is study was 
approved by the Local Ethics Committee and conducted in adherence to the tenets 
of Declaration of Helsinki. 
4.2.2 Fibroblast culture
Skin biopsies were obtained from two healthy individuals (male and female), one 
FEVR patient (female), and one unaected mutation carrier (female). Primary 
broblast cultures were derived from the obtained skin biopsy. e broblasts 
were cultured in DMEM supplemented with 20% FCS, 1% sodium pyruvate, and 
1% Pen/Strep. 
4.2.3 Fibroblast reprogramming to iPSCs
Primary broblast lines were reprogrammed into iPSCs by lentiviral transduction 
of pluripotency genes OCT3/4, NANOG, KLF4, and c-MYC, following the standard 
procedures of the Stem Cell Technology Center of the Radboud University Medical 
Center, as previously described [20]. e pluripotency of the obtained cells was 
examined by immunocytochemistry of pluripotency markers (Figure S1 and S2). 
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4.2.4 iPSC and hESC culture
Human embryonic stem cells (hESCs, WA09(H9)) were obtained from WiCell. 
iPSCs and hESCs were cultured in Essential 8 ex medium (ermo Fisher 
Scientic) on Matrigel coated culture dishes (1:15 dilution, BD Biosciences). e 
colonies were split every 4-7 days.  
4.2.5 iPSC and hESC differentiation to endothelial cells
e dierentiation of hESCs and iPSCs to endothelial cells was performed following 
the protocol described earlier by Patsch et al. [21]. Briey, iPSCs were seeded as 
single cells with the density of 300,000 cells per well of a 12-well plate coated with 
Matrigel (1:15 dilution, BD Biosciences). e cells were seeded in Essential 8 Flex 
medium (ermo Fisher Scientic) supplemented with 10 µM Rock inhibitor 
Y-27632 (Sigma Aldrich). e following day the medium was changed into 
mesoderm induction medium, which consisted of DMEM/F12 (Sigma Aldrich) 
and Neurobasal (ermo Fisher Scientic) medium in 1:1 ratio, supplemented 
with 1% N2 (ermo Fisher Scientic), 2% B27 (ermo Fisher Scientic), 25 
ng/µl BMP4 (Sigma Aldrich), and 6 µM CHIR-99021 (Bio-Techne). ree days 
later, the cells were further specied to an endothelial lineage for two days. e 
endothelial induction medium contained StemPro-34 SFM medium (ermo 
Fisher Scientic) supplemented with 1% L-alanyl-L-glutamine (Sigma Aldrich), 2 
µM forskolin (Sigma Aldrich) and 200 ng/µl VEGF (Peprotech). e endothelial 
induction medium was renewed daily until day 6. On the sixth day, the cells were 
sorted for CD31+ cells by ow cytometry (see below) and were re-plated on 12-
well plate coated with 0.01 mg/ml bovine bronectin (Promocell). e endothelial 
cells were expanded to conuency in Endothelial Growth Medium 2 (Promocell) 
supplemented with 50 ng/µl VEGF (Peprotech). e medium was refreshed every 
48 hours until the cells reached conuency and were harvested.
4.2.6 Fluorescent activated cell sorting (FACS)
At day 6 of dierentiation, the cells were dissociated as single cells. ree million 
cells were resuspended in 200 µl FACS buer (1 mM EDTA, 25 mM HEPES pH 7, 
and 1% FCS in PBS), and stained with CD31-FITC antibody (Beckman Coulter) 
for 45 min on ice. e stained cells were washed once with PBS and ltered through 
70 µm lter to remove cell clumps. Subsequently, the cells were sorted through 
85 µm nozzle of Aria cell sorter (Becton Dickinson). e percentage of CD31+ 
cells was analyzed using Kaluza Analysis 2.1 soware (Beckman Coulter) based 
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on 10,000 events. One-way ANOVA followed by Tukey’s multiple comparison test 
was employed in the statistical analysis of three independent experiments.
4.2.7 DNA analysis
Genomic DNA was isolated from broblasts, hESC-derived endothelial cells 
instead of hESC- derived endothelial cells (hESC-ECs), and iPSC-ECs using 
QIAamp DNA mini kit (Qiagen) following the manufacturer’s instructions. 
e region containing ZNF408 c.1363C>T mutation was amplied from 
25 ng DNA using fw 5’-CCTGGCCAAGAAGTTACACAG-3’ and rev 
5’-TTTCTCCTGTATGGAGCCTCA-3’ primers. e amplied products were 
subsequently subjected to Sanger sequencing.
4.2.8 In vitro tube formation assay
e hESC-ECs and iPSC-ECs were seeded on 96-well plate coated with Matrigel 
(BD Biosciences) at a density of 1.5 x 104 cells per well. Twenty hours later, the cells 
were stained with 6 µM Calcein Red (ermo Fisher Scientic). Cells were imaged 
on an EVOS cell imaging station. e tube networks were quantied using the 
online Wimtube tool from Wimasis (https://www.wimasis.com/en/products/13/
WimTube). Two images were quantied per condition in three independent 
experiments. e data obtained were subjected to one-way ANOVA with Tukey’s 
multiple comparison post-hoc analysis. 
4.2.9 Immunocytochemistry
Fibroblasts were cultured on a 12-well plate with coverslips, whereas hESC-ECs 
and iPSC-ECs were grown on a 12-well plate with coverslips coated with 0.01 mg/
ml bovine bronectin (Promocell). Upon conuency, the cells were xed with 2% 
PFA for 20 min at room temperature. e cells were then permeabilized using 
1% Triton X-100 in PBS (v/v) for 5 min, followed by 2 x 5 min washes in PBS and 
blocking with 2% BSA in PBS (w/v) for 20 min. e broblasts were stained with 
rabbit anti ZNF408 (1:100, Biorbyt) for 2h at room temperature. Alternatively, the 
iPSC-ECs were stained with the following primary antibodies, sheep anti CD31 
(1:100, R&D Systems), goat anti VE-cadherin (1:100, R&D Systems), and rabbit 
anti ZNF408 (1:100, Biorbyt) for 2 h at room temperature. Aer 3 x 5 min washes 
in PBS, secondary antibodies were introduced. e secondary antibody used 
in broblast staining was goat anti rabbit Alexa Fluor 488, while the secondary 
antibodies used in iPSC-EC staining were donkey anti sheep Alexa Fluor 488, 
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donkey anti goat Alexa Fluor 647, and donkey anti rabbit Alexa Fluor 568. 
Secondary antibodies were used in a dilution of 1:500 (ermo Fisher Scientic). 
Following 3 x 5 min washes in PBS and rinsing in Milli-Q, the cells were mounted 
using Vectashield with DAPI (Vector Laboratories). e slides were imaged on 
Zeiss Axio Imager.
 
4.2.10 Gene expression analysis by qPCR
Total RNA was isolated from broblasts, hESC, and iPSC-derived endothelial 
cells using the Macherey Nagel RNA extraction kit, following the manufacturer’s 
instructions. e obtained RNA (1000 ng) was used to synthesize cDNA using 
the iScript cDNA synthesis kit (Bio-Rad) according to the instruction manual. 
Quantitative real-time PCR (qPCR) was performed using GoTaq qPCR master mix 
(Promega). e primers used are listed in Supplementary Table 1. ree technical 
replicates of each condition were measured in three independent experiments. 
One-way ANOVA with Dunnet’s post-hoc analysis was utilized in the statistical 
analysis of broblasts qPCR and Kruskal-Wallis test followed by Dunns post-hoc 
analysis was used in the analysis of hESC-ECs and iPSC-ECs qPCR.
4.2.11 Statistical analysis
Statistical tests used in the data analysis of the dierent experiments are described 
in detail in the sections that belong to the corresponding experiments.
4.3 Results
Skin biopsies were obtained from an FEVR patient and her unaected sibling 
who also carries the p.His455Tyr mutation (Figure 1). Haplotype analysis showed 
that both individuals inherited the mutant allele from the father, but inherited a 
dierent wild-type allele from the mother (Figure 1) [7].
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Figure 1. Pedigree of the autosomal dominant FEVR family. Square denotes male and circle represents 
female. Filled squares or circles indicate aected individuals. Haplotype analysis of chromosome 11p11.2 is 
shown below each individual. Unaected ZNF408 c.1363C>T mutation carriers (V:1 and V:4) are indicated 
with red arrows. e individuals participating in this study (V:1 and V:2) are marked with a green rectangle. 
Modied from Collin et al. [7].   
Primary broblast cultures were derived from these skin biopsies. Subsequently, 
the obtained cells were characterized at DNA, RNA, and protein level. Sanger 
sequencing showed that broblasts derived from both individuals have the 
heterozygous ZNF408 c.1363C>T mutation (Figure 2a), that was absent in a 
broblast culture derived from a healthy control. Gene expression analysis showed 
no signicant dierence in ZNF408 expression between the three conditions 
(Figure 2b). Immunocytochemistry showed that ZNF408 is expressed at the 
protein level and localized in the nuclei of the broblasts (Figure 2c).
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Figure 2. Preliminary study in skin biopsy-derived broblasts. A) Sanger sequencing to conrm the 
presence of ZNF408 c.1363C>T variant at genomic DNA level in broblasts. B) Gene expression analysis of 
ZNF408 in control individual, FEVR patient and UMC. Gene expression is plotted as fold-change relative to 
housekeeping gene, GUSB. No signicant dierence was observed. C) Immunostaining of ZNF408 in 
control individual, FEVR patient and UMC broblasts. Scale bar is 10 µm. 
Since primary broblasts are not a completely relevant in vitro model to study 
vasculature-related diseases such as FEVR, we opted to use these cells to generate 
patient-specic endothelial cells in this study. To generate such an in vitro model, 
the obtained broblasts were reprogrammed into iPSCs and subsequently, 
dierentiated into endothelial cells. e reprogramming into iPSCs was performed 
by lentiviral transduction of pluripotency genes OCT3/4, NANOG, KLF4, and 
c-MYC. e pluripotency of the obtained iPSCs was veried by immunostaining 
of pluripotency markers (Figure S1). We used two control iPSC lines in this study, 
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which were also reprogrammed by lentiviral transduction. e pluripotency tests 
of these lines are presented in Figure S2. Additionally, the iPSC lines and hESC 
line used in this study were subjected to Sanger sequencing to conrm that both 
patient and UMC line carry the ZNF408 c.1363C>T mutation and that it is absent 
in the control iPSC lines as well as in the hESC line (Figure S3). 
e iPSC and hESC were dierentiated into the endothelial lineage following a 
protocol previously described by Patsch et al. [21]. Briey, the pluripotent cells 
were directed to the mesodermal lineage for 4 days and subsequently, specied to 
the endothelial lineage for 2 days. e obtained endothelial cells were sorted for 
cells expressing CD31, an endothelial cell marker, at day 6 to obtain a homogeneous 
cell population. e CD31+ cells were then grown to conuency and harvested 4-5 
days aer sorting (Figure 3). All the obtained endothelial cells showed a similar 
morphology (Figure 3). Nevertheless, dierent survival rate upon post-sorting 
seeding and growth rate between the dierent iPSC-EC lines were observed. ese 
were based on daily observations and were not quantied in this study, therefore, 
no data could be shown.
Figure 3. Dierentiatiation of pluripotent cells into endothelial cells. A) Schematic illustration of 
dierentiation procedure. B) Phase contrast images of the obtained CD31+ endothelial cells. e images 
were taken at 10x objective magnication using a Canon IXU 95 IS camera attached to the microscope. 
erefore, no scalebar could be drawn.
As indicated above, the hESC and control iPSC lines seem to dierentiate slightly 
more ecient into the endothelial lineage, compared to the patient iPSC and 
UMC iPSC lines. In three independent dierentiation experiments performed in 
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this study, there were less CD31+ cells obtained from patient iPSC and UMC iPSC 
lines, compared to the control lines. Although this dierence was not statistically 
signicant, there seems to be a trend which is consistent in three independent 
experiments. Figure 4 shows representative ow cytometry results of one of the 
dierentiation experiments as well as the average of CD31+ cells obtained from 
each line in the three experiments.
Figure 4. A trend of lower dierentiation eciency of patient iPSC and UMC iPSC. A) - E) Dot plots of 
the ow cytometry for cells positively labeled with CD31-FITC (red dots). Black dots represent CD31-
negative cells. e percentage of CD31+ cells is indicated in each plot. F) Bar graph depicting the average of 
CD31+ cells (in percentage) in three independent experiments. Error bars indicate standard deviation. 
Statistical analysis was performed using one-way Anova followed by Tukey’s multiple comparison test. No 
statistical signicance dierence was observed.
Immunocytochemistry was employed to further determine whether the obtained 
cells contained endothelial characteristics. Besides CD31, another endothelial cell 
marker, VE-cadherin (also known as CD144), was studied. Based on the results 
obtained in the immunostaining, the cell populations obtained were purely 
endothelial cells, expressing both CD31 and VE-cadherin (Figure 5). Additionally, 
we also stained for ZNF408 to determine whether there is any dierence in 
ZNF408 localization in control, patient and UMC-derived endothelial cells. In all 
lines, ZNF408 is localized in the nucleus of the cell (Figure 5). We also observed 
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some signal in the cytoplasm in some cells. However, this signal was occasionally 
present in endothelial cells derived from dierent sources without an apparent 
pattern in three independent experiments. erefore, it is tempting to suggest that 
these are aspecic signals. 
Figure 5. e obtained endothelial cells expressed endothelial cell markers, CD31 and VE-cadherin, and 
ZNF408 is localized in the nuclei of these cells. Immunostaining images were taken with similar exposure 
time for all the cell lines. Scale bar is 50 µm.
Gene expression analysis showed that the expression of OCT4, a pluripotency 
marker, was highest at day 0 and decreased throughout the dierentiation (Figure 
S4). is indicates that the cells used to start the dierentiation were pluripotent 
and subsequently, underwent dierentiation. Two mesoderm lineage markers 
tested, T and MIXL1, were upregulated at day 4, suggesting that the cells were 
specied to a mesoderm lineage at that point. 
Gene expression analysis of endothelial cell markers, CDH5 and PECAM1 (coding 
for VE-cadherin and CD31, respectively), conrmed the immunostaining results. 
Both genes were upregulated when dierentiated, compared to day 0 and day 4. 
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Harvest day is dened as the day the endothelial cells were conuent and therefore, 
harvested for immunostaining, RNA isolation, and in vitro tube formation assay. 
Day 0 and day 4 refers to pluripotent and mesodermal state, respectively. Another 
endothelial cell marker, von-Willebrand factor (VWF) was also upregulated, 
further conrming the endothelial specication of the cells. e expression level of 
ZNF408 was also measured and interestingly, it seems to be quite variable between 
individuals and also between the three independent experiments performed. It is 
also intriguing that the expression level of ZNF408 in UMC is approximately half 
of the one observed in the patient. is was also observed previously in another 
independent experiment (Figure S5). 
Figure 6. e obtained endothelial cells expressed endothelial cell markers and variable ZNF408 
expression. Gene expression is plotted as fold-change relative to housekeeping gene, GUSB. Error bars 
represent standard deviation of three independent experiments. Statistical analysis was performed using 
Kruskal-Wallis test, followed by Dunns post-hoc analysis. Statistical signicance (p-value <0.05) is denoted 
with *. Ns in VWF graph indicates that among the 5 conditions compared between the Day 4 and Harvest 
day, no statistical signicance was observed for control 2.
Finally, the obtained endothelial cells were subjected to an in vitro tube formation 
assay to study their endothelial behavior. In this assay, the endothelial cells were 
seeded at low density on extracellular matrix (Matrigel) and incubated for 16-20 
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hours to allow them to form capillary networks in vitro. However, no apparent 
dierence in their ability to form capillary networks was observed between the 
dierent cell lines (Figure 7). e images obtained were quantied for branching 
points, number of tubes, as well as tube length. No signicant dierence was 
observed between the conditions, suggesting that the obtained endothelial cells 
have comparable angiogenic ability. 
Figure 7. No apparent dierence was observed in in vitro tube formation assay. A) Representative images 
of tube networks formed by the obtained endothelial cells. Scale bar is 1000 µm. B) Quantication of the 
tube networks from three independent experiments, each of which consists of two technical replicates. Error 
bars depict standard error of the mean. No signicance dierence was observed between the conditions.
 
4.4 Discussion
In this study, we aimed to use iPSC-ECs as in vitro model to study reduced 
penetrance in FEVR. Skin biopsy-derived broblasts from an FEVR patient with 
the ZNF408 c.1363C>T mutation and her sister who is unaected despite carrying 
this mutation were reprogrammed into iPSCs. Subsequently, the obtained iPSC 
lines were dierentiated into endothelial cells. e dierentiation protocol used 
proved to be robust and yielded consistent results in three independent experiments. 
No remarkable dierence in morphology and endothelial cell characteristics was 
observed between endothelial cells derived from control, patient and UMC iPSC 
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lines. Patient and UMC iPSC lines showed a slightly lower dierentiation eciency 
towards endothelial cell lineage. Lastly, endothelial cells derived from UMC iPSC 
showed lower ZNF408 expression in comparison to those derived from patient 
and controls.
Although the iPSC-ECs derived from controls, patient, and UMC did not show 
any remarkable dierence in the aforementioned endothelial characteristics, 
dierent survival and growth rate post-sorting was observed (data not shown). 
Gu et al. showed in a reduced penetrance study using iPSC-EC that despite similar 
behavior in the in vitro tube formation assay, cells may have dierent survival and 
adhesion ability [19]. Besides, cell migration is also one of the functional assays 
oen used to characterize endothelial cells. It would be valuable to characterize 
the obtained iPSC-ECs in more detail with cell survival, cell adhesion, and cell 
migration assays, to further learn about the potential similarities and dierences 
of the iPSC-ECs lines. Additionally, the iPSC-ECs used in the experiments in this 
study were passage 1, obtained directly aer the sorting procedure, which was due 
to time constraints. Other studies using endothelial cells derived from pluripotent 
cells oen used later passages, such as passage 3-8 in Gu et al. and passage 4 in 
Patsch et al. [19, 21]. e experiments performed in this study would need to be 
repeated at other passages, to ensure reproducibility of the results and thereby, a 
just conclusion can be drawn about the in vitro behavior of the cells.
A trend of lower dierentiation eciency towards the endothelial lineage was 
observed in patient and UMC iPSC lines. is was seen consistently in three 
independent experiments conducted. Although it is tempting to assume that 
this showed that patient and UMC iPSC lines are not able to optimally generate 
endothelial cells, it may also be inuenced by the unique characteristics of each 
iPSC line. Patsch et al., the authors of the dierentiation protocol, mentioned 
that the optimal seeding density and CHIR 99021 concentration (i.e. GSK3β 
inhibitor used to direct dierentiation towards mesoderm lineage) may dier for 
each pluripotent cell line [21]. In this study, similar seeding density and CHIR 
concentration were utilized for all the lines to enable a fair comparison. erefore, 
the possibility that the conditions applied are not always optimal for patient and 
UMC iPSC lines cannot be excluded. 
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An intriguing dierence between iPSC-ECs is the lower expression of ZNF408 in 
UMC-derived endothelial cells, compared to patient and controls. Although the 
dierence is not statistically signicant, such dierence was observed consistently 
in several experiments and only observed at the endothelial state. It is tempting 
to hypothesize that this dierence in ZNF408 expression may be the underlying 
cause in the observed non-penetrance. However, it is unclear how lower ZNF408 
expression in UMC would protect against FEVR, while controls have comparable 
or higher ZNF408 expression than patient-derived cells. Cooper et al. summarized 
some examples of non-penetrance cases with dierential allelic expression, none 
of which is similar to this [16]. Furthermore, in our previous study, we showed 
that ZNF408 is involved in the development of vasculature [22]. Such hypothesis 
is only logical if the mutant p.His455Tyr allele is inactive in UMC, leading to the 
approximately 2-fold lower expression compared to patient-derived cells. As such, 
the inactivity of the mutant allele may protect the UMC against FEVR and that 
50% expression of the wild-type ZNF408 is likely to be sucient for proper retinal 
vasculature development. An allele-specic expression experiment on the iPSC-
ECs is required to prove this hypothesis. If conrmed, the investigation should 
be continued to discover what causes this allele-specic expression and what the 
molecular consequences of it are. Regardless whether this hypothesis is proven 
or not, a transcriptome proling of iPSC-ECs obtained may shed further light 
into the molecular mechanisms underlying ZNF408-associated non-penetrance 
observed in this family.
Considering the images obtained from immunostaining experiments, there seems 
to be background staining of ZNF408 in the cytoplasm of iPSC-ECs generated in 
this study. It may be improved by optimizing the staining protocol or choosing 
an alternative antibody. Nonetheless, it is interesting how immunostaining of 
endogenous ZNF408 in broblasts and iPSC-ECs showed nuclear staining in 
individuals with and without the p.His455Tyr mutation, despite the previous 
nding in which overexpression of p.His455Tyr mutant in COS1 cells showed 
cytoplasmic localization [7]. Such discrepancy has been observed previously, when 
comparing endogenous and articial overexpression systems [23]. Furthermore, 
the dierence in cellular system used and ZNF408 expression in each system may 
also inuence the localization. 
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As interesting as these ndings are, one must realize that this preliminary study 
is only based on experiments performed on one clone of each iPSC line. It has 
been demonstrated that such iPSC-based modelling studies require more controls 
and patients to attain reliable data [24]. It may be advantageous to repeat the 
experiments on other clones of these iPSC lines in order to exclude any ndings 
inuenced by interclonal variability. Furthermore, the generation of isogenic 
control iPSC lines by CRISPR/Cas9 technology may exclude the variability of 
dierent genetic backgrounds of the donor. Additionally, this study only consists 
of one example of non-penetrance of ZNF408 c.1363C>T in FEVR. Expanding 
the study to the other ZNF408 c.1363C>T non-penetrance branch of the family as 
well as other cases of non-penetrance in (ZNF408-associated) FEVR, would allow 
a better investigation and a deeper understanding of the underlying mechanism, 
provided that the individuals are willing to participate. 
Since only the patient was subjected to whole exome sequencing in the previous 
study by Collin et al. [7], we cannot exclude the possibility that there are other 
genetic variants that dier between patient and UMC that may contribute to the 
non-penetrance observed. Haplotype analysis showed that patient and UMC 
inherited a dierent wild-type allele from their mother [7]. Comprehensive 
sequence analysis, such as whole exome sequencing or whole genome sequencing, 
may aid in identifying any other genetic variant(s) that may inuence the dierence 
in phenotype between these individuals. 
Altogether, this study showed that it is possible to robustly generate patient-
specic endothelial cells to model FEVR in vitro, which open the avenues to 
study reduced penetrance in FEVR. Further investigations are required to validate 
the ndings observed in this study. It has yet to be determined whether reduced 
penetrance in FEVR has a universal cause, regardless of the genetic cause. Lastly, 
although as a developmental disease the window of opportunity is rather small, 
the identication of the factor(s) that protect the UMCs from FEVR may lead the 
path to the development of a potential treatment for FEVR patients. 
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Supplementary Materials
Figure S1. Immunocytochemistry of pluripotency markers of one clone of A) control 1 and B) control 2. 
Scale bars of all images of control 1 is 50 µm. Scale bars of the images in the top and middle row of control 
2 are 100 µm, whereas those of the images in the last row are 50 µm. Images courtesy of Stem Cell Technology 
Center, Radboudumc.
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Figure S2. Immunocytochemistry of pluripotency markers of one clone of A) patient and B) UMC. Scale 
bars of all images are 50 µm. Images courtesy of Stem Cell Technology Center, Radboudumc.
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Figure S3. iPSCs derived from the patient and UMC carried the heterozygous ZNF408 c.1363C>T 
mutation, which is absent in the controls. Sanger sequencing of the obtained pluripotent stem cells used in 
this study. e mutation is indicated.
Figure S4. Gene expression analysis of pluripotency and mesoderm markers. Gene expression is plotted 
as fold-change relative to housekeeping gene, GUSB. Error bars represent standard deviation of three 
independent experiments. Statistical analysis were performed using Kruskal-Wallis test, followed by Dunns 
post-hoc analysis. Statistical signicance (p-value <0.05) is denoted with *. 
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Figure S5. Gene expression analysis in an independent dierentiation experiment showing lower ZNF408 
expression in UMC. Gene expression is plotted as fold-change relative to housekeeping gene, GUSB. 
Control iPSC line used in this experiment is similar to control 1 used in the other experiments described in 
this chapter. 
Table S1 qPCR primer sequences
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’)
GUSB AGAGTGGTGCTGAGGATTGG CCCTCATGCTCTAGCGTGTC
OCT4 GTTCTTCATTCACTAAGGAAGG CAAGAGCATCATTGAACTTCAC
CDH5 AGGACGCTTTCACCATTGAG TCATGTATCGGAGGTCGATG
VWF GACTGTCCAGTGTGTGAGGTG AGGCTTCACAGGTGAGGTTG
PECAM1 TCGGACAGTGGGACGTATATC ATGACCTCAAACTGGGCATC
ZNF408 GAGGAGTCTGCCTCCAAGG CCAGCCAGAACTCTGCTCAC
T TGCTTCCCTGAGACCCAGTT GATCACTTCTTTCCTTTGCATCAAG
EOMES CGCCACCAAACTGAGATGAT CACATTGTAGTGGGCAGTGG
MIXL1 GTATGGTTCCAGAACAGGCG GTTCCAGGAGCACAGTGGTT
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Abstract
Familial exudative vitreoretinopathy (FEVR) is an inherited retinal disorder 
which is primarily characterized by abnormal development of retinal vasculature. 
In this study, we reported a subject presenting the clinical features of FEVR as 
well as microcephaly. Screening of the KIF11 gene in this patient revealed a novel 
heterozygous protein-truncating variant (c.2717del, p.(Leu906*), NM_004523.3). 
Segregation analysis in the unaected parents using Sanger sequencing suggested 
the variant to be present in a mosaic state in the unaected mother. KIF11 exon 
19 which harbors the variant was amplied from the proband and her father as 
well as three dierent tissues of the mother, followed by amplicon-based deep 
sequencing. is analysis revealed that the variant is present in dierent tissues 
of the mother at various rates, i.e. in blood (16.9%), saliva (20.7%), or skin 
biopsy-derived broblast cells (6.6%). ese data demonstrate the importance 
of deep sequencing in unaected parents upon detection of a genetic defect in 
isolated cases to detect possible mosaicism, enabling more reliable recurrence risk 
assessment and thereby improve genetic counseling.
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5.1 Introduction
Familial exudative vitreoretinopathy (FEVR) is a clinically and genetically 
heterogeneous disorder, primarily characterized by abnormal development of the 
retinal vasculature [1, 2]. A serious manifestation of FEVR is a falciform retinal 
fold, a condition leading to visual impairment at young age [3].
Variants in KIF11 have been reported in individuals with FEVR plus microcephaly, 
as well as in progressive retinal dystrophy and syndromic patients exhibiting 
microcephaly, lymphedema, chorioretinal dysplasia and/or intellectual disability 
[4-8]. KIF11 variants can occur de novo, or be inherited from one of the parents [4-
6]. Although missense variants have been reported, the majority of KIF11 variants 
that lead to FEVR are protein-truncating variants [4-6, 9]. KIF11 encodes the 
protein Eg5, which is involved in mitosis [10]. In vitro inhibition of Eg5 resulted 
in impaired endothelial cell proliferation and migration [11]. Furthermore, 
kif11 zebrash mutants showed defects in glial development [12]. ese data 
underscore the importance of Eg5 in angiogenesis and central nervous system 
development, which may explain the abnormal retinal vasculature development 
and microcephaly observed in patients carrying variants in KIF11. 
In this study, a novel heterozygous protein-truncating variant in KIF11 was 
identied in a subject presenting FEVR and microcephaly. e variant was 
detected in mosaic state in the mother. e level of mosaicism in dierent tissues 
of the mother was accurately determined by deep sequencing. 
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5.2 Materials and Methods
5.2.1 Subjects and clinical evaluation
A subject with FEVR and microcephaly as well as both her unaected parents 
participated in this study. e proband underwent ophthalmological and 
neurological examination. Clinical examinations were followed-up for 17 
years. Following the identication of a genetic mosaicism, the mother was also 
extensively examined with dierent ophthalmological tests as well as a measure of 
head circumference. Written informed consent was obtained from all participants. 
is study was approved by the local Ethics Committee and conducted according 
to the tenets of the Declaration of Helsinki.
5.2.2 Genetic analysis
All exons and intron-exon boundaries of the KIF11 gene were screened for potentially 
causative DNA variants in the proband by Sanger sequencing and a causative variant 
was identied. Subsequently, exon 19 of KIF11 was amplied from the proband, her 
father, and three dierent tissues of her mother. e amplicons were subjected to Sanger 
sequencing as well as Ion semiconductor sequencing (Ion Personal Genome Machine, 
ermo Fisher Scientic, Waltham, Massachussetts, USA) as described previously 
[13]. e genetic analysis are explained in detail in the Supplementary Information. 
e variant that was detected has been submitted to the LOVD database (https://
databases.lovd.nl/shared/genes/KIF11, individual IDs: 00154935 and 00154936). 
5.3 Results
e proband is a female patient who was born aer a normal gestation and delivery. 
She was found to have nystagmus, convergent strabismus and mild microcephaly 
at an early age. At 3 years of age, low visual acuity and strabismus of the right eye 
was noted. Occlusion of the le eye was tried for a short period without success and 
strabismus was corrected by surgery. At the age of 7, best corrected visual acuity 
(BCVA) of the right eye was nger counting and of the le eye 20/50. Neurological 
examination at the same age disclosed slight psychomotor retardation. A computer 
tomography (CT) scan showed no structural abnormalities of the brain and 
ventricles, nor any cerebral calcications; the skull circumference was 48 cm (<p2; 
second percentile). Laboratory tests for metabolic disorders and toxoplasmosis 
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were negative. Fundus examination at the age of 9 showed a prominent falciform 
retinal fold running from the optic disk to the inferior-temporal periphery in the 
right eye (Figure 1a). Some retinal vessels were observed outside the fold and no 
abnormalities were noted in the peripheral retina. Besides those shown in the 
fundus picture, some white tissue  attached to the pars plana was also observed. 
In the le eye, areas of retinal pigmented epithelium atrophy (Figure 1b) and an 
abrupt termination of the temporal retinal vessels was observed in the equatorial 
area: the more peripheral part of the retina is avascular and shows some local 
areas of RPE atrophy. During 17 years of follow-up, no signicant changes in the 
anterior segments and fundi of both eyes were noted, nor did visual acuity decline. 
e patient died at 28 years of age by a cause that is unrelated to the phenotype 
described here.
Figure 1. Fundus photographs of the posterior retina of the proband demonstrating FEVR. A) Fundus 
picture of the right eye, showing a prominent falciform retinal fold (indicated with a dashed box) with 
several retinal vessels (indicated with white arrowheads) extending from the optic disk in inferior-temporal 
direction to the fundus periphery. e posterior retina is included in the fold and no macula could be 
detected. e retina outside the fold is attached and shows some retinal vessels. B) Fundus picture of the le 
eye reveals areas of retinal pigmented epithelium (RPE) atrophy (indicated with a solid box) around the 
optic disk and along the inferior-temporal vessels. e macula (indicated with a white arrowhead) is slightly 
ectopic. 
Since the clinical features present in the proband resemble those of FEVR 
and microcephaly, KIF11 was Sanger sequenced from blood DNA to detect 
potentially causative DNA variants. A novel heterozygous one base-pair deletion 
that immediately results in premature termination of the protein (c.2717del; 
p.(Leu906*), hg19, NM_004523.3) was detected (Figure 2a-c). While the variant 
was not present in the father (Figure 2c), small peaks of the mutant allele were 
detected in the mother’s blood DNA, suggesting a mosaicism. 
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Figure 2. Genetic analysis of KIF11 in a patient with FEVR and microcephaly. A) Pedigree of the family 
described in this study.  e a ected proband is depicted with a  lled symbol. Slash indicates deceased 
person. M denotes germ line variant, m denotes mosaic variant; B) Schematic representation of the KIF11
gene and the encoded Eg5 protein (adapted from Ostergaard et al. [7]).  e variant identi ed in this study 
is depicted above the scheme. Other KIF11 variants reported in subjects with FEVR and microcephaly cases 
are indicated below the protein [4-6, 9]. cDNA positions corresponding to the indicated protein variants are 
listed in Table 1; C) Sequencing results of the KIF11 variant. Sanger sequencing electropherograms are 
shown in the upper panel, whereas the relative amount of reads obtained from Ion semiconductor 
sequencing are depicted below in bar graphs.  e percentage of reads per given nucleotide is de ned as the 
amount of reads called for a base among the total reads that cover that speci c nucleotide.  e percentage of 
reads having the c.2717del variant are indicated above the graph.
To further investigate this  nding, KIF11 exon 19 which harbors the variant was 
ampli ed from blood-derived DNA from the proband and her father as well as 
DNA of three di erent tissues from the mother (peripheral blood lymphocytes, 
skin biopsy-derived  broblasts, and saliva), followed by amplicon-based deep 
sequencing using the Ion Personal Genome Machine. For each sample, more than 
200,000 reads were obtained.  is analysis con rmed that the variant was present 
heterozygously (45.5% of the reads) in the proband (Figure 2c) and absent in the 
father. It also revealed that the variant was present in the mother’s blood, saliva, 
and  broblasts at a frequency of 16.9%, 20.7%, and 6.6%, respectively.  is not 
only con rms that the mother is mosaic for this variant, but also demonstrates 
that the degree of mosaicism can di er between tissues (Figure 2c). 
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Table 1 KIF11 variants associated with FEVR
Variant (cDNA) Variant (protein) Reference
c.131_132dup p.(Pro45Ilefs*92) Hu et al. [5]
c.139C>T p.(Arg47*) Robitaille et al. [4]
c.511C>G p.(Leu171Val) Li et al. [6]
c.652dup p.(Ala218Glyfs*16) Robitaille et al. [4]
c.661A>G p.(Arg221Gly) Robitaille et al. [4]
c.790-2A>C p.(?) Li et al. [6]
c.790-1G>T p.(?) Robitaille et al. [4]
c.1408G>T p.(Glu470*) Robitaille et al. [4]
c.1573C>T p.(Gln525*) Li et al. [6]
c.1830_1833del p.(Glu610Aspfs*3) Rao et al. [9]
c.2230C>T p.(Gln744*) Hu et al. [5]
c.2524C>T p.(Gln842*) Li et al. [6]
c.2717del p.(Leu906*) is manuscript
c.2807C>G p.(Ser936*) Li et al. [6]
c.2863C>T p.(Gln955*) Hu et al. [5]
c.2952_2955del p.(Gln985Ilefs*6) Hu et al. [5]
c.3073A>G p.(Arg1025Gly) Li et al. [6]
Following the identication of the mosaicism in the mother, a detailed clinical re-
examination was performed, at an age of 57. At a young age, no visual or ocular problems 
had been reported. When she was 18 years old, she started wearing contact lenses to 
correct a light myopia of both eyes. Operations for cataract with lens implantation 
were done in both eyes at age 53. Ophthalmological examination showed normal best 
corrected visual acuity (right eye: 20/30 and le eye: 20/25). Her head circumference 
was 55 cm and thereby falls within the normal range. e eye position was straight 
and good binocular functions were present. Both anterior segments showed a well-
positioned articial lens with minimal opacication of the posterior lens capsule. 
Slitlamp-biomicroscopy showed posterior poles with a normal conguration of the 
macula and the vascular arcades of the retina. e peripheral retina was completely 
vascularized and did not show any dystrophic signs. In conclusion, no signs of FEVR 
or microcephaly were present in the mother of the proband.
5.4 Discussion
A heterozygous variant in KIF11 (c.2717del, p.(Leu906*)) was detected in a patient 
presenting FEVR and microcephaly. It was inherited from the mother, who carries 
the variant in mosaic state at various rates in dierent tissues (blood, broblasts, 
and saliva). Besides the identication of the genetic defect in this patient, this 
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study also demonstrates the importance of genetic testing in parents and provides 
insight in the required amount of Eg5, the protein encoded by KIF11, for normal 
development.
To date, two suspected KIF11 mosaic cases have been reported in literature [4, 5]. 
Robitaille et al. reported  two siblings carrying identical KIF11 variants that were 
not detected in the healthy parents by Sanger sequencing [4], whereas Hu et al. 
reported a case in which a mosaicism was suspected via subcloning experiments 
[5]. To our knowledge, this is the rst report in which a KIF11 mosaicism is 
accurately detected in dierent tissues of an individual using amplicon-based 
deep sequencing. is technique may allow the detection of mosaicism that 
occurs at a low rate which may be undetectable by Sanger sequencing. e 
presence of the variant in germ cells and somatic cells of the mother indicates 
that the variant has arisen early in embryonic development, prior to primordial 
germ cell dierentiation (before ~15 mitotic divisions) [14]. Although it cannot 
be assessed experimentally, we can assume a similar degree of mosiacism present 
in the germline compared to those detected in saliva and blood, which contain 
cells originating from ectoderm and mesoderm, respectively. ereby, we can also 
hypothesize on the chance of ospring being aected. us, the robust detection 
of mosaicism in unaected parents can allow more accurate recurrence risks 
assessments and thereby facilitate better genetic counseling. 
In this study, the mosaicism was quantied in three dierent tissues populated by 
cells originating from mesoderm (blood and broblasts) and ectoderm (saliva). 
Leukocytes (mesoderm) contamination in the saliva sample may occur [15]. e 
presence of the variant in these tissues corresponds with the abnormal development 
of retinal vasculature and microcephaly observed in the patient, which are defects 
in the development of organs predominantly populated by cells originating from 
mesoderm and ectoderm, respectively. 
A dierence in the mosaicism rate was detected in blood vs. broblasts, despite 
both originating from mesoderm. Although this may indicate that the variant 
occurred aer further mesoderm specication, its presence in the germ cells of 
the mother suggests that the dierence is more likely due to an artifact of the in 
vitro culturing of broblasts, which has been shown previously in lymphoblastoid 
cell lines [15]. erefore, fresh materials which have not undergone any in vitro 
culturing should be used to detect mosaicisms. 
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KIF11 variants reported in subjects with FEVR and microcephaly are equally 
distributed throughout the Eg5 protein (Figure 2b) [4-6, 9], further highlighting 
the importance of both the N- and C- terminal part of Eg5 for proper functioning 
in spindle localization, as shown previously [10]. e variant that is identied 
in this study lies in the bimC box, a sequence motif surrounding a potential 
phosphorylation site at the C-terminus of the protein. It is known that Eg5 
phosphorylation at this site (specically at threonine residue 927) is required 
for its mitotic spindle association during mitosis [10, 16]. e data obtained in 
this study also allow the speculation of the amount of Eg5 required for a cell 
to function normally. Assuming a full loss-of-function of the mutated allele 
and considering the average mosaicism rate detected in the mother (20%), it is 
tempting to assume that a similar degree of mosaicism is present in other tissues, 
and thus that ~80% of normal Eg5 protein is sucient for normal development. 
Given that a heterozygous variant results in developmental defects, the minimum 
required amount of Eg5 likely lies between 50 and 80%.
In summary, the ndings in this study demonstrates the importance of deep 
sequencing of parental DNA following the identication of genetic defects in 
isolated cases to detect possible mosaicism. It will allow a reliable recurrence risk 
assessment and thereby improve genetic counseling. It is not only relevant for 
subjects with FEVR and microcephaly, but also for other genetic disorders with a 
similar mode of inheritance. 
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Supplementary materials
Genetic analysis
DNA was isolated from peripheral blood lymphocytes of proband and her 
parents using a standard salting-out procedure. In addition, DNA was isolated 
from saliva and skin biopsy-derived broblasts cell line of the unaected mother 
using Chemagic STAR DNA Saliva4k (Perkin Elmer Chemagen, Baesweiler, 
Germany), kit and QIAamp DNA mini kit (Qiagen, Hilden, Germany), according 
to manufacturer’s instructions, respectively.
All exons and intron-exon boundaries of the KIF11 gene were screened for 
potentially causative DNA variants in the proband by Sanger sequencing.  e 
primers used for this screening are listed in  Supplementary Table 1. Exon 19 of 
KIF11 that harbors the causative mutation was amplied from the proband, her 
father, and three dierent tissues of her mother (peripheral blood lymphocytes, 
saliva, and broblasts). e amplicons were subjected to Sanger sequencing as well 
as Ion semiconductor sequencing (Ion Personal Genome Machine, ermo Fisher 
Scientic). e resulting fastq les were analyzed and converted into BAM les 
in SeqNext soware (JSI), and visualized in Integrated Genomics Viewer (IGV, 
Broad Institute).
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Table S1 KIF11 primers 
Fragment Name Sequence (5’- to 3’-) Fragment size (bp)
KIF11_ex1_F AGTACCGGGTAGAGAGCGGG 315
KIF11_ex1_R CTGGACCGCGCAGTAGG
KIF11_ex2_3_F TAGTTAGTGAAAATGTCATTGATAACC 627
KIF11_ex2_3_R GCAACAAGAGTGAAACTCCG
KIF11_ex4_F CCACTGTGCCTGGCTTG 259
KIF11_ex4_R CAAGACAGAGGCCCTCAAAC
KIF11_ex5_6_F GGCCCATGTATTTTAACTGCC 639
KIF11_ex5_6_R CACCCCAATTTGACTTTCTCC
KIF11_ex7_F TCCTGTTTTCAGTATTTCAGAAGC 236
KIF11_ex7_R GGACAAAATTTCAAGCTGCTC
KIF11_ex8_F TTATTTTGCTGGCGATTTAATAC 489
KIF11_ex8_R ATCCGCCCACCTTGGAC
KIF11_ex9_F AAAGGTTGGGCATAGTGGTC 360
KIF11_ex9_R CCTTCCATGGGCAATTTAAC
KIF11_ex10_F ATTTGTTGCATGTCCTTCCC 234
KIF11_ex10_R AAGTTTTACTTCAAATAGCCTGTTATC
KIF11_ex11_F CACTTGGGTATCAAGTGATGG 404
KIF11_ex11_R GACCCTGGGAGGCAGAG
KIF11_ex12_F CCGGGTAACTTCTTACAACTTTTG 417
KIF11_ex12_R GGACAGAAATACCATTTGGGG
KIF11_ex13_F TATGTACCACCACACCCAGC 475
KIF11_ex13_R TGACACCGTCATCTATGTTTCAC
KIF11_ex14_F TCTTTGAAATGGTTTGAACGG 367
KIF11_ex14_R GGAAGAAAGAATAGCAGTTAACATTG
KIF11_ex15_16_F TTTAATGTGAATGTTTAGCTACCAAAG 576
KIF11_ex15_16_R TCAGCTTTTACAGTATTCAGATTGTG
KIF11_ex17_F TCACTTCCACTGCTTTCCTC 564
KIF11_ex17_R GCACAAATACGCAATGAAAAG
KIF11_ex18_F GAGCCAGACTGTCCACGTTC 557
KIF11_ex18_R CACAAAACGAGATCATCTGTAAGC
KIF11_ex19_F GGAAAAGGTAAGGGAAAATATGATG 417
KIF11_ex19_R AAATTTCTGTCAGGCAATGG
KIF11_ex20_F TGACAGGTAGCAAGACTGATCC 368
KIF11_ex20_R TCACATGAAGTCAGCCACATC
KIF11_ex21_F TCAAAGCTGCTGTTACTCTTGTG 277
KIF11_ex21_R TTCTGCTCACCACGAACAATAC
KIF11_ex22_F TTTTGCCTATAACCCAGAGAAC 578
KIF11_ex22_R GGAGTGTAGTGGTGTACCTTTGG
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Familial exudative vitreoretinopathy (FEVR) was rst described by Criswick 
and Schepens in 1969 [1]. Since then, eorts have been made to elucidate the 
genetic cause of this inherited retinal defect. A few years ago, a missense mutation 
(p.His455Tyr) in ZNF408 was identied as the underlying genetic cause in an 
autosomal dominant FEVR family [2]. Aerwards, more genetic variants in 
ZNF408 were found to be associated with FEVR in other studies [3-6], as well as 
in another inherited eye disease, retinitis pigmentosa [7, 8]. Nevertheless, how 
defects in ZNF408 result in these diseases is poorly understood. In this study, 
we focused on deciphering the molecular role of ZNF408, particularly in the 
development of (retinal) vasculature, and how defect(s) in ZNF408 can give rise 
to the clinical features observed in FEVR. We also aimed to identify other genetic 
cause(s) of FEVR and related diseases.
6.1 ZNF408 in the development of (retinal) vasculature
e identication of a genetic variant in ZNF408 that causes FEVR suggested 
its involvement in the development of the (retinal) vasculature. Since this rst 
nding, more genetic studies have reported other ZNF408 variants in a handful of 
FEVR cases [3-6], emphasizing the role of ZNF408 in vasculature development. 
Abnormal eye and trunk vasculature development observed upon morpholino-
induced knockdown of znf408 in zebrash further strengthened this hypothesis 
[2]. We continued modeling of znf408 in zebrash and showed abnormal retinal 
vasculature development in znf408 mutant zebrash (Chapter 3)
FEVR is hallmarked by the absence of or abnormal vasculature in the peripheral 
retina, while the primary vascular layer can be either normal or abnormal, 
depending on the severity of the disease. is suggests that FEVR is likely a 
disorder of angiogenesis instead of vasculogenesis. is was supported by the 
observation in murine models of FEVR in which the deeper retinal plexuses are 
absent, whereas the primary retinal plexus is still present [9]. e znf408 zebrash 
models described in this thesis also showed presence of retinal vasculature, albeit 
delayed and abnormally developed (Chapter 3). Altogether, these indicate that 
ZNF408 plays a role in retinal angiogenesis.
To better understand the molecular role of ZNF408, particularly in (retinal) 
angiogenesis, we opted to use endothelial cells as an in vitro model. In Chapter 2, 
we overexpressed wild-type and p.His455Tyr mutant ZNF408 in human umbilical 
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vein endothelial cells (HUVEC) and observed that the overexpression of mutant 
ZNF408 disrupts the ability of HUVEC to form a capillary-like network in an in vitro 
tube formation assay, thus mimicking the abnormal retinal vasculature observed 
in FEVR patients. Transcriptomics analysis was performed on these cellular 
models whose results suggested a role for ZNF408 in various biological processes. 
Importantly, this analysis showed that the p.His455Tyr mutation alters the normal 
gene expression regulated by ZNF408, which may underlie the observed cellular 
phenotype. Gene ontology analysis of the dierentially regulated genes showed 
that wild-type ZNF408 upregulates genes that are associated with nucleosome 
assembly and protein heterotetramerization, whereas its downregulated genes 
are associated with biological processes relevant to the vasculature development 
(e.g. response to hypoxia, cell adhesion, and angiogenesis). e latter led us to the 
hypothesis that wild-type ZNF408 supports the development of vasculature by 
downregulating the expression of genes that inhibit this process. 
We further looked for the mechanism by which ZNF408 regulates gene expression. 
Since it has ten zinc nger domains, we assumed that it functions by binding 
to DNA and acting as a transcription factor. Chromatin immunoprecipitation 
followed by next generation sequencing (ChIP-Seq) performed in HEK293T 
cells showed that the p.His455Tyr mutation reduced the DNA binding ability of 
ZNF408 (Chapter 2). Nonetheless, little overlap was observed between the genes 
identied in the transcriptomics analysis and the ChIP-Seq experiment. e 
dierence in cellular systems used in both experiments as well as the relatively low 
number of binding sites detected may contribute to this. e latter also implies that 
ZNF408 does not bind directly to DNA to regulate gene expression and suggests 
that its eect on gene expression is likely to be an indirect eect. Although DNA 
binding is the most commonly described activity of zinc nger domains, RNA 
binding and protein binding have also been described [10, 11]. Besides zinc nger 
domains, ZNF408 is also predicted to have a PRDM (positive regulatory domain 
I-binding factor 1/PRD1-BF1 and retinoblastoma-interacting zinc nger protein 
1/RIZ1 homology domain containing) domain, near its N-terminus. e PRDM 
domain is a subfamily of SET methyltransferase. Such PRDM proteins typically 
have multiple adjacent zinc nger domains, as predicted in ZNF408. Members 
of this family are usually involved in the regulation of gene expression by acting 
as histone methyltransferase or as co-factor by binding to other proteins [12, 13]. 
Further investigation on ZNF408 interacting partners may shed more light into its 
mechanism of action in regulating gene expression. 
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To further study the role of ZNF408 in vivo, we generated two truncated and 
one missense znf408 zebrash model using CRISPR/Cas9 technology (Chapter 
3). In both truncated znf408 models, a frameshi was created that is predicted 
to result in a truncated protein. Alternatively, in the missense model, one of the 
core histidines of the fourth zinc nger domain was substituted with a tyrosine 
residue, mimicking the p.His455Tyr mutation identied in FEVR patients. e 
znf408 zebrash models showed a delay in retinal vasculature development at 
5 days post-fertilization, abnormal sprouting at 3 months post-fertilization, as 
well as vascular leakage at 6 months post-fertilization (Chapter 3). In Chapter 
2, we observed altered gene expression by the p.His455Tyr mutation, which 
may underlie the cellular phenotype observed. It is tempting to hypothesize that 
the phenotypes observed in the zebrash models are also due to altered gene 
expression caused by modied znf408. Seventy percent of human genes have an 
orthologue in the zebrash genome [14]. Indeed, 188 out of 227 genes that are 
dierentially regulated by wild-type and p.His455Tyr ZNF408, as described in 
Chapter 2, have a zebrash orthologue based on the Biomart database. It would 
be interesting to do transcriptomics analysis in the znf408 zebrash models to 
determine whether similar sets of genes are aected by the genetic modication 
of znf408 in these models. A time-course transcriptomics analysis would be very 
informative, since the gene expression may change over time, which may underlie 
the dierent phenotypes that were observed at dierent time points. 
FZD4, LRP5, TSPAN12, and NDP are the genes that are most frequently mutated 
in FEVR and thus are also the most studied [9]. e proteins encoded by these 
genes are involved in the Norrin/β-catenin signaling pathway [15]. In this pathway, 
TSPAN12 aids the formation of the FZD4-LRP5 receptor complex for Norrin (the 
protein encoded by NDP). Binding of Norrin to its receptor complex activates 
the pathway, which leads to the translocation of β-catenin to the nucleus where it 
regulates the expression of its downstream target genes [15]. Recently, mutations 
in CTNNB1, the gene encoding for β-catenin, were identied in FEVR patients, 
further corroborating the association of the Norrin signaling pathway to FEVR 
[16]. Additionally, a recently identied causative gene for FEVR, RCBTB1, was 
also suggested to be involved in the nuclear localization of β-catenin [17]. Based 
on these ndings, it is tempting to hypothesize that ZNF408 is also involved in 
this pathway. None of the FEVR genes, however, were found to be regulated by 
ZNF408 (Chapter 2). us, it is unlikely that ZNF408 is located upstream of the 
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pathway, regulating its activity. ZNF408 is neither included in the list of β-catenin 
target genes in Wnt homepage maintained by the Nusse lab (https://web.stanford.
edu/group/nusselab/cgi-bin/wnt/target_genes) nor in a comprehensive study 
of β-catenin target genes by Herbst et al. [18]. Furthermore, ZNF408 is also not 
included in the knowledge map of β-catenin molecular function developed by 
Celen et al., which comprises its post-translational modications, protein-protein 
interactions, disease-associated mutations, transcription factors co-activated by 
β-catenin and their targets, as well as the major processes in which β-catenin is 
known to participate [19]. erefore, it is unlikely that it is involved in that pathway 
neither as an interaction partner of β-catenin nor as one of the target genes of 
β-catenin. Additionally, almost none of ZNF408-regulated genes were found in 
this knowledge map, suggesting dierent roles of ZNF408 and β-catenin in the 
regulation of gene expression. Involvement in the Norrin/β-catenin pathway has 
also not been observed for ATOH7, another FEVR gene [20]. ATOH7 encodes a 
bHLH transcription factor which is crucial for retinal ganglion formation [21]. is 
indicates that, although the majority of FEVR genes are involved in the Norrin/β-
catenin pathway, it is well possible that ZNF408, similar to ATOH7, is involved in 
another pathway, defects in which eventually can lead to FEVR features. 
6.2  A surprise from ZNF408
In Chapter 2, we described how the p.His455Tyr mutation alters the normal gene 
expression regulated by wild-type ZNF408. Besides downregulating genes that 
are involved in the development of vasculature, wild-type ZNF408 upregulates 
the expression of genes associated with nucleosome assembly and protein 
heterotetramerization. e majority of these genes encode for histone proteins. 
ese suggest the involvement of ZNF408 in chromatin remodeling. It is known 
that the expression of histone genes are cell-cycle regulated and controlled, both 
at the transcriptional and post-transcriptional level [22].  Furthermore, 8 out of 15 
genes within the minute overlap between the transcriptome data and the ChIP-
Seq results, encode histone proteins. As mentioned previously, ZNF408 belongs to 
the family of PRDM proteins and members of this family have been described to 
play a role in histone modications, either directly or indirectly [12]. Taking this 
into account, it is very well possible that ZNF408 is also involved in chromatin 
remodeling. In addition, the enrichment of these gene ontology terms were found 
in the transcriptome analysis as well as the ChIP-Seq data, experiments which 
were performed on two dierent cell systems. is tempted us to hypothesize that 
it is the major role of ZNF408 in dierent cellular systems, although the genes 
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regulated may dier per system. In this light, the dierential expression of the 
histone genes we observed could well be the driving force of the other dierential 
expression observed in this analysis. Further investigation of interaction partners 
of ZNF408, such as by proteomics proling and RNA pull-down assays, as well as 
other epigenetic proling experiments may shed more light on this.
6.3 Defects in ZNF408 lead to different phenotypes
Mutations in ZNF408 have also been reported in autosomal recessive retinitis 
pigmentosa (RP) cases [7, 8], which is characterized by a rod-cone photoreceptor 
degeneration. Although it is not uncommon that dierent mutations in one gene 
manifest dierent clinical features, the clinical features of RP and FEVR are quite 
distinct and the genotype-phenotype correlations still need to be established. 
Mutations causing FEVR and RP are either missense or stop mutations that are 
spread throughout the gene (Figure 1, Table 1), implying that there is no clear 
correlation between the type and position of the mutation and the resulting 
clinical features. Immunohistochemistry in human and mouse retina showed 
that ZNF408 is expressed in the vasculature as well as the photoreceptor cells. 
We were not able to reliably detect znf408 in zebrash retina (Chapter 3). e 
truncated znf408 zebrash models we generated are supposedly a good model for 
ZNF408-associated RP which is inherited in autosomal recessive manner. Despite 
the mild visual impairment observed at 5 dpf, no apparent neuronal degeneration 
was observed at dierent stages of these models. Instead, we observed abnormal 
vasculature development similar to the missense zebrash model.
Mutations in ZNF408 that are detected in FEVR are inherited in an autosomal 
dominant manner, whereas those found in RP cases have an autosomal recessive 
inheritance pattern [2-8]. Such an inheritance pattern was also observed in RCBTB1, 
in which mutations were detected in (autosomal dominant) FEVR or (autosomal 
recessive) retinal degeneration with RP as one of the ocular features [17, 23]. Such 
a correlation has not been observed for other FEVR genes. Although this suggests a 
correlation between the inheritance pattern and the phenotypic outcome, it is still 
unclear which mutations cause which phenotype and how. Further studies on the 
genotype-phenotype correlation of ZNF408 and the resulting clinical features will 
be required to understand this. e studies described in this thesis may have paved 
a way towards elucidating the role of ZNF408, particularly in the pathogenesis of 
FEVR, but similar studies in the context of RP would shed further light on this and 
thereby, assist in disease management. 
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Figure 1. Schematic representation of variants reported in ZNF408. Variants reported in FEVR cases are 
depicted on the top, whereas those reported in RP and other cases are illustrated on the bottom. e protein 
variant nomenclature is based on transcript NM_024741. 
6.4  Complexity of FEVR genetics
e advancement of molecular technologies has allowed researchers to identify 
the genetic causes in a large number of FEVR cases. As mentioned previously, 
FZD4, LRP5, TSPAN12, and NDP, are the genes most frequently mutated in 
FEVR. Recent gene hunting eorts have added ZNF408, RCBTB1, ATOH7, and 
CTNNB1 to the list of causative genes for FEVR [2, 16, 17, 20]. However, there 
are still a number of unsolved FEVR cases [9]. e remaining genetic causes of 
the unsolved cases can be either defect(s) in a novel gene or variant(s) located 
outside the coding region of known genes. A series of digenic cases of FEVR has 
also been recently reported [4]. Most of the FEVR genes were identied either by 
targeted Sanger sequencing or whole-exome sequencing, which does not allow 
the investigator to identify genetic defects outside the coding region or structural 
variants. e ever-decreasing cost of sequencing, together with the improvement 
in data analysis, will soon allow whole-genome sequencing (WGS) to be broadly 
available for the identication of the genetic cause of any inherited disease, thereby, 
providing means to identify underlying causes in the unsolved FEVR cases.
e clinical features of FEVR have also been found to be accompanied by other 
symptoms. For example, a syndrome called osteoporosis pseudoglioma, in 
which patients present bone abnormalities and FEVR characteristics, is caused 
by mutations in LRP5 [25]. Another example is Norrie disease, an X-linked 
disease caused by NDP mutations, in which hearing impairment and sometimes 
intellectual impairment are detected next to FEVR-like ocular features [26]. 
FEVR symptoms have also been observed accompanied by microcephaly, a 
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clinical presentation associated with mutations in KIF11 [27]. In Chapter 5, we 
demonstrated that a KIF11 variant can be present in a mosaic manner in a healthy 
individual. If the variant is present in the germ cells, the variant can be transmitted 
to the ospring causing unexpected manifestation of the disease. Although we 
were the rst to quantify the mosaicism of KIF11 associated with FEVR and 
microcephaly in dierent tissues, it has been previously suspected in other KIF11 
cases [27, 28]. is nding raises the question whether mosaicisms can also be 
present in other cases of FEVR. Low grade mosaicisms can be dicult to detect 
using Sanger sequencing, and therefore may be missed. Based on our ndings, it is 
important to screen both parents of FEVR patient with deep sequencing to detect 
potential mosaicisms in isolated FEVR cases, in which the genetic variant in the 
patient would commonly be considered as de novo, to improve genetic counseling. 
Phenotypic variability, even within a family, is oen observed in FEVR. In 
addition, reduced penetrance has been observed in approximately 25% of FEVR 
mutation carriers [29]. e penetrance of a genetic variant can be inuenced by 
many factors, e.g., epigenetic modication, allele dosage, modier gene(s), copy 
number variants, gene expression level, environmental factors [30]. In Chapter 
4, we present a preliminary study of in vitro investigation of reduced penetrance 
in ZNF408-associated FEVR. ere are two unaected individuals who carry the 
ZNF408 p.His455Tyr mutation in the large autosomal dominant FEVR family 
described by Collin et al. [2]. One of these unaected mutation carriers (UMC) 
is included in this preliminary study, together with her aected sister (Chapter 
4). Due to the requirement of relevant patient material, an in vitro study of the 
underlying cause of non-penetrance can be challenging. For instance, in case of a 
disease such as FEVR, patient material from retinal vasculature would be required, 
which is both practically and ethically challenging. Fortunately, advances in the 
application of induced pluripotent stem cell (iPSC) technology have allowed the 
generation of theoretically any relevant material from patient-derived iPSCs. In 
the study described in Chapter 4, we used iPSCs obtained from the UMC and 
her sister to generate patient-specic endothelial cells, a relevant cell type for 
vasculature-related disorders. is pilot study showed us how iPSC-derived 
endothelial cells can be used as an in vitro model to study reduced penetrance in 
FEVR. Further molecular and cellular characterization of the generated endothelial 
cells may reveal the underlying cause of reduced penetrance of ZNF408-associated 
FEVR. e cause of reduced penetrance in ZNF408 associated-FEVR may or may 
7-5 Dyah Karjosukarso.indd   172 17-05-19   12:19
General discussion
173
6
not be similar to the cause of reduced penetrance observed in FEVR cases with 
mutations in other genes. Nevertheless, the method presented can be applied to 
any FEVR case to have better insight on the reduced penetrance oen observed 
in this disease. 
6.5 Implications of this study to diagnostics
e clinical diagnosis of FEVR is usually performed by ocular examination 
accompanied by uorescein angiography. e diagnosis may be facilitated by 
screening of asymptomatic family members. Furthermore, genetic analysis is 
recommended for proper counseling, taking into account that FEVR is a lifelong 
disease, whose unpredictable progression requires regular follow-up [31]. 
So far, the majority of molecular diagnosis of FEVR is performed either by Sanger 
sequencing or targeted next-generation sequencing of known genes. Whole exome 
sequencing was employed in the genetic analysis of FEVR cases in which no defect 
was found in the known genes, which led to the identication of several novel 
genes in recent years [2, 16, 17]. As mentioned previously, whole exome sequencing 
analysis only allowed the detection of variants within the coding regions of the 
genome. With the decreasing sequencing costs and development of analysis tools, 
whole genome sequencing is likely to be more powerful in the identication of 
novel genetic defects in FEVR, within as well as outside the coding regions. e 
identication of genetic defects in the unsolved FEVR cases not only provides more 
insight into the molecular basis of the disease, but also is essential for diagnostics 
and thereby, disease management and counseling. Additionally, deep sequencing 
may be required to identify mosaicisms in isolated cases of FEVR, such as the case 
presented in Chapter 5 of this thesis. 
Detection of known variants in known genes can easily facilitate diagnosis and 
future counseling. ere are plenty of in silico programs, databases, and guidelines 
that can aid in the classication of a new variant in a known gene. However, if 
the candidate pathogenic variant is a new variant in a novel gene, it can be 
quite challenging to determine whether it is the causative variant. Functional 
characterization of such variants is required, next to the in silico predictions. In 
this thesis, we subjected two in vitro models of ZNF408-associated FEVR to in 
vitro tube formation assay (Chapter 2 and 4). One of the in vitro models is HUVEC 
overexpressing wild-type and mutant ZNF408 via lentiviral transduction, in 
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which there was a striking dierence between wild-type and mutant ZNF408. 
We also performed a pilot study in which we dierentiated patient-derived iPSCs 
into endothelial cells, for which no striking dierence was observed between cells 
obtained from healthy individual vs a patient. As this is a pilot study, there are 
plenty of technical improvements which may inuence the results of the in vitro 
tube formation assay. Nonetheless, such in vitro models and assay can be employed 
to assess the eect of the candidate variant in relevant models and assays, thereby 
facilitating the molecular diagnosis and disease management.
6.6 Towards treatment or prevention of FEVR
Laser photocoagulation is one of the common treatments for the vascular 
leakage and exudates observed in FEVR patients. Surgical intervention is oen 
recommended in cases with retinal detachment [31]. Several dierent groups have 
tried to employ intravitreal injection of anti-VEGF therapy, such as those used 
in treating wet age-related macular degeneration, as additional treatment of the 
neovascularization in FEVR [32-34]. Despite the promising results, these studies 
were conducted on a small scale and for relatively short period of time. erefore, 
further research into the ecacy and safety is required.
Gene therapy has been successfully applied in the treatment of some inherited 
retinal disorders and is under development for some other retinal diseases. A 
hallmark example is the delivery of RPE65 for the treatment of Leber congenital 
amaurosis [35]. However, FEVR is a developmental disease, which means there 
is a small window of opportunity to correct the developmental defect. In the 
era of iPSC dierentiation technologies, cell replacement therapy may have 
more potential in restoring the absent or abnormal retinal vasculature in FEVR. 
Nevertheless, such a therapy is commonly patient-specic, i.e. iPSCs need to be 
obtained from the specic patient, the genetic defect needs to be be corrected, and 
patient-specic cells must be generated. As such, it requires a lot of time, money, 
and facilities to treat a patient with FEVR. Considering these, together with the 
heterogeneity of FEVR, a more universal treatment is required.  
Since the Norrin/β-catenin signaling is decient in FEVR (and alike diseases), 
targeting this pathway is a potential therapeutic approach. Treatment with Norrin 
has been shown to restore the vascular defects in the retinas of mice with Norrie 
disease as well as in oxygen-induced retinopathy mice [36-40]. However, other 
7-5 Dyah Karjosukarso.indd   174 17-05-19   12:19
General discussion
175
6
components of the Norrin/β-catenin signaling pathway may also be defective 
in FEVR, for instance, loss of function of FZD4 and LRP5, the receptor and co-
receptor of Norrin. As a more general therapeutic approach, Wang et al. targeted 
GSK3β, a component of Norrin/β-catenin signaling that phosphorylates β-catenin 
which results in the degradation of β-catenin [41]. Intraperitoneal injection of 
lithium to Lrp5/- mice reversed the vascular phenotype and partially restored 
visual function [41]. Although this eect should still be tested on other FEVR 
animal models, this nding opens a new avenue for a universal treatment of 
FEVR and other Norrin/Wnt-related vascular eye diseases. In addition, lithium 
is an FDA-approved treatment that has been used to treat mental disorders, even 
during pregnancy, rendering its safety. However, considering that human retinal 
vasculature develops in utero instead of postnatally as in mice, the safety to treat 
fetuses and infants with lithium should still be determined. 
FEVR can also be caused by mutations in ZNF408 and ATOH7, both of which have 
not been shown to be related to the Norrin/β-catenin signaling. Lithium treatment 
may or may not be advantageous for FEVR caused by mutations in these genes. 
Other molecules may also have potential in the treatment of FEVR, for which 
the screening can be done in vitro and in vivo. In vitro tube formation assays can 
be applied in studies determining angiogenesis-modulating activity of drugs in a 
high-throughput manner [42]. Furthermore, Kitambi et al. performed a screening 
of small molecules to study their inuence on retinal vasculature development 
in zebrash [43]. Taking such possibilities into account, the in vitro and in vivo 
models of FEVR, such as some that are described in this thesis (Chapter 2, Chapter 
3, and Chapter 4), can thus be used in identifying potential drugs for the treatment 
of FEVR.  
Given its heterogenous nature, it is likely that combination of treatments will 
be required to halt the disease progression of FEVR. e deeper insight into the 
molecular mechanisms underlying this disease not only facilitates diagnosis and 
disease management, but also paves the way to design and recommend better 
treatments for FEVR. 
6.7 Concluding remarks
Advancement of technologies in the eld of ophthalmology, genetics, and molecular 
biology has advanced the knowledge into FEVR and its cause signicantly, since 
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its rst description in 1969. Diagnosis methods and classication of disease stages 
are established. e genetic cause of a large number of FEVR cases also can be 
explained, thanks to the persistent genetic studies in the last decades. In vitro 
and in vivo studies of FEVR-associated genes have shed light into the molecular 
aetiology of the disease. Nevertheless, there are many more aspects to investigate, 
such as identifying the genetic causes of the remaining FEVR cases, mechanisms 
that lead to FEVR, as well as development of potential treatments. e studies 
presented in this thesis were aimed to touch upon these issues and have deepened 
the understanding of the molecular basis of FEVR, particularly ZNF408-associated 
FEVR, as well as providing new tools for the investigation of disease mechanisms 
and potential treatments. 
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Summary
Vision plays a crucial role in one’s life. e human eye consists of numerous 
delicate parts which have dierent functions. e retina is the part of the eye that 
is responsible to catch the light signal from the environment and convert it into 
neural impulses for the brain to perceive. e retina has a high metabolic activity, 
which is supported by nutrients supplied through blood vessels. Vasculature 
defects in the retina represent one of the major causes of visual impairment. 
Background information on the structure of the retina and the development of 
retinal vasculature are provided in Chapter 1. is thesis focuses on a subtype 
of visual impairment termed familial exudative vitreoretinopathy (FEVR). It is 
an inherited retinal disorder hallmarked by abnormal or absence of vasculature 
in the peripheral retina. is disease is also explained extensively in Chapter 1. 
Finally, relevant in vivo and in vitro models to study retinal vasculature as well as 
molecular and cellular technologies used in this thesis are described in Chapter 1.
A few years ago, a mutation in ZNF408 (c.1363C>T, p.His455Tyr) was identied 
in an autosomal dominant FEVR family. Despite subsequent experiments in cells 
and zebrash which suggest the involvement of ZNF408 in the development of 
retinal vasculature, little is known about its molecular function. In Chapter 2, an 
in vitro study on the role of ZNF408 in regulating gene expression and how the 
p.His455Tyr mutation aects its function is presented. Transcriptome proling 
showed that ZNF408 regulates the expression of genes relevant to the development 
of vasculature, which is altered by the p.His455Tyr mutation. Further molecular 
experiments suggest that ZNF408 regulates gene expression in an indirect manner.
To further study the function of znf408 in vivo, znf408 zebrash models were 
generated (Chapter 3). Deletions that are predicted to lead to a truncated protein 
were introduced in two zebrash models, one with a 1 bp deletion and the other with 
a 4 bp deletion. A missense model was also generated, in which a 1 bp substitution 
was applied to mimic the human p.His455Tyr mutation. Characterization of the 
mutant models showed delayed retinal vasculature development at larval stage, 
abnormal sprouting in young adults, and vascular leakage in adults. ese indicate 
the suitability of these models as animal model of FEVR and also to further study 
znf408 in retinal vasculature development in vivo.
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FEVR is a clinically and genetically heterogeneous disease. Furthermore, reduced 
penetrance has been observed in approximately 25% of mutation carriers in FEVR. 
It is still unclear what is the underlying cause of the observed reduced penetrance. 
In Chapter 4, a pilot study of reduced penetrance in ZNF408-associated FEVR is 
presented. Induced pluripotent stem cells of an FEVR patient with the ZNF408 
c.1363C>T mutation and her sister who is unaected despite carrying the same 
mutation, as well as those from control individuals were dierentiated into endothelial 
cells. e obtained endothelial cells showed comparable morphology, expression of 
endothelial cell markers, and angiogenic behavior. A trend of lower dierentiation 
eciency towards endothelial lineage was observed in the induced pluripotent stem 
cell lines derived from the patient and the unaected mutant carrier. Furthermore, 
endothelial cells derived from the unaected mutant carrier had an approximately 
2-fold lower ZNF408 expression compared to patient and controls. Further research is 
required to determine whether these results are reproducible in other circumstances 
and also to gain deeper insight into the molecular mechanisms of reduced penetrance 
in FEVR. Nonetheless, this pilot study showed how patient-specic endothelial 
cells can be generated from induced pluripotent stem cells and that the obtained 
endothelial cells can be employed in studying reduced penetrance in FEVR.
As a genetically heterogeneous disease, mutations in other genes have been 
reported in FEVR patients. In Chapter 5, the identication of a mutation in KIF11 
in a patient presenting FEVR and microcephaly is described. Further genetic 
study revealed that the mutation was inherited from the unaected mother who is 
mosaic for the mutation. is study showed the importance of thorough genetic 
assessment of unaected parents, particularly in an isolated cases, to enable more 
reliable recurrence risk assessment and hence, better genetic counseling.
Finally, in Chapter 6, the role of ZNF408 in the development of (retinal) 
vasculature based on in vitro and in vivo ndings is discussed. Transcriptome 
proling suggested a possible role of ZNF408 in chromatin remodeling. is 
unexpected nding is also discussed in Chapter 6. Besides monogenic FEVR, 
variants in ZNF408 have also been reported in retinitis pigmentosa and digenic 
FEVR. All variants that have been reported in ZNF408 and how dierent variants 
lead to dierent phenotypes are summarized and discussed in Chapter 6, followed 
by a discussion on the complexity of FEVR genetics. Finally, the impact of the 
studies presented in this thesis to diagnostics, disease management, and potential 
therapeutics for FEVR are discussed.
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Samenvatting
Het vermogen om te kunnen zien speelt een cruciale rol in iemands leven. Het 
menselijk oog bestaat uit talloze gevoelige delen met verschillende functies. Het 
netvlies is het deel van het oog dat verantwoordelijk is voor het opvangen van 
lichtsignalen uit de omgeving, en deze om te zetten in neurale impulsen voor de 
hersenen om waar te nemen. Het netvlies hee een hoge metabole activiteit, die 
wordt ondersteund door voedingsstoen die via bloedvaten worden aangevoerd. 
Een defect vaatstelsel in het netvlies is dan ook een belangrijke oorzaak van visuele 
stoornissen. Achtergrondinformatie over de structuur van het netvlies en de 
ontwikkeling van het vaatstelsel van het netvlies wordt gegeven in Hoofdstuk 1. 
Dit proefschri richt zich op een subtype van visuele beperking genaamd ‘familial 
exudative vitreoretinopathy’ (FEVR). Dit is een erfelijke netvliesaandoening 
gekenmerkt door abnormale of afwezigheid van vaatstelsels in het randgebied van 
het netvlies. Deze ziekte wordt ook uitgebreid toegelicht in Hoofdstuk 1. Tot slot 
worden relevante in vivo en in vitro modellen voor het bestuderen van vaatstelsels 
van het netvlies, alsook de moleculaire en cellulaire technologieën die in dit 
proefschri worden gebruikt beschreven in Hoofdstuk 1.
Enkele jaren geleden werd een mutatie in ZNF408 (c.1363C>T, p.His455Tyr) 
geïdenticeerd in een autosomaal dominante FEVR-familie. Ondanks latere 
experimenten in cellen en zebravissen, die wijzen op de betrokkenheid van ZNF408 
bij de ontwikkeling van het vaatstelsel in het netvlies, is er weinig bekend over de 
moleculaire functie ervan. In Hoofdstuk 2 wordt een in vitro studie gepresenteerd 
over de rol van ZNF408 bij het reguleren van gen expressie en hoe de p.His455Tyr-
mutatie dit proces beïnvloedt. Transcriptoom analyse toonde aan dat ZNF408 
de expressie reguleert van genen die relevant zijn voor de ontwikkeling van het 
vaatstelsel, en hoe deze werden veranderd door de mutatie p.His455Tyr. Verdere 
moleculaire experimenten wijzen erop dat ZNF408 genexpressie op een indirecte 
manier reguleert.
Om de functie van znf408 in vivo verder te bestuderen, werden znf408 
zebravismodellen gegenereerd (Hoofdstuk 3). Deleties waarvan werd voorspeld 
dat ze tot een frameshi mutatie zouden leiden, werden geïntroduceerd in twee 
zebravismodellen, één met een deletie van 1 bp en de andere met een deletie van 4 
bp. Een missense-model werd ook gegenereerd, waarbij een 1 bp substitutie werd 
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toegepast om de menselijke p.His455Tyr-mutatie na te bootsen. Karakterisering 
van de mutante modellen toonde vertraagde ontwikkeling van het vaatstelsel van 
het netvlies in het larvale stadium, abnormale vertakkingen bij jongvolwassen 
vissen, en vasculaire lekkage bij volwassen vissen. Deze resultaten geven de 
geschiktheid van deze modellen aan als diermodel voor FEVR en ook voor verdere 
studies van znf408 in de ontwikkeling van in vivo vaatstelsels van het netvlies.
FEVR is een klinisch en genetisch heterogene ziekte. Verder wordt een verminderde 
penetrantie waargenomen bij ongeveer 25% van mutatiedragers bij FEVR. Het is 
nog steeds onduidelijk wat de onderliggende oorzaak is van deze verminderde 
penetrantie. In Hoofdstuk 4 wordt een pilotstudie van verminderde penetrantie 
in ZNF408-geassocieerde FEVR gepresenteerd. Geïnduceerde pluripotente 
stamcellen van een FEVR-patiënt met de ZNF408 c.1363C>T-mutatie en haar 
zuster, die niet is aangedaan ondanks het dragen van dezelfde mutatie, alsook die 
van controle-individuen, werden gedierentieerd in endotheelcellen. De verkregen 
endotheelcellen vertoonden vergelijkbare morfologie, expressie van endotheliale 
celmarkers en angiogeen gedrag. Een trend van lagere dierentiatie-eciëntie 
naar endotheliale origine werd waargenomen in de geïnduceerde pluripotente 
stamcellijnen afgeleid van de patiënt en de gezonde mutatie drager. Bovendien 
hadden endotheelcellen afgeleid van de gezonde mutatie drager een ongeveer 
2-voudig lagere ZNF408-expressie in vergelijking met de patiënt en controles. 
Verder onderzoek is nodig om te bepalen of deze resultaten reproduceerbaar 
zijn in andere omstandigheden en ook om een  dieper inzicht te krijgen in de 
moleculaire mechanismen van verminderde penetrantie in FEVR. Niettemin 
toonde deze pilotstudie aan hoe patiënt-specieke endotheelcellen kunnen 
worden gegenereerd uit geïnduceerde pluripotente stamcellen en dat de verkregen 
endotheelcellen kunnen worden gebruikt voor het bestuderen van verminderde 
penetrantie in FEVR.
Zijnde een genetisch heterogene ziekte, zijn er ook mutaties in andere genen 
gerapporteerd bij FEVR patiënten. Hoofdstuk 5 beschrij de identicatie van een 
mutatie in KIF11 bij een patiënt met FEVR en microcefalie. Verdere genetische 
studies onthulden dat de mutatie werd geërfd van de niet-aangedane moeder die 
drager en mozaïek is voor de mutatie. Deze studie toonde het belang aan van een 
grondige genetische beoordeling van niet-getroen ouders, met name in geïsoleerde 
gevallen, om betrouwbaardere risicobeoordelingen mogelijk te maken en dus betere 
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genetische counseling.
In Hoofdstuk 6 wordt de rol van ZNF408 in de ontwikkeling van het vaatstelsel 
(netvlies) op basis van onze in vitro en in vivo bevindingen besproken. 
Transcriptoomprolering stelde een mogelijke rol van ZNF408 in chromatine-
hermodellering voor. Deze onverwachte bevinding wordt ook besproken in 
Hoofdstuk 6. Naast monogene FEVR zijn ook varianten in ZNF408 gerapporteerd 
bij retinitis pigmentosa en digene FEVR. Alle varianten die zijn gerapporteerd 
in ZNF408 en hoe verschillende varianten leiden tot verschillende fenotypen 
worden samengevat en besproken in Hoofdstuk 6, gevolgd door een discussie 
over de complexiteit van FEVR-genetica. Ten slotte worden de bevindingen van 
de onderzoeken uit dit proefschri gekoppeld aan de diagnostiek, het omgaan met 
de ziekte, en potentiële nieuwe behandelingen voor FEVR.
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Intisari
Penglihatan memiliki peranan penting dalam kehidupan seseorang. Mata manusia 
terdiri dari berbagai bagian yang fungsinya beragam. Retina adalah bagian dari 
mata yang berfungsi untuk menerima rangsangan cahaya dari lingkungan dan 
mengubahnya menjadi impuls saraf untuk kemudian diproses oleh otak. Retina 
memiliki aktivitas metabolisme yang tinggi. Aktivitas ini didukung oleh nutrisi 
yang disalurkan melalui pembuluh darah. Kerusakan pembuluh darah di retina 
merupakan salah satu penyebab utama gangguan penglihatan. Struktur retina dan 
perkembangan pembuluh darah di retina dijelaskan di Bab 1. Salah satu subtipe 
gangguan penglihatan yang disebut familial exudative vitreoretinopathy (FEVR) 
adalah fokus dari tesis ini. FEVR adalah kelainan retina turunan yang ditandai oleh 
tidak adanya atau abnormalitas pada pembuluh darah di retina perifer. Penyakit 
ini juga dijelaskan secara mendalam pada Bab 1. Model in vivo dan in vitro yang 
relevan untuk mempelajari pembuluh darah di retina serta teknologi molekuler 
dan seluler yang digunakan dalam tesis ini diuraikan pada Bab 1.
Beberapa tahun yang lalu, mutasi pada ZNF408 (c.1363C>T, p.His455Tyr) 
diidentikasi dalam keluarga dengan FEVR yang diturunkan secara dominan 
autosom. Meskipun percobaan selanjutnya dalam sel dan ikan zebra menunjukkan 
keterlibatan ZNF408 dalam perkembangan pembuluh darah di retina, belum 
banyak yang diketahui tentang fungsi molekulernya. Bab 2 berisi penjelasan 
mengenai studi in vitro tentang peranan ZNF408 dalam mengatur ekspresi gen 
dan bagaimana mutasi p.His455Tyr dapat mempengaruhi fungsinya. Analisa 
transkriptomik menunjukkan bahwa ZNF408 mengatur ekspresi gen yang relevan 
untuk perkembangan pembuluh darah, yang diubah oleh mutasi p.His455Tyr. 
Hasil eksperimen molekuler lebih lanjut mengindikasikan bahwa ZNF408 
mengatur ekspresi gen secara tidak langsung..
Untuk mempelajari lebih lanjut fungsi znf408 in vivo, rekayasa gen znf408 
dilakukan pada ikan zebra (Bab 3). Dua delesi yang diperkirakan untuk 
menimbulkan protein yang lebih pendel diaplikasikan pada gen znf408 di ikan 
zebra, yang pertama delesi 1 bp dan yang kedua delesi 4 bp. Satu model missense 
juga dihasilkan, yang mana substitusi 1 bp diaplikasikan untuk menyerupai mutasi 
p.His455Tyr pada manusia. Karakterisasi model-model mutan ini menunjukkan 
terhambatnya perkembangan pembuluh darah retina pada tahap larva, kelainan 
7-5 Dyah Karjosukarso.indd   187 17-05-19   12:19
Chapter 7
188
pertumbuhan cabang pada tahap ikan muda, dan kebocoran pembuluh darah 
pada tahap ikan dewasa. Hasil karakterisasi ini menunjukkan bahwa model-
model ini sesuai untuk meneliti peranan znf408 lebih lanjut dalam perkembangan 
pembuluh darah retina secara in vivo.
FEVR adalah penyakit yang heterogen, baik secara klinis maupun genetik. Reduced 
penetrance telah diamati pada sekitar 25% mutasi carrier dalam FEVR. Namun, 
penyebabnya belum diketahui secara jelas. Studi awal mengenai reduced penetrance 
dalam FEVR yang disebabkan oleh ZNF408 diuraikan di dalam Bab 4. Sel punca 
ber-pluripotensi dari seorang pasien FEVR dan saudara perempuannya yang tidak 
menunjukkan gejala FEVR walaupun juga mempunyai mutasi di gen ZNF408, dan 
juga sel punca ber-pluripotensi dari individu sehat (kontrol), didiferensiasikan 
menjadi sel endotel. Sel-sel endotel yang dihasilkan dari beberapa individual ini 
menunjukkan morfologi, ekspresi marker-marker sel endotel, dan karakteristik 
angiogenik yang sebanding satu sama lain. Esiensi diferensiasi sel-sel punca 
dari pasien FEVR dan saudarinya untuk menjadi sel endotel cenderung lebih 
rendah dibandingkan dengan sel-sel punca dari kontrol. Lebih lanjut, sel endotel 
yang dihasilkan dari individu sehat yang mempunyai mutasi pada gen ZNF408 
memiliki ekspresi gen ZNF408 sekitar 2 kali lebih rendah dibandingkan dengan 
pasien FEVR dan kontrol. Penelitian lebih lanjut diperlukan untuk menentukan 
apakah hasil ini dapat direproduksi dan juga untuk mendapatkan wawasan yang 
lebih dalam tentang mekanisme molekuler dari reduced penetrance dalam FEVR. 
Meskipun demikian, penelitian awal ini menunjukkan bagaimana sel endotel 
dapat didiferensiasikan dari sel punca pasien dan sel endotel yang dihasilkan 
dapat digunakan untuk mempelajari reduced penetrance dalam FEVR. 
Sebagai penyakit yang heterogen secara genetik, mutasi pada gen selain ZNF408 
telah dilaporkan pada pasien FEVR. Bab 5 mendeskripsikan identikasi mutasi 
pada gen KIF11 pada pasien dengan FEVR dan mikrosefali. Studi genetik lebih 
lanjut menunjukkan bahwa mutasi ini diwarisi dari ibu yang tidak memiliki FEVR 
yang mosaik untuk mutasi ini. Studi ini menunjukkan pentingnya evaluasi genetik 
menyeluruh dari orang tua meskipun tidak memiliki FEVR, terutama dalam kasus 
yang sporadik, sehingga  penilaian risiko turunan dapat lebih akurat dan pada 
akhirnya konseling genetik yang lebih baik dapat diberikan.
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Peran ZNF408 dalam perkembangan pembuluh darah (di retina) berdasarkan 
temuan in vitro dan in vivo dibahas di dalam Bab 6. Hasil analisa transkriptomik 
mengacu pada kemungkinan peran ZNF408 dalam modikasi kromatin. Temuan 
tak terduga ini juga dibahas di dalam Bab 6. Semua varian yang telah dilaporkan 
dalam ZNF408 dan bagaimana varian yang berbeda menimbulkan  fenotip yang 
berbeda dirangkum dan dibahas di dalam Bab 6, diikuti dengan diskusi tentang 
kompleksitas genetika FEVR. Selanjutnya, dampak dari studi yang disajikan dalam 
tesis ini untuk diagnostik, manajemen penyakit, dan kemungkinan terapi untuk 
FEVR juga dibahas di Bab 6.
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enrolment of the best and most motivated students.
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IT sector and management position in pharmaceutical industry. In general, the 
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For more information on the DGCN as well as past and upcoming defenses please 
visit:
http://www.ru.nl/donders/graduate-school/phd/
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Data management
Type of data Subject to 
privacy 
(yes/no)
Way of 
anonymization
Storage
Research data Yes All patients received 
an untraceable 
number, the identity 
of the patient is 
only known by the 
research PI and 
treating physician.
Research data were stored in numbered lab journals 
from October 2014 – November 2016. From 
then onwards, research data were documented in 
Labguru in the Vitreoretinopathies project: https://
radboudumc.labguru.com/knowledge/projects/711. 
Access to the data are restricted to PI and direct users.
Antibodies No Not applicable Antibodies were registered in the antibody database 
from the Department of Human Genetics in Labguru: 
https://radboudumc.labguru.com/biocollections/
antibodies. Antibodies were stored with a traceable 
number in the assigned freezer/fridge at the 
Department of Human Genetics, according to the 
manufacturer’s instructions.
Fluorescence 
images
No Not applicable Fluorescence imaging data were stored on the private 
network of the Blindness Genetics erapy group at 
the Department of Human Genetics: T:\PIgroup-Rob-
Collin\02 Microscopy images\06 Dyah Karjosukarso.
Plasmids and 
viruses
No Not applicable Plasmids were registered in the Blindness Genetics 
erapy database and assigned to a pGT-number. 
H:\GR eme groups\10 PI Group Rob Collin\05 
Vector_AAV_AON Database. Plasmids were stored 
in the assigned freezer at -80°C at the Department of 
Human Genetics.
Patient-
derived cell 
lines
Yes All patients received 
an untraceable 
number, the identity 
of the patient is 
only known by the 
research PI and 
treating physician.
Cell lines received a traceable number and were 
registered at the cell culture facility of the Department 
of Human Genetics. Cell lines were frozen in 
liquid nitrogen and stored in the assigned freezer 
at -80°C at the Department of Human Genetics. 
e number of the cell lines used can be found in 
the labjournal of Dyah Karjosukarso, stored at the 
Department of Human Genetics or in Labguru in 
the Vitreoretinopathies project: https://radboudumc.
labguru.com/knowledge/projects/711. Contact 
person to nd the cell lines in the assigned freezer: 
Saskia van der Velde-Visser.
Other cell 
lines
No Not applicable Cell lines were stored with a traceable number 
at the cell culture facility at the Department of 
Human Genetics, according to the manufacturer’s 
instructions. e number of the cell lines used can 
be found in the labjournal of Dyah Karjosukarso, 
stored at the Department of Human Genetics or in 
Labguru in the Vitreoretinopathies project: https://
radboudumc.labguru.com/knowledge/projects/711. 
Contact person to nd the cell lines in the assigned 
freezer: Saskia van der Velde-Visser.
Next 
generation 
sequencing 
data
Yes All patients received 
an untraceable 
number, the identity 
of the patient is 
only known by the 
research PI and 
treating physician.
Raw data of next generation sequencing experiments 
were stored on the private network of the Blindness 
Genetics erapy group at the Department of Human 
Genetics: T:\PIgroup-Rob-Collin\12 NGS_data_DK.
n.a.: not applicable.
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